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INTRODUCTION 
 
Siddha System of Medicine was introduced by Siddhars who practiced 
spiritual practise to attain salvation. Siddhars are persons who practiced Meditation, 
Pranayamam and other Yogam practices to reach a stage of insight which would provide 
them super natural power to cure the sufferings. They discovered many natural medicines 
which are widely used for treating many diseases. 
  Siddha System of Medicine is a special significant and scientific system 
being in practice. Since time immemorial it is one of the ancient system of medicine 
contemporaneous with Grecian, Egyptian, Mesopotamian, Chinese medicines. It is a 
unique system which dealt among the tamil people of south India rendering service to 
humanity for more than five thousand years in combating diseases and then maintaining 
Physical, Mental, Social and Spiritual Health. 
  Siddha System of Medicines includes 32 types of internal medicines and 32 
types of external medicines. Siddhars have contributed tremendous work on raw materials 
from herbal, herbo - Mineral, Metal and Animal origin and formulated by many 
medicines. The medicines like Chooranam, Legiyum, Manapagu, Parpam, Chendurum, 
Chunnam, Kattu, Kalangu, Etc..,,where prepared by the following special techniques like 
Calcination, Sublimation, Dissolution, Fusion, Distillation, Separation, Conjunction & 
Combination, Coagulation, Fermentation, Exaltation, Fixation, Purification, Incineration 
Of Metals, Liquefaction, Extraction
 
Etc., These medicines where used to treat chronic 
diseases especially in cases where in the prognosis is grave. 
  Varmam is the special branch of Siddha System of Medicine still in practice 
in Southern parts of Tamil Nadu especially in Kanya Kumari and in Southern parts of 
Kerala. Though it gained popularity as a martial art in the past two decades, its immense 
medical benefits for many ailments are still ignored. The basic principles of Varmam 
science explain the fundamentals of Siddha system of medicine. This treatment 
methodology is employed in the clinical practice, especially for musculo - skeletal 
disorders, neuro-musculature disorder and neurological disorders. 
  Siddhar  Yugi  munivar  has classified vali disease into 80 types in the text 
Yugi vaithya chindamani 800, Cagana vaatham is one among them. The symptoms are 
pain around the neck, giddiness, pain in the upper limbs burning sensation of the eyes and 
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pain all over the body like a sting of a scorpion. This condition may be correlated with 
cervical spondylosis in modern science. 
  Cervical spondylosis is a disease which causes pain, swelling, restriction of 
movements in the cervical region and produces lot of troubles in day to day activities of an 
individual. Nowadays Neck pain has become a matter of major concern which is mainly 
due to life style modifications. Most of the people are following sedentary way of life and 
occupational issues such as laboratory investigator, IT sector. So the chances of 
developing Cervical Spondylosis is also highly increased. 
  Degenerative changes in the body which used to happen only after the 5
th
 
decades of life Nowadays degenerative changes started in the 3
rd
 decades itself. Many 
youngsters are affected by cervical spondylosis due to degenerative changes of the 
spine.50% of people over the age of 50 and 75% of those over the age of 65 have typical 
radiographic changes of cervical spondylosis 40% of people have some restriction of neck 
movements and 60% have neurological abnormality.  
  The hectic schedule followed by the people has reduced the time which was 
utilized for doing yoga, physical exercises, relaxation etc.. 
  So, the need of the hour is to search an effective drug and therapy to treat 
cervical spondylosis with less or no adverse effects. Hence an attempt had been made to 
validate the drugs and therapy for the management of cagana vaatham. Therefore, I have 
chosen this polyherbal formulation „SIGAMANI CHOORANAM‟ from the classical 
literature Kannusamy parambarai vaithyam for internal administration and external 
medicine „ARKKASHEERATHY THYLAM‟ from Siddha vaithya thirattu. Most of the 
ingredients of the trail drug have anti-inflammatory and analgesic activity. Moreover most 
of the ingredients possess veppaveerium (Hot potency) and kaippusuvai (Pungent taste) 
which will balance and rectify the deranged Pitha Vathadhosham. 
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AIM AND OBJECTIVES 
AIM: 
Preclinical and Comparative clinical trial of Siddha drugs “SIGAMANI 
CHOORANAM” (Internal) and “ARKKASHEERATHY THYLAM” (External) in the 
treatment of CAGANA VAATHAM (Cervical Spondylosis) with and without “VARMAM” 
therapy. 
OBJECTIVE:   
a). PRIMARY OBJECTIVE:   
        To evaluate the safety and therapeutic efficacy of “SIGAMANI CHOORANAM” 
(Internal) and “ARKKASHEERATHY  THYLAM” (External) in “CAGANA VAATHAM” 
(Cervical Spondylosis) through clinical study along with and without Varmam. 
b). SECONDARY OBJECTIVE: 
             1). To evaluate the Safety of the trail drug. 
      2). To study the Siddha parameters before and after treatment of the trail drug. 
     3). To evaluate biochemical analysis of the trial drug.  
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SIDDHA ASPECTS 
CAGANA VAATHAM: 
Cagana vaatham is one among the 80 types of Vaatha diseases. It is a 
condition involving pain around the neck, giddiness, pain in the limbs, burning sensation 
of the eyes, pain all over the body like a sting of a scorpion. 
 
“¾¡¦ÉýÈ ¸ºô§À¡Î ÐÅ÷ôÒ¨ÈôÒ 
  º¡¾¸Á¡ö Á¢ïÍ¸¢Öõ º¨Áò¾ Åñ½õ 
¬¦ÉýÈ Å¡È¢ÉÐ ¦À¡º¢ò¾Ä¡Öõ 
  ¬¸¡Âò§¾ÈÄÐ ÌÊò¾¡Öõ 
À¡¦ÉýÈ À¸ÖÈì¸ Á¢Ã¡ Å¢Æ¢ôÒ 
  ÀðÊÉ¢§Â Á¢¸×Ú¾ø À¡Ã¦Áö¾ø 
§¾¦ÉýÈ ¦Á¡Æ¢Â¡÷ §Áüº¢ó¨¾Â¡¾ø 
  º£ì¸¢ÃÁ¡ö Å¡¾Á¢Ð ¦ºÉ¢ìÌó¾¡§É” 
 
“À¸Ã§Å Å¡¾ÁÐ §¸¡À¢ò¾ô§À¡  
  ÀñÀ¡¸ ¦Àñ§À¡¸ ÁÐ¾¡ý  
¿¸Ã§Å ¦ÅÌàÃÅÆ¢ ¿¼ì¸¢ø  
  ¿Ç¢Ã¡É ¸¡üÚ§Á ÀÉ¢ §ÁüôÀð¼¡ø  
Á¢¸Ã§Å ¸¡ö¸û ¸É¢ ¸¢ÆíÌ ¾ý¨É  
  Á¢¸ ÅÕó¾¢ Á£È¢§Â ¾Â¢÷¾¡ý ¦¸¡ñ¼¡ø  
Ó¸Ã§Á ÓÐ¦¸Öõ¨À ÓÚì¸¢ ¦¿¡óÐ  
  ÓÆí¸¡Öõ ¸¨½ì¸Öõ ¸ÎôÒ¯ñ¼¡§Á” 
 
AETIOLOGY: 
 
 Excessive consumption of bitter, astringent and pungent food items  
 Consumption of food cooked on the previous day  
 Drinking polluted water  
 Changing sleep pattern 
5 
 
 Excessive starvation  
 Lifting heavy weight  
 Excessive lust  
 Sexual indulgence  
 Walking long distance  
 Living in cold environment  
 Excessive consumption of Tubers, Fruits, Curd, Etc  
 
CLINICAL FEATURE OF CAGANA VAATHAM: 
 
The signs and symptoms of Cagana vaatham are described in Yugi Vaidhya 
Chinthamani and Pararasasekaram as: 
 
“§¸Ù§Á ¸Øò¾¢ý¸£ Æ¨ÃìÌ §ÁÖí  
  ¦¸ÊÂ¡É ¸ÃÁ¢ÃñÎ Á¢¸§Å ¦¿¡óÐ  
Å¡Ù§Á º¡¢Ã¦ÁÄ¡í ¸Éò¾¢ÕìÌõ  
  Å¡Ä¢À÷ìÌ ÁÉí¸ñÏ ÁÂì¸Á¡Ìõ  
²Ù§Á Â¢ÃñÎ¸ñÏ ¦Á¡¢îºÖñ¼¡  
  §ÁüÈÁ¡ö ºÄó¾¡Û Á¢Ú¸¢ì ¸¡Ïó  
§¾Ù§Á ¦¸¡ðÊÉÐ §À¡üì ¸ÎìÌõ  
  º¸ÉÅ¡ ¾ò¾¢É¢¼ ¾£÷ì¸ó¾¡§É”  
  - ä¸¢ ¨Åò¾¢Â º¢ó¾¡Á½¢ 
 Pain in the neck  
 Radiating pain in the shoulders and upper limbs  
 Heaviness of the body  
 Mental depression  
 Giddiness  
 Burning sensation of the eyes  
 Constipation  
 Pain felt like sting of a scorpion  
 Numbness and tingling sensation of the upper limbs. 
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VAATHAM 
Vaatham represents Vaayu, Dryness, Pain, Sensitiveness and Lightness. 
“Vaatham = Vali + Aagayam”.  
LOCATION: As per Yugi muni, “Vaatham” lives in, 
1. Abaanan 
2. Edakalai 
3. Kamakodi 
4. Undhiyin Keezh moolam 
5. Iduppu 
6. Elumbu 
7. Thasai 
8. Narambu 
9. Thol 
10. Malam 
FUNCTIONS OF VATHAM: 
 
1. Body ache 
2. Bony Prickling pain 
3. Tearing pain 
4. Nerve weakness 
5. Mental distress 
6. Joint pain 
7. Dislocation of joints 
8. Weakness of organs 
9. Paralysis of limbs 
10. Polydypsia 
11. Severe pain in calf and thigh muscles 
12. Anuria and constipation 
13. Unable to do flexion and extension of the limbs 
14. All tastes felt as astringent. 
 
NATURAL PROPERTIES OF VATHAM: 
1. To create spirit 
2. Expiration and Inspiration 
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3. To tone up the activities of the Mind, Speech & Body. 
4. Regulation of the “Fourteen Physiologically Reflexes” (Vegam) 
5. Functioning of the “Seven Udal Kattukal” uniformly 
6. Protection and strengthening of the five sensory organs (lymphorigal). 
 
TYPES OF VATHAM : 
 
1.PRAANAN: 
It maintains the action of the heart, the functioning of the mental faculties of 
perception and concentration it also cares for the arteries, veins and nerves. It regulates the 
respiration and digestion. It is otherwise called as “Uyirkkal”. 
2.ABAANAN: 
It controls the excretion. It is focussed in the lower part of the gut and also 
occupies the sites in the bladder and genitalis. It has a tendancy to travel downwards. It 
Completely occupies the Genito urinary tract and regulates Defaecation, Micturition, 
Parturition and Ejaculation. Its is otherwise termed as “Kezhnokkumkaal”. 
3.VIYAANAN: 
It helps in the circulation of energy throughout the entire nervous system and 
the movements of various parts of the body. It also transports nutrients and blood 
throughout the body. It is also known as “Paravukaal”. 
4.UDHAANAN: 
It controls speech and breathing. It is also responsible for the physiological 
reflex actions like vomiting, hiccup, cough, etc.., It has the tendancy to travel upwards. It 
is otherwise named as “Melnokkukaal”. 
5.SAMANANAN: 
It corresponds to the solar plexus in the navel region and controls digestion. It 
selects the useful substances from the swallowed food and supplies them to the whole 
body. It balances the other “Vayus” and it is also called as “Nadukkal”. 
8 
 
6.NAAGAN: 
It is responsible for the intelligence of an Individual, Blinking, Singing and Pilo 
Erection. 
7.KOORMAN: 
It is responsible for yawning, closing of mouth, blinking shedding of tears, 
vision and opening of the eyes. 
8.KIRUGARAN: 
It is responsible for salivation and nasal secretion. It helps in digestion and 
remembering things. It produces cough and sneeze. 
9.DHEVATHATHAN: 
It is responsible for laziness, latitude, arguing and also anger. It helps 
movements of the eyeball in various directions. It dwells in between the anus and the sex 
organ. 
10.DHANAJEYAN: 
It start from the nose and  it causes the whole body to swell. It leaves from the 
body by blowing up the cranium only on the third day after death. 
In Cagana vaatham, Viyanan, Samanan are afftected. 
QUALITIES OF VAATHAM: 
 
1. Kadinam - Roughness 
2. Varatchi - Dryness 
3. Elesu - Lighter 
4. Kulirchi - Coldness 
5. Asaithal - Unstableness 
6. Anuthuvam - Subtleness 
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OPPOSITE QUALITIES OF VAATHAM: 
 
1. Mirudhu - Softness 
2. Pasumai - Unctuous 
3. Baluvu - Heaviness 
4. Akkini - Hot 
5. Isthiram - Stableness 
6. Katti - Solidity 
 
 
 
 
INCREASED FEATURES OF VAATHAM: 
 
1. Reduced immunity 
2. Giddiness 
3. Insomnia 
4. Laziness 
5. Body weakness and dark complexion 
6. Desire to eat hot foods 
7. Shivering 
8. Abdominal distension 
9. Constipation 
 
DECREASED FEATURES OF VAATHAM: 
 
1. Generalized body pain 
2. Hoarseness of voice 
3. Loss of memory 
4. Semi consciousness 
5. Difficulty in performing work 
 
 
PITHAM: 
Pitham is located in the Urinary bladder, Heart, Head, Umbilicus, Pinkalai, 
Abdomen, Stomach, Sweat, Blood, Eye and Skin. It is classified into five types as, 
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Anala pitham  - It digests all the food substance 
 Ranjaga pitham - It gives colour to the blood 
 Saadhaga pitham - It is used to accomplish a work properly 
 Alosaga pitham - It gives vision to the eye 
 Piraasaga pitham - It gives colour to the skin 
1). Involvement of Saadhaga Pitham produces the features like mental depression and 
difficulty in performing regular duties because of the pain in the neck and upper limbs. 
2). Saadhaga pitham is affected in Cagana vaatham. 
  
KABAM: 
 Kabam is located in Semen, Fat, Bone Marrow, Nose, Chest, Nerves, Bones, Brain, 
Large Intestine, Stomach, Pancreas. It is divided into five types they are, 
1. Avalambagam - It controls all other four types of kabam  
2. Kiledhagam  - It moistens the food 
3. Podhagam  - It helps to feel the taste 
4. Tharpagam  - It gives cooling effect to the eyes 
5. Sandhigam  - It gives lubrication to the joints 
Tharpagam and sandhigam are affected in Cagana vaatham. 
UDAL THATHUKKAL: 
 1.Saaram  - It strengthens the body and mind 
 2.Senneer  - It gives power, knowledge and boldness to a person 
 3.Oon    - It is responsible for the movement of the body 
 4.Kozhupu  - Lubricates the joints and facilitates their function 
 5.Enbu   - Protects all the internal organs and gives structure  
    to the body. 
 6.Moolai  - It is present in bones and strengthens them 
 7.Sukkilam (or)  
    suronitham   - Useful in reproduction  
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 Panchaboothangal forming the basic constituents of Seven Udal thathukkal 
(Saaram, Senneer, Oon, Kozhuppu, Enbu, Moolai and Sukkilam) also get deranged.  
 Commonly affected Udal thathukkal in Cagana vaatham are Saaram, Oon and 
Enbu.  
KANMENDHIRIYAM: 
 1.Kai   - Work done  by hands 
 2.Kaal   - For walking 
 3.Vaai   - For speaking 
 4.Eruvai  - For defecation 
 5.Karuvai  - For reproduction 
Commonly affected Kanmenthiriyum in Cagana vaatham  (organs of actions) are Kai. 
GNAANENDHIRIYAM : 
 1.Mei   - Feels all types of sensation 
 2.Vaai   - For taste 
 3.Kan   - For vision 
 4.Mooku  - For smell 
 5.Sevi   - For hearing 
Commonly affected Gnanenthiriyams in cagana vaatham are Mei, Kan.  
 
DIAGNOSIS: 
 
ENVAGAI THERVU 
 
"¿¡Ê ŠÀÃ¢ºõ ¿¡ ¿¢Èõ ¦Á¡Æ¢ Å¢Æ¢  
    ÁÄõ ãò¾¢Ãõ þ¨Å ÁÕòÐÅÃ¡Ô¾õ"  
"¦ÁöìÌÈ¢ ¿¢Èò¦¾¡É¢ Å¢Æ¢¿¡Å¢ÕÁÄõ ¨¸ìÌÈ¢" 
 Naadi 
 Sparism 
 Naa 
 Niram 
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 Mozhi 
 Vizhi 
 Malam 
 Moothiram 
1.NAADI 
Naadi means a vital force it is divided into three humours Vaatham, Pitham, 
Kabam. It can be assessed in 10 sites.The commonest site is radial artery. 
 In Cagana vaatham,Naadi felt are Vathapitham and Pithavatham. 
2.SPARISAM: 
By sparisam the temperature of the Body, Smoothness Or Roughness, Dryness, 
Hardness, Patches, Abnormal Growth, Sweating, Tenderness and Nourishment can be felt. 
 In Cagana vaatham, general body temp-slight warmth (Mitha vaeppam) and 
Tenderness present in neck and upper extremities. 
3.NAA: 
Colour, coating, dryness, movement, deviation, sensory, changes, ulcer, conditions of 
Tooth and gums are noted 
 In Cagana vaatham, the Tongue may be coated. 
4.NIRAM: 
Colour of the skin,mucous membranes,hair and nail are examined. 
 In Cagana vaatham there is no change in Niram. 
5.MOZHI: 
Disturbance in Speech, Hoarseness of voice are assessed. 
  In Cagana vaatham, No change or Disturbance of voice were found.  
6.VIZHI: 
Testing for acuity of vision, colour, redness, pallor, whiteness, burning sensation, 
Excessive lacrimation. 
 In Cagana vaatham, burning sensation of the eyes is present.  
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7. MALAM: 
The excretory products of the body are called as malam. The feaces should be 
semi-solid without hardness and looseness. 
Nature, quantity, colour odour, froth, presence of blood and mucous are noted.  
 In Cagana vaatham, Constipation is present in some of the patients. 
8.MOOTHIRAM 
The urine is examined by two methods 
 Neerkuri 
 Neikuri 
 
NEERKURI: 
Urine is collected after taking well balanced diet, which do not alter the three 
thodams. It should be examined within 3 ¾  nazhigai (90 minutes). 
In Neerkuri the Niram (colour), Manam, Nurai (Froth), Edai (Specific Gravity), 
Enjal (Quantity) are noted. Apart from these the frequency of urination, presence of 
abnormal constituents such as sugar, proteins, etc., and sediments are also noted. 
NEIKURI: 
The collected urine is kept in a glass bowl and is placed under direct sunlight. A 
drop of gingelly oil is dripped on the surface and nature of neikuri is noted. If the drop of 
oil lengthens like a snake it indicates vatham, if it appears like a ring it indicates 
pitham, if it appears like a pearl it indicates kabam. 
When the drop of oil shows two shapes enclosed within one another it 
indicates thontha neer. 
NOI KANIPPU VIVADHAM: 
Other type of vatha diseases which shows similar symptoms of Cagana 
vaatham are mentioned. They are 
 Karnaavarthan nookkadu 
 Kumbavatham 
 Kazhuthu vaaham (kooni kirigavatham) 
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 Pani kambavatham 
 Sirakamba vatham 
 
1. Karnaavartham nookkadu: 
 
 “Å÷ò¾Á¡ö Á¡÷§À¡Î À¢¼Ã¢ ¸¡Ð  
ÅÄ¢òÐ§Á Å¡ôÒ¦¸¡ñ ¼Êò¾¡ü 
ÌüÈÁ¡ö ¸¡¾¢ÃñÎí Ì¨¼îºÄ¡Ìí  
§¸¡½¢§Â ¸ÀòÐí ¸¡Ðí ¸ÉìÌõ  
«üÈÁ¡ Ôîº¢Â¢Öõ ¦¿üÈ¢ ¾ýÉ¢ø  
«Êì¸ÊìÌ §¿¡Â¡¸¢Âº¾¢ Â¡Ìõ  
ÀüÈÁ¡öô Àº¢Â¢ýÈ¢ ¯Èì¸ Á¢ý§Èø  
À¡Ã¸÷É¡ Å÷ò¾¦Áý§È À¸Ã Ä¡Á’’. 
-(ä¸¢ ÓÉ¢ Å¡¾ §¿¡ö¸û & ¸ýÉ¢Â¡ÌÁÃ¢ 
Á¡Åð¼ Å¡¾§¿¡ö ¦¾¡Ì¾¢) 
 Heaviness of neck  
 Referred pain to the ear and nape of the neck 
 Headache  
2.Kumba Vaatham: 
 
 “¿Å¢Ä§Å §¾¡ûÁ£Ð ¸Ã¸ò¾¢ý Á£Ðõ  
¿Ä¢óÐ ¦Áò¾ Å¡¸¢§Â ¿º×ñ¼¡Ìõ  
¸Å¢Ä§Å ¸ýÉ¦Á¡Î ¿ÂÉó ¾¡Ûõ  
¸ØòÐ§Á Å¢ÚÅ¢ÚôÒ ¦ÁÃ¢×í ¸¡Ïõ  
ÐÅ¢Ä§Å ÐÊôÀ¡Ìï º¢ÃÍ ¾ýÉ¢ü  
ÍÆüº¢§Â ¿¡À¢ì¸¢ú ÅÄ¢Ô Óñ¼¡õ  
«Å¢Ä§Å ÂÊ¿¡ì¸¢ ÄÆýÚ ¸¡Ïõ  
«ÄÕ§Á ÅÕ ÌõÀÅ¡¾ó ¾¡§É’’. 
– (º¢ò¾ ÁÕòÐÅõ ¦À¡Ð) 
 Burning sensation in shoulder and upper limbs  
 Burning sensation in the cheek and the eyes  
 Twitching over the scalp  
 Spasmodic pain in the lower abdomen  
 Glossitis  
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3. Kazhuththu Vaatham (Kooni Kiraga Vaatham): 
 
 “¸Øò¨¾ ¾¢ÕôÀ¡§¾ À¢ÊòÐ  
¸¾¢¡¢ðÎ ¯¨Çó¾¡ü §À¡§Ä ¸¡Ïõ  
¦ºÆ¢ò§¾ ¿ÃõÒ ¾ÊòÐ ¿¢üÌõ  
º£Ã¡¸ «¨ºì¸ ¦Å¡ð¼¡Ð  
¸Øò§¾ À¢ÊòÐ þÃ¡ôÀ¸Öõ  
þ¼§Ã ¦ºöÔõ ¸ØòÐ Å¡¾õ  
ÅØòÐõ Ì½í¸û ¾Ã½¢ ¾ýÉ¢ø  
Å¨ºÂ¡ö «È¢Å£÷ ÀñÊ¾§Ã”. 
- (Å¡¾§¿¡ö ÁÕòÐÅõ)  
 Stiffness and restriction of movements of the neck  
 Burning pain in neck  
 Thickening of nerves in neck  
 Symptoms continuing day and night  
4). Paanikamba vatham: 
 
“Á¡÷ì¸Á¡ö Å¡ö×Á¡ö ¦Áö¿¢ ¨ÈóÐ 
ÅÂ¢Ú¾É¢ü Àº¢Â¢Ä¡ àÏ ÁüÈ 
¿¡÷ì¸Á¡ö »¡ÄòÐ ¿¼ì¨¸ ÂüÚ 
¿Îì¸Á¡í ¨¸Â¢ÃñÎó ¾¢Á¢Õ Óñ¼¡õ 
°÷ì¸Á¡ ÔÈì¸Á¢øÄ¡ Ð½÷îº¢ ÂüÚ 
¯¾È¢¦Â ºÃ£Ã¦ÁíÌ ÓÄ÷óÐ ¸¡Ïõ 
À¡÷ì¸Á¡ö Å¡öÅ¢ðÎ «Äò¾ Ä¡Ìõ 
À¡½¢ì¸õÀ Å¡¾ò¾¢ý À¡íÌ ¾¡§É”. 
 - (º¢ò¾ÁÕòÐÅõ ¦À¡Ð)  
 Anorexia 
 Tingling sensation of upper limbs 
 Tremor of upper limbs 
 Sleeplessness 
 Dryness all over the body 
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5). Sirakamba vatham: 
 
“¾õÀÁ¡ö ¯¾¢Ã¸ñ¼ ¿ÃõÀ¢ü Òì¸¢ò 
¾¨Ä§Â¡Î º¡Ã£¦ÁÄ¡ó ¾¡ì¸¢ô ÒìÌõ 
¸õÀÁ¡ö ¸¡¾¢ÃñÎ Á¢¸×í §¸Ç¡ 
¨¸§Â¡Îý ¸¡Ä¢ÃñÎõ Åºì§¸ ¼¡Ìõ 
¿¢õÀÁ¡ö ¿¢¨É×¾¡ý ¸Äí¸¢ì ¸¡Ïõ 
¦¿ÎãîÍí ¦¸¡ð¼¡Å¢ ¿¢ò¾¢¨Ã Â¡Ìõ 
º¢õÀÁ¡ö ¾¨Ä¿Îí¸¢ì ¸ÉôÒ Óñ¼¡ï 
º¢Ãì¸õÀ Å¡¾¦Áý§È ¦ºôÀ Ä¡§Á. 
- (º¢ò¾ ÁÕòÐÅõ ¦À¡Ð) 
 
 Stiffness of neck 
 Deafness 
 Yawning 
 Hypersomnia  
 Tremor in the head and neck 
 Difficulty in using lower and upper limbs 
LINE OF TREATMENT: 
In Siddha system the treatment is based upon the Mukkutram 
principle. Treatment is not only for perfect cure but also for the prevention of diseases 
and rejuvenation of Body Constituents. 
 1).Purgation 
 2).Internal Medicine 
 3).External Medicine 
PURGATION : 
Agasthiyar kuzhambu – 200 mgs given with ginger juice, in early morning with 
empty stomach (for the first day only).  
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INTERNAL MEDICINE: 
 Sigamani Chooranam – 1 gm bd, with water for 21 days.  
 
EXTERNAL MEDICINE: 
Arkkasheerathy Thylam (QS).  
 
DIET TO BE AVOIDED: 
  Bottle gourd, Pumpkin, Cucumber, Snake gourd, Ridged gourd, Black gram, 
Indian butter Bean, Cow gram ,Horse gram, Mustard, Gingellyoil, Sour, Salt, Vatha diet, 
Potato, Plantain, Tobacco, Alcohol, Sexual intercourse. 
 
“¸ÎÌ ¿üÈ¢Äò ¦¾ñ¦½ö ÜúÀ¡ñ¼í¸û ¸¼¨Ä  
 ÅÎÅ¾¡¸¢Â ¦¾íÌÁ¡ ÅÕì¨¸ ¿ü¸¡Âõ  
ÁÊÅ¢Ä¡¾ ¦ÅûÙûÇ¢ ¦¸¡û Ò¨¸Â¢¨Ä ÁÐ¦Àñ  
 ­¼Ú À¡¸§Ä¡ ¼¸ò¾¢ ¿£ì¸¢¼Ä¢îº¡ Àò¾¢Âõ”  
  - º¢ò¾ ÁÕòÐÅ¡í¸ ÍÕì¸õ 
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MODERN ASPECT 
 
THE VERTEBRAE: 
 The Vertebrae can be divided into vertebral body and a dorsal vertebral 
arch.The Vertebral Arch has 2 Pedicles, 7 Process and 2 Laminae. Pedicles are 
thick bars projecting backward from the body. The Laminae are vertical plate like 
structures, fuses together to form spinous process. The Spinous process projects 
downwards and is the level for the muscles. The articular process are four in 
number,bearing the articular facets and articulate with the adjacent vertebrae. Transverse 
processes project laterally from the junction of pedicle and laminae. In thoracic region 
they articulate with ribs. 
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THE CERVICAL VERTEBRAE: 
The Cervical segment of Vertebral column contains 7 Vertebrae. The 1
st
 , 2
nd
 and 
the 7
th
 are Atypical vertebrae and the 3-6 are Typical. All the cervical vertebrae have a 
foramen in the transverse process known as Foramen transversarium.It is identical to the 
Cervical Vertebrae. 
 
 
ATYPICAL VERTEBRAE: 
THE ATLAS (FIRST CERVICAL VERTEBRAE): 
The atlas is ring shaped and has four parts. The anterior arch, the posterior arch 
and two lateral masses. It have five articular surfaces. It has no body and no spine. The 
atlas is the top most vertebra and along with the axis forms the joint connecting the 
skull and spine. 
THE AXIS (SECOND CERVICAL VERTEBRAE): 
The axis forms the pivot upon which the atlas rotates. The most distinctive 
characteristic of this bone is the strong odontoid process (dens) that rises perpendicularly 
from the upper surface of the body. The body is deeper in front than behind, and prolonged 
downward anteriorly so as to overlap the upper and front part of the third vertebrae. 
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THE SEVENTH CERVICAL VERTEBRAE: 
It is also known as the vertebra prominens because of its long spinous process. The 
spine is thick, long and nearly horizontal. It is not bifid, but ends in a tubercle. The 
transverse processes are comparatively large in size. The anterior tubercle is absent. 
The transversarium is relatively small, sometimes double or may be entirely. 
 
 
TYPICAL CERVICAL VERTEBRAE: 
BODY 
 The bodies of these four vertebrae are small, and broader from side to side than 
from front to back. The bodies are separated from each other by intervertebral disc and are 
held together by anterior and posterior longitudinal ligaments. They have four surfaces, 
superior, inferior, anterior and posterior surfaces. 
 
21 
 
THE VERTEBRAL FORAMEN 
 It is larger than the body. It is triangular in shape because the pedicles are directed 
backwards and laterally. 
PEDICLE 
 The pedicles are directed laterally and backward and are attached to the body 
midway between its upper and lower borders, so that the superior vertebral notch is as deep 
as the inferior, but it is at the same time narrower. 
LAMINAE: 
 The laminae are relatively long and narrow, being thinner above than below. 
ARTICULAR PROCESSES 
 The transverse processes are each pierced by the foramen transversarium which 
in the upper six vertebrae gives passage to the vertebral artery and vein, as well as a 
plexus of sympathetic nerves. Each process consists of an anterior and a posterior part. 
These two parts are joined outside the foramen by a bar of bone that exhibits a deep 
sulcus on its upper surface for the passage of the corresponding spinal nerve. 
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THE INTERVERTEBRAL DISC 
 The intervertebral disc is thicker in infants than in adults. At birth the discs occupy 
half the length of the cervical spine. In adults the length is one third of the cervical 
spine and after the age of 50 it is reduced further. The nucleus changes its shape to 
accommodate the changes due to motion. It bears loads during movements of the 
spine. The dense collagen fibres of the annulus are running vertically in the front and are 
strong. Posteriorly run horizontally and are prone to be fissured. 
THE LIGAMENTS: 
 1.Capsular Ligament. 
 2.The Anterior Atlanto-Occipital Ligament 
 3.The Posterior Atlanto-Occipital Ligament 
THE MUSCULATURE: 
 Several muscles support the vertebrae of the spine. The spinalis moves the spine and 
helps maintain correct posture. 
Spinalis cervicis: This muscle begins in the middle region of the spine and travel up to the 
axis. It may begin at the lower cervical vertebrae or the upper thoracic vertebrae (the 
section of the spinal column just below the cervical spine) it helps extend the neck. 
Spinalis dorsi: This muscle begins at the upper thoracic vertebrae and extends down to the 
lower back. 
Spinalis capitis: This muscle begins at the upper and middle thoracic spine and lower 
cervical spine. It extends up to the occipital bone, near the base of the skull. This 
muscle is inseparably connected with another muscle in the neck, the semispinalis capitis. 
BLOOD SUPPLY OF VERTEBRAL COLUMN: 
  The vertebrae and the longitudinal muscles attached to them are supplied by 
segmental arteries.The arteries give multiple small branches to the vertebral bodies.The 
extensor muscles of the neck are supplied by the occipital, the deep cervical and the 
transverse cervical arteries. 
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VENOUS DRAINAGE: 
 The Internal vertebral venous plexus lie within the vertebral canal,but outside 
the spinal dura.It receives tributaries from. 
i)The vertebrae through the basilo vertebral veins. 
ii)The meninges and the spinal cord. 
 The internal vertebral venous plexus is drained by the intervertebral veins,which 
pass out through the inter vertebral foramen.Here they are joined by the tributaries from 
the external vertebral and sacral veins.The internal venous plexus communicates with 
the occipital and basilar veins through the foramen magnum. 
NERVE ROOT SUPPLY TO THE MUSCLES: 
SPINAL ACCESSORY NERVE 
Trapezius       C3C4 
BRACHIAL PLEXUS 
Rhomboidus       C4C5 
Serratus anterior      C5C6C7  
Clavicular       C5C6 
Axillary nerve deltoid      C5C6 
MUSCULO CUTANEOUS NERVE 
Biceps        C5C6 
Brachialis       C5C6 
RADIAL NERVE 
Triceps lateral head      C6C7C8 
Medail head bracheoradialis     C5C6 
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MEDIAN NERVE 
Pronator teres       C6C7 
Flexor carpi radialis      C6C7 
Flexor digitorum superficialis    C7C8T1 
ANTERIOR INTEROSSEOUS NERVE 
Flexor digitorum profundus     C7C8 
Flexor pollicis longus      C7C8 
ULNAR NERVE 
Flexor carpi ulnaris      C7C8T1 
Hypothenar muscle      C8T1 
Abductor pollicis      C8T1 
CERVICAL SPONDYLOSIS: 
It is characterised by degeneration of the intervertebral disc and osteophyte 
formation. Such “wear and tear” is extremely common and radiological changes are 
frequently found in asymptomatic individuals over the age of 50. Spondylosis may be 
associated with neurological dysfunction. In order of frequency, the C5/C6, C6/C7 & 
C4/C5 vertebra levels affect C6,C7 & C5 roots, respectively. 
EPIDEMIOLOGY: 
SEX: The prevalence of cervical spondylosis is similar for both sexes, although the 
degree of severity is greater for males. Spondylotic changes in the cervical spine occur at 
solitary disc space levels in 15-40% of patients and at multiple levels in 60-85%. The discs 
between the third and seventh cervical vertebrae are most commonly affected.  
AGE: It occurs as early as 25 years of age. As age increases so does the incidence 
rate. 60% of the population older than 45 years of age and 8% older than 65 years of age 
account for the case of cervical spondylosis reported. In males, the prevalence was 13% in 
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the third decade, increasing to nearly 100% by age 70 years. In females, the prevalence 
ranged from 5% in the fourth decade to 96% in women older than 70 years. 
 
 
 
 
 
 
 
 
 
 
MECHANISM OF DEGENERATION: 
 1).Narrowing of the intervertebral disc space ( due to nucleus pulposus herniation or 
annulus bulging) 
 2).Osteophytic spur formation ( dorsal surface of vertebral bodies) 
 3).Partial subluxation of vertebrae 
 4).Hypertrophy of the dorsal spinal liganment and dorsolateral facet articulations. 
 5).Hypertrophied ligamentum flavum with fibrosis and calcification. 
 6).C5-C6 intervertebral disc has strong attachement to the vertebral column and thid 
predisposes to degenerative changes 
The most common intervertebral joint to undergo degenerations is between C5-C6. 
It is due to maximal movements occuring at this cervical spine. However, C6-C7 and at 
times C4-C5 can also be involved. 
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AETIOLOGY: 
1.DEGENERATIVE CHANGES: 
 Primary-Senility, Genetic factors, Metabolic factors and Manual labour. 
Secondary Osteoarthritis, Rheumatoid arthritis, Metastatic carcinoma or Lymphomas of 
the spine and TB spine. 
2.OCCUPATIONAL CAUSES: 
 The physical discomfort, which arises through an occupation is occupational stress. 
The physical strain, intensity of work and duration of working hours all constitutes 
the occupational strain. 
3.INJURY: 
 Automobile accidents”Whiplash” injury, Athletic injury. Sudden jerks on the 
arms during fall down previous injury with fracture or Disc prolapses. 
4.HEREDITORY FACTOR: 
 Congenital narrowing of the cervical spinal canal(myelopathy is often seen 
when anal‟s sagital diameteris 12mm or less) Segmental defects-Hemi vertebra,Fused 
vertebra. 
5.ACQUIRED NARROWING OF CERVICAL SPINAL CANAL DUE TO 
OSTEOPHYTES: 
Ossified Posterior Longitudinal Ligament (OPLL) Facet joint hypertrophy (results 
formainal stenosis and compression of root of radicular artery). Hypertrophoid 
Ligamentum Flavum (Compress the cord during extension). Outgrowths of bone 
that sometimes occur with ageing. Intervertebral disc protrusions are commonest in the 
cervical region which is due to degeneration of the intervertebral disc and if it involves 
severe discs with osteoartheosis liable to interfere with blood supply of the cord and thus 
leads to further damage. 
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SYMPTOMS AND SIGNS: 
RADICULOPATHY 
 Neck pain (local or referred pain) 
 Sensory loss and paraesthesia in the corresponding dermatomes (due to 
sensory nerve root involvement) 
 Weakness and wasting of the muscles supplied (due to motor root 
involvement) and vertebral biceps reflex (C5 lession) 
 The wasting of the small muscles of the hand is uncommon. 
CLINICAL FEATURES OF CERVICAL SPONDYLOSIS: 
 Neck pain 
 Stiffness 
 Weakness 
 Pain referred to the interscapular area and upper limb. 
 Numbness and parasthesia in the upper limb or side of the face. 
EXAMINATION OF CERVICAL VERTEBRAE: 
 Sprulings test 
 Chin chest test 
 Lateral roatation 
 Lateral flexion 
 
SPULINGS SIGN: 
In cervical spondylosis, cervical extension results in narrowing of vertebral canal 
therby producing pain in neck. 
 
SHOULDER ABDUCTION RELIEF SIGN: 
Abbduction of shoulder relieves pain in cervical spondylosis. 
 
MYELOPATHY: 
 The most common presentation of spondylitic myelopathy. It presents with 
insidious onset of spastic weakness of the legs, dragging of the toes and stiffness of the 
legs. An accompanying radiculopathy is reported in 40 to 80% of cases. The features of 
root involvements are asymmetric, asymptomatic or present with focal weakness or wasting 
or loss of a reflex. 
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 The sensory signs (loss of VS PS, rombergism +) in myelopathy is due to posterior 
column involvement. 
SYMPTOMS:  
  Tingling, numbness, and/or weakness in the arms, hands, legs or feet‟ s  
 Lack of coordination and difficulty walking 
 Abnormal reflexes 
 Muscle spasms 
 Loss of control over bladder and bowel (incontinence) 
PATHOLOGY: 
 Narrowing of cervical vertbra with disc space reduction 
 Friction between two vertebral bodies created by this narrowing, with an 
osteophyte (bony spur formation) 
 Loss of normal concavity in the cervical region, i.e. loss of lordosis 
 Symptoms of vascular insufficiency 
 Numbness and tingling sensation in the hands or feet due to compression of 
the cervical nerve roots. 
COMPLICATION: 
 1. Incontinence of urine and feaces  
 2. Loss of muscle function or permenanet disability 
DIFFERENTIAL DIAGNOSIS: 
 Compression of cord or root (TB or neurofibromas) 
 Syringomyelia 
 Multiple sclerosis 
 Peripheral nerve lession (distal ulnar or median nerve) 
 Motor neuron disease 
 Spinal cord tumors 
COMPLICATIONS: 
o Cord compression  
o Nerve root compression 
o VBI (vertebro bascillary insuficiency) 
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INVESTIGATIONS: 
1). Plain X-ray of Neck 
Antero posterior view 
Lateral view 
Oblique view 
 
 
 
 
 
Features, 
1). Loss of  normal cervial lordosis 
2). Spondylotic bars 
3).Disc narrowing and subluxation 
4). Reduction of sagital diameter is less than 11mm or 7mm (in neck extension) 
2. Myelogram-May show compression of the spinal cord 
3. C.T Scan (Computerised Tomography) 
o Comprises degenerative changes 
o May demonstrate posterior osteophytes and disc herniation 
4.MRI-(Magnetic Resonance Imaging) 
o Neural compression 
o Intristic cord changes 
o Disc generation 
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5 Examination of CSF 
 Very high protein 
6. EMG(electromyelogram): 
It is used to check that your nerves are functioning normally when sending 
signals to muscles. 
7. Other tests: 
 Nerve conduction studies. 
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VARMAM ASPECT 
VARMAM: 
 Varmam is the subtle energy that functions inside the body. It is the manifestation of 
the five elements (Iym Bootham), vital airs (Vayu-10), Naadis, Vaasi, Kundalini. This is 
revealed in the following verse of Vagada Nithanam and Varma sara nool as, 
 
 

 
 
 
 
 

 
 
VARMAM POINTS: 
 The places where the Varmam energy resides and activates both body and life-
energy are Varmam points. These points are located in the nerves, naadi, muscle and bones. 
They are the sites of bio-energy which aid physiological functions of the body. 
  It is also said that Varmam points are the places where the vital energy Vaasi 
strikes. The following lines express this as  
 
     
 
 
   

 
 

CLASSIFICATION OF VARMAM: 
There are two kinds of classification. One is based upon region wise distribution 
and the other is based upon aadharams. In both kinds, the total number of Varmam points 
is said to be 108 in number.  
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 The number of Varmam points located in upper limb is 15, lower limb is 14, below 
the navel is 9, above the navel is 45 and above the neck is 25.  



 
 



TYPES OF VARMAM: 
 Varmam points are the places which activate, regulate, supplies energy and 
functions according to the body needs. The Varmam text “Varma Vilvisai” enumerates 
8000 Varmam points and Kumbamuni narambarai
 
 describes 251 points. Most of the 
Varmam texts enlist 108 Varmam points of which 12 are padu varmams and 96 are thodu 
varmams. Other types of Varmam mentioned in the texts are vatha varmam (64), pitha 
varmam(26), silaethuma varmam(6).  
       







 








 


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Padu varmams are the varmam points which are directly connected to brain energy 
and serve as major energy storage points. According to “Pingala nigandu”, the word 
„padu‟ means brain. Thodu varmams are the varmam points which are connected to padu 
varmams. The word „thodu‟ refers to touch. It means through the act of touch, one varmam 
point is connected to another varmam point. Such a way, eight thodu varmams are 
connected to one padu varmam i.e 8 x12 = 96 Thodu varmam. They serve as minor energy 
storage points. 
  
  
  
  
  
  

The total number of Varmam points which accounts to 108 comprises two 
terminologies Varmam and Kaalam. The word Varmam refers to static energy and the term 
Kaalam refers to kinetic energy.  
   
 


VARMAM APPLICATION: 
When anyone of the basic functions of Varmam is affected it leads to disease. The 
treatment Protocol includes  
1) Stimulation of Varmam points 
2) External treatment like Oileation, Ilaikizhi, Neikizhi, etc. 
 


   



 
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













 The stimulation of Varmam points is called as „Kaibaham‟, „seibhagam‟.  This is 
executed in 12 different ways like anukkal, asaithal, thattal, thadaval, yenthal, oondral, 
pidithal, nazhukkal, amarthal, pathukkal, karakkal, pinnal. 







Each Varmam can be applied in 12 different ways in four different amount of 
pressure (Mathirai) i.e. Mathirai Kanakku – Pathi Kanakku. These parameters refer to 
amount of pressure applied during Varmam treatment. The depth of touch is Mathirai 
Kanakku and the Pressure of touch is Pathi Kanakku.  Thus a Varmam point can be 
activated in 48 ways.  A sound knowledge of application of Varmam points in this context 
can be best gained in Gurukula Training, 


 

  A deep knowledge about Medical Varmalogy is needed to exhibit the Siddha 
pathology. It is further needed to execute Thadaval Murai (Massage).  Because each and 
every stroke advocated is based upon thuvathasa naadi, thasa vaayu, vaasi, ethirkalam, 
marukalam, adangal, adukkugal, sarappai, amirtha nilaigal, kona nilaigal. Treatment 
should be started considering the Naadi, Ethir Kaalam, Maru Kalam.  
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  
  
 
 

Adangals are the places of enormous energy storage.  They are used for emergency 
treatment to revive a person from unconsciousness.  When adangals are ineffective, 
thiravukols are advocated. Varmam texts describe in detail about 110 adangals and 13 
thiravukols. 
LOCATIONS OF VARMAM POINTS: 
Varmam Points in the body can be determined by  
 Anatomical location 
 Proportional Measurement 
 Graphical measuring method 
 Locating by reference to adjacent Varmam points 
 Location by Classification 
 Finger breadth Measurement Method 
 Thread - Measurement Method 
VARMAM STIMULATION FOR CAGANA VAATHAM: 
The following Varmam points will be given thrice in a week for cagana vaatham 
1).Sara Mudichu Varmam: 








 

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It is located at the back in the cervical prominence, at the C7- T1 junction. 
 
2).Kakkattai Kaalam. 

 


 
 




 

It is located in the supraclavicular fossa. 
 
  


 
 
  

 The above verse from varma sootcham explains the physiological functions of 
kakkatai kalam. It reveals that kakattai kalam supplies energy and acts as an anchorage to 
the whole body below the neck and it helps in the movement of neck. 




 




 
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 The above lines from varma kaandam describe the technique of stimulation of 
kakkatai kalam. 



 

Varma sootcham reveals the clinical symptoms of any energy loss to this varmam leads to 
weakness of the upperlimbs, radiculopathy with numbness and movement restriction. 
3).chavvu Varmam: 
   








 





 
 It is located medially in the upper arm down the meeting place of the shoulder and 
the axilla. The narambu traversing this region helps in the movement of the hand and vil 
visai travels through this point strengthens the shoulders. 
4).Kavuli Kaalam: 








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




 

It is located in the first web space between the thumb and index finger. It surpasses 
the blood vessels supplying posterior part of the head and suzhiyadi and it gives strength to 
the shoulder joint. 
5).Manibantha Varmam
,
 







It is located in the middle of the wrist joint  
 
  
The above lines reveal the application method of manibantha varmam. 
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
  MATERIALS AND METHODS 
 
STUDY TYPE   : An open clinical trial.  
STUDY PLACE:    : Ayothidoss Pandithar Hospital, 
National Institute of Siddha,  
Tambaram sanatorium, Chennai-47.  
STUDY PERIOD   : 12  months   
SAMPLE SIZE    40  patients 
(20 patients with Trial Medicine 
20 patients Trial Medicine with Varmam) 
TRIAL DRUGS: 
INTERNAL MEDICINE:  
Drug    : SIGAMANI CHOORANAM 
Reference book              : Kannusamy parambarai vaidhyam 
Page No    : 118 
Dosage         : 1gm (Thirikadi alavu) bds/after food 
Adjuvant     : water 
Duration      : 20 days 
Edition    : fifth print-2006 
Author    : C.Kannusamy pillai  
Publication    : B.Rathna nayakkar & sons 
 
PREPARATION OF TRIAL DRUGS: 
 
Ingredients: 
 
Arugam ver (Cyonodon dactylon)  
                   
Veppam pattai ( Azaridacta indica,A.juss)         Each 4 palam(140gms) 
Narsangan ver pattai (Azima tetracantha,lam)                
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Chukku (Zingiber officinale,Roscoe) 
Omam (Carum copticum,linn)  
Narseeragam (Cuminum cyminum,linn) 
Thippili (Piper longum,linn) 
Milagu (Piper nigrum,linn) 
Poolangkizhangu (Curcuma zeodora,Roscoe)          each ½ palam  (17.5gms) 
Arathai (Alpinia galanga,linn) 
Vaalmilagu (Piper cubeba,linn) 
Vaivilangam (Embelia ribes,Burm.f) 
Parangisakkai (Smilax china,linn) 
Kurosaaniomam (Hyoscyamus niger,linn) 
Kadukurogini (Veratri virdi Rhizome) 
Akkarakaram (Anacyclus pyrethrum,linn)              
              
Siruthekku (Cleodendrum serratum) 
Kirambu (Syzygiyum aromaticum,linn)                     each ½ kazhanju (2.56gms) 
Jaathikaai (Myristica fraganans)       
Elam (Eletteria cardomum,linn) 
Karunjeeragam (Nigella sativa,linn) 
Lavangapattai (Cinnamomum verum) 
Jaathipathiri (Myristica fragnans,houtt) 
Koshtam (Costus specious)                              
PURIFICATION OF RAW DRUGS: 
1). Arugamver:  
  Dried under sunlight.  
2). Veppampattai:  
 Gently scraped the outer layer of the bark. 
3). Narsanganverpattai:  
  Gently scrapped the outer layer of the drug dried under sunlight. 
41 
 
4). Chukku:  
 Fried in lime stone water and  peeled  the outer portion. 
5). Omam:  
 The drug soaked in lime stone water and then dried.  
6). Narseeragam: 
 Removed the dust particles and dried under sunlight. 
7). Thippili: 
 The drug Soaked in lemon juice and dried.  
8). Milagu: 
 The drug soaked in butter milk and fried. 
9). Poolankizhangu: 
 Washed with pure water and then peeled out the outer layer. 
10). Arathai: 
  Scrapped the outer layer and then dried under sunlight. 
11). Vaalmilagu: 
  Gently removed the knob of vaalmilagu and dried under direct sunlight. 
12). Vaaivilangam: 
 Removed the dust and dried under sunlight. 
13). Parangisakkai: 
 Powdered and purified with milk by steaming method. 
14). Kurosaani omam: 
 Removed the dust particles. 
15). Kadugurogini: 
  Soaked in neem leaf juice or nochi leaf juice for 3 hours and then dried under 
sunlight.      
16). Akkarakaaram: 
 Scraped out the outer layer.   
42 
 
17). Sirutheku: 
 Removed the dust and dried under sunlight. 
18). Kiraambu: 
 Removed the dust and dried under sunlight. 
19). Jaadhikkai: 
 Removed the dust and dried under sunlight.  
20).Elam: 
 Removed the dust and dried under sunlight. 
21).Karunseeragam: 
    Drug soaked in lime water and dried.  
22).Elavangapattai: 
 Removed the dust and dried under sunlight. 
23).Jaadhipathiri: 
 Removed the dust and dried under sunlight. 
24).Koshtam:    
  Removed the dust and dried under sunlight. 
        (REF: Sarakku Suthimurai) 
 
METHOD OF PREPARATION: 
 1). The drugs which is mentioned above ingredient no.1 is made into small 
pieces and allowed to boil in the drug milk mixture under low flame without evaporating 
the whole milk then dried in sunlight and powdered it finely.  
 2). Rest of the drugs should be roasted and powdered along with above 
powdered drug and filtered through a dry clean cloth (Vasthirakayam). 
 3). Finally finishing the whole procedure to adding equal quantity of sugar 
(Naattu Sarkarai) to the drug.  
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DRUG STORAGE: 
The trial drug Sigamani Chooranam is stored in clean dry air tight container and it 
is dispensed to the patients in packets. 
EXTERNAL MEDICINE: 
 
Drug    :   “ARKKASHEERATHY THYLAM” 
Dosage     :  Q.S(for external application) 
Reference    :  Siddha vaithiya thirattu 
Page no    :  261 
Edition    : 2009 
Author    :           Dr.Ka.Na.Kuppusamy muthaliyar, 
               Dr.Ka.Su.Utthamarayan 
Publication    :           Kannan press private limited. 
 
B. EXTERNAL MEDICINE: 
Ingredients: 
Erukkampaal (milk of Calotropis gigantea) 
Erukkanilaisaaru (juice of leaves Calotropis gigantea) 
Sathurakallipaal (milk of Euphorbia antiqurom)    
Sathurakallisaaru (juice of Euphorbia antiqurom)   Each 5  
Pirandairasam (juice of Cissus quadrangularis)   palam (875gms) 
Parpadaga kudineer (decotion of Indoneesiella echioides) 
Merugankizhangu saaru (juice of Dioscorea esculenta)                  
Nallennai (oil of Sesamum indicum)        10 palam (350gms) 
Saerangkottai (Semicarous anacardium)     5   palam (875gms) 
Naervaalam (Croton tiglium)                1/2 palam (17.5 gms) 
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PURIFICATION OF DRUG:  
1). Saerangakottai:  
            Removed the knob of serangkottai and boiled in cowdung water (Saanappal).  
   (Ref: Gunapadam mooligai vaguppu) 
2). Naervaalam: 
           Boiled the drug in cowdung water and then soaked in  lemon juice after that 
removed the inner portion and then fried with ghee. (Ref: Marunthu Sei iyalum kalaiyum) 
METHOD OF PREPARATION: 
                     Mix all the ingredients together and boiled it in low flame and allowed it to 
attain favorable consistency (Manal Patham).  
DRUG STORAGE:  
                   The trial drug “Arkkasheerathy thylam” is stored in clean dry bottles and 
distributed in dry plastic container. 
VARMAM POINTS: 
 
     1). Mudichu 
   2). Kakkattai  
   3). Chavvu 
   4). Kavuli 
   5). Manibandham 
 
SUBJECT SELECTION: 
                  Patients reporting with symptoms of inclusion criteria will be subjected to 
screening test and documented using screening proforma. 
 
INCLUSION CRITERIA: 
 Age: 20 - 60Yrs 
 Sex: Both male and female, transgender. 
 Pain present in the cervical region radiating to the back of the head,  
     top of the shoulders, shoulder blades, upper arms and hands.  
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 Numbness and paraesthesia. 
 Difficulty in flexion and extension of neck. 
 Degenerative changes of cervical vertebra. 
 Patients willing to undergo radiological investigation and Laboratory         
     investigations. 
 Patients willing to sign the informed consent.  
 
EXCLUSION CRITERIA: 
 
 Spondylolisthesis 
 Rheumatoid arthritis  
 Cervical injury 
 Tuberculous arthritis 
 Cervical myelopathy 
 Cervical rib 
 Torticollis (wry neck)  
 Pyogenic bone infection 
 Vertebral fracture 
 Tumour in vertebral body              
 Osteochondritis 
 Ankylosing spondylitis 
 Sexually transmitted disease. 
 
WITHDRAWAL CRITERIA: 
 
 Intolerance to the drug and development of adverse reactions during trial. 
 Poor patient compliance and defaulters. 
 Patient turning unwilling to continue in the course of clinical trial. 
 Occurrence of any serious illness 
TESTS AND ASSESSMENTS: 
A. Clinical assessment  
B. Laboratory investigations 
C. Radiological investigations 
D. Siddha system assessment 
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A. CLINICAL ASSESSMENT: 
 Tenderness  
 Pain in nape of neck 
 Numbness 
 Difficulty in flexion and extension 
 Difficulty in lateral rotation 
 Neck Stiffness  
 Radiating pain. 
 
B. LABORATORY INVESTIGATION: 
 
Blood : 
 Hb 
 Total WBC Count 
 DC-   
        1. Polymorphs 
        2. Lymphocytes  
        3. Eosinophil  
        4. Monocytes  
         5. Basophils  
 Total RBC count 
  ESR 
 ½ Hr:                  
 1 Hr: 
 Blood sugar 
          Fasting :    
         Post prandial :  
Urine: 
 
 Albumin 
 Sugar  
Fasting            : 
Post prandial   : 
 Deposit 
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Renal function tests: 
 
 Urea 
 Creatinine 
 
Liver function tests: 
 
 Serum total bilirubin 
 Direct bilirubin 
 Indirect bilirubin 
 Serum Alkaline phosphatases 
 SGOT 
 SGPT 
 
 Lipid profile: 
 
 Total cholesterol 
 TGL 
 LDL 
 VLDL 
 HDL         
 
 SPECIFIC INVESTIGATIONS: 
 
 CRP 
 ASO TITRE 
 RA FACTOR 
 
C.SIDDHA PARAMETERS: 
    Envagai thervugal: 
 Naadi 
 Sparisam 
 Naa 
 Niram 
 Mozhi 
 Vizhi  
 Malam 
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 Moothiram 
A. NeerkKuri 
B. Neikkuri 
 
C. RADIOLOGICAL INVESTIGATION 
  X-ray for cervical region  
  AP & Lateral view 
 
DATA COLLECTION FORMS: 
  Required information will be collected from each patient by using 
the following forms: 
FORMS:  
Form I    Screening and selection Proforma  
Form II    History taking & Clinical assessment Proforma  
Form III    Laboratory investigation Proforma  
Form IV  Drug compliance form 
Form V  Patient information sheet 
Form VI  Consent form 
Form VII  Withdrawal form  
Form VIII  Dietary Advice form  
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PATIENT SCREENING 
Inclusion/Exclusion 
 
INCLUSION CRITERIA EXCLUSION CRITERIA 
EXCLUDED FROM TRIAL 
METHODOLOGY 
       STUDY NUMBER 
     HISTORY TAKING 
LAB INVESTIGATION 
 TRIAL DRUG  
CLINICAL ASSESSMENT 
OUTCOME 
INFORM ABOUT STUDY 
AND TRIAL DRUG 
 
INFORMED CONSENT  
 
ADVERSE REACTION 
ADVICED TO TAKE 
TREATMENT IN OPD 
ABNORMAL VALUES 
VALUES 
FURTHER MANAGEMENT 
OF ADVERSE DRUG 
REACTION 
PHARMACOLOGICAL 
ASSESSMENT INFORMED TO PHARMACO 
VIGILANCE 
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STUDY ENROLLMENT: 
Patients reporting at the OPD with clinical features of pain in nape of the neck 
radiating to upper limbs, stiffness are chosen for enrollment based on the inclusion 
criteria. 
The patients who are enrolled had been informed (Form V) about the study, trial 
drug, possible outcomes and the objectives of the study in the language and terms 
understandable to them and then informed consent would be obtained in writing from 
them in the consent form (Form VI). 
Complete clinical history, complaints, duration, examination findings and 
laboratory investigations - would be recorded in the prescribed Proforma. Screening Form- 
I would be filled up: Form –II and Form –III would be used for recording the patients 
history, clinical examination of symptoms, signs and laboratory investigation. 
  If  there is any abnormal laboratory reports obtained then the patient excluded from 
that study. Patients would be advised to take the trail drug and to follow the 
appropriate dietary advice (Form VIII). 
 
CONDUCT OF THE STUDY: 
On the first day of the treatment Purgation had been given with Agasthiyar 
kuzhambu - 200 mg early morning with Ginger juice for balancing the vitiated 
humous. The next day onwards the trial drugs Sigamani Chooranam (internal) 
Arkkasheerathy Thylam (external) would be given for 45 days. 20 patients would be 
given varmam treatment along with trial medicine and remaining 20 would be given 
trial medicine only. If there is a need of IP the patient would be admitted for 
clinical assessment. 
For out-patients, the trial drugs had been given in the Out-patient Department 
of Sirappu Maruthuvam of National Institute of Siddha. The out-patients would be asked 
to have a regular follow-up in the OP Department once in 7 days. (Form IV) In each and 
every visit, the clinical assessment had been recorded in the prescribed proforma. The 
laboratory investigations would be done before and after treatment and recorded in the 
prescribed format. At the end of the trial the patients are advised to have follow-up for 2 
months Defaulters would not be allowed to continue and had been withdrawn (Form VII) 
from the study. 
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DATA ANALYSIS: 
 After enrolling the patient for the study, a separate file for each patient will be 
opened and all forms will be kept in the file. Study No. and Patient No. will be written on 
the top of file for easy identification. Whenever the patient visits OPD during the study 
period, the respective patient‟s file will be taken and necessary entries will be made at the 
assessment form or other suitable form.  The screening forms will be filed separately.  The 
data recordings will be monitored for completion and adverse event by HOD. All forms 
will be further scrutinized in presence of Investigators by Sr. Research Officer (Statistics) 
for logical errors and incompleteness of data to avoid any bias.  No modification in the 
results is permitted for unbiased report. 
PHARMACO VIGILANCE: 
ADVERSE EFFECT/SERIOUS EFFECT MANAGEMENT 
 If the trial patient develops any adverse reaction, he/she would be immediately 
withdrawn from the trial and proper management will be given in OPD of National 
Institute of Siddha and the same will be informed to the Pharmaco-vigilance (FormVII) 
committee of NIS. 
OUTCOME: 
The outcome will be assessed by using Universal Pain assessment scale      
(before and after treatment). 
 
UNIVERSAL PAIN ASSESMENT SCALE: 
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Grade 0    :   No Pain             0 - Good improvement 
Grade 1-3 :   Mild pain             1-3 - Moderate improvement   
Grade 4-6 :   Moderate pain           4-6 - Mild improvement 
Grade 7-10 :   Severe pain            7-10 - No improvement 
 
ETHICAL ISSUES: 
1. To prevent any infection, while collecting blood sample from the patient, 
only disposable syringes, disposable gloves, with proper sterilization of laboratory   
equipment will be used.      
2. No other external or internal medicines will be used, other than the trial 
drug for CAGANA VAATHAM. There will be no infringement on the rights of the patient. 
3. The data collected from the patient will be kept confidential.  
4. After getting the consent of the patient only (through consent form in their 
own vernacular language) they will be enrolled in the study. 
5. Treatment would be provided free of cost. 
6. In any adverse reaction observed during the trial the patients will be      
withdrawn and given alternative treatment at National Institute of Siddha for further 
management.  
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             PROPERTIES OF TRAIL DRUG 
                   «Ú¸ý §Å÷ 
Tamil name     : «ÚÌ    
Botanical name   : Cyonodon dactylon 
Family     : Poaceae 
Parts used    : Herbs & Root Stalks 
Í¨Å     :  þÉ¢ôÒ 
¾ý¨Á    : ¾ðÀõ 
À¢Ã¢×     : þÉ¢ôÒ 
Chemical constituents   : Ergonorine, Ergine 
Therapeutics actions   : Astringent, Emolient, Styptic, Diuretic 
¦À¡Ð Ì½õ: 
 
 “«Ú¸õÒø Å¡¾À¢ò¾ ³Â§Á¡ Ë¨Ç 
 º¢Ú¸ «ÚìÌÁ¢ýÛï ¦ºôÀ «È¢×¾Õõ 
 ¸ñ§½¡ ¦Â¡Î¾¨Ä§¿¡ö ¸ñÒ¨¸Â¢ Ãò¾À¢ò¾õ 
 ¯ñ§½¡ ¦Â¡Æ¢ìÌ Ó¨Ã”. 
 
                      §ÅõÒ 
Tamil name     : §ÅõÒ 
Botanical name   : Azaridacta indica 
Family     : Meliaceae 
Parts used    : Whole tree 
Í¨Å     :  ¨¸ôÒ 
¾ý¨Á    : ¦ÅôÀõ 
À¢Ã¢×     : ¨¸ôÒ 
Chemical constituents   : Azadiractin, Nimbin, Tannin, 
    Margositostrol, Margosine, Nimbinin, Nimbidin. 
Therapeutics actions   : Antihelmenthic, Stimulant. 
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¦À¡Ð Ì½õ: 
 
“¸¢ÕÁ¢Ìð¼õ Á¡ó¾í ¦¸ÎÅ¢¨¼ïÍ Ã¸íû 
¦À¡ÕÁ¢ÂÁ ÝÃ¢¨¸Â¢ý Òñ¸û ´ÕÁ¢ì¸ 
¿¢õÀò ¾¢¨ÄÂ¢Îì¸ ¿£ÎÄ¸¢ø ¿£í¸¡Áø 
¸õÀò ¾¢¨ÄÂ¢Õì¸ì ¸¡ñ”. 
 
                     ºí¸ý 
Tamil name     : ºí¸õ ¦ºÊ     
Botanical name   : Azima tetracantha 
Family     : Salvadoraceae 
Parts used    : Root, Bark, Leaves, Milk 
Í¨Å     :  ¨¸ôÒ 
¾ý¨Á    : ¦ÅôÀõ 
À¢Ã¢×     : ¸¡÷ôÒ 
Chemical constituents   : Azcarpine, Azimine, Carpaine. 
Therapeutics actions : Antipyretic, Diuretic, Stimulant, Astringent, 
 Tonic, Expectorant. 
¦À¡Ð Ì½õ: 
 
“Å£ì¸õ ¸ÃôÀ¡ý Å¢¾¡¸õ ¸¢Ãó¾¢ÌýÁõ 
°ì¸Á¢Ì Ý¨ÄÅ¡ö §Å¡ÎÀ¢ò¾õ ¾¡ìÌÅ¢¼õ 
Å£Ú§Á¡ ¸ñÐÄíÌõ Å£ÍÀº¢ Ãò¾Óñ¼¡õ 
ÜÚºí¸õ §ÅÃ¢¨Ä ¸ðÌ”. 
 
                       ÍìÌ 
Tamil name     : ÍìÌ     
Botanical name   : Zingiber officinale 
Family     : Zingiberaceae 
Parts used    : Scraped and dried rhizomes 
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Í¨Å     :  ¸¡÷ôÒ 
¾ý¨Á    : ¦ÅôÀõ  
À¢Ã¢×     : ¸¡÷ôÒ 
Chemical constituents   : Phellandrene, Gingerol, Gingerin 
Therapeutics actions  : Sialogogue, Stomachic, Carminative,  
  Stimulant, Rubefacient 
¦À¡Ð Ì½õ: 
“Ý¨Ä¨Áó¾õ  ¦¿ï¦ºÃ¢ôÒ §¾¡¼§Áô ÀõÁÆ¨Ä 
ãÄõ þ¨ÃôÀ¢ÕÁø ãìÌ¿£÷ Å¡Ä¸À 
§¾¡¼Á¾¢ º¡¨Ãó ¦¾¡¼÷Å¡¾ ÌýÁ¿£÷ò 
§¾¡¼õ¬ Áõ§À¡ìÌï ÍìÌ”. 
 
                   µÁõ 
Tamil name     : µÁõ    
Botanical name   : Carum copticum 
Family     : Umbelliferae (Apiaceae) 
Parts used    : Seeds 
Í¨Å     :  ¸¡÷ôÒ 
¾ý¨Á    : ¦ÅôÀõ 
À¢Ã¢×     : ¸¡÷ôÒ 
Chemical constituents   : Tymol, Aromatic Oil 
Therapeutics actions   : Stomachiac, Antispasmodiac,Carminative,  
      Antiseptic, Stimulant, Tonic, Sialogogue.  
¦À¡Ð Ì½õ: 
“º£¾ÍÃí ¸¡ºí ¦ºÃ¢Â¡Áó ¾õ¦À¡ÕÁø 
§À¾¢Â¢¨Ãî ºø¸ÎôÒ §ÀÃ¡Áõ µ¾¢ÕÁø 
Àø§Ä¡ÎÀø ãÄõ À¸Á¢¨Å§¿¡ ¦Âó¦ºÔ§Á¡ 
¦º¡ø§Ä¡Î§À¡õ µÁ¦ÁÉî ¦º¡ø”. 
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                        º£Ã¸õ 
Tamil name     : º£Ã¸õ   
Botanical name   : Cuminum cyminum 
Family     : Umbelliferae (Apiaceae) 
Parts used    : Seeds and essential oil 
Í¨Å     :  ¸¡÷ôÒ, þÉ¢ôÒ 
¾ý¨Á    : ¾ðÀõ 
À¢Ã¢×     : þÉ¢ôÒ 
Chemical constituents   : Thymene, Cuminol, Cymene 
Therapeutics actions   : Carminative, Stimulant, Stomachiac,  
      Astringent 
¦À¡Ð Ì½õ: 
 
“À¢ò¾¦ÁÛõ Áó¾¢Ã¢¨Âô À¢ýÉô ÀÎ¾¢ÂÅý 
ºòÐÕ¨Å ÔóÐÈóÐ º¡¾¢òÐ Áò¾ÉÛõ 
Ã¡º¦ÉÔ Á£¦ÅýÚ ¿ñ¨Àô ÀÄôÀÎò¾¢ 
§À¡ºÉÌ ¼¡Ã¢¦ºÔõ §À¡÷”. 
 
                  ¾¢ôÀ¢Ä¢ 
Tamil name     : ¾¢ôÀ¢Ä¢     
Botanical name   : Piper longum 
Family     : Piperaceae 
Parts used    : Dried unriped fruits 
Í¨Å     :  þÉ¢ôÒ 
¾ý¨Á    : ¦ÅôÀõ 
À¢Ã¢×     : þÉ¢ôÒ 
Chemical constituents   : Piperine, Aromatic Oil 
Therapeutics actions   : Stimulant, Alterative, Diuretic, Carminative, 
      Aphrodisiac. 
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¦À¡Ð Ì½õ: 
 
“¬ºÉ§¿¡ö ¦¾¡ñ¨¼§¿¡ö ¬ÅÃ½ À¢ò¾Ó¾ø 
¿¡º¢Å¢Æ¢ ¸¡¾¢¨Å§¿¡ö ¿¡ðÒØ§¿¡ö Å£ÍÎÅ¢ 
Âí¸¡¨Äïº Éïº¢¨¾Ôõ «õÀ¡ö «Æ¢Å¢ýóÐõ  
¦À¡í¸¡Ä¡ïº ¨¿í¨¸Â÷§¸¡ð§À¡ø”. 
 
                   Á¢ÇÌ 
Tamil name     : Á¢ÇÌ     
Botanical name   : Piper nigrum 
Family     : Piperaceae 
Parts used    : Dried unriped fruits 
Í¨Å     :  ¨¸ôÒ, ¸¡÷ôÒ 
¾ý¨Á    : ¦ÅôÀõ 
À¢Ã¢×     : ¸¡÷ôÒ 
Chemical constituents   : Chavicine, Piperine, Piperidine, Piperetine,  
      Aromatic Oil 
Therapeutics actions   : Acrid, Carminative, Antiperiodic,   
      Rubefacient, Stimulant, Resolvent. 
¦À¡Ð Ì½õ:  
“«Ç¨ÅÔÈ¡ì¸¡Ãõ «¨¼ó¾¢ÕìÌõ Å¡¾ 
Å¢¨Ç¨Å¦Âø Ä¡ÁÚìÌõ ¦Áö§Â Á¢Ç¸¢ý¸¡ö 
¸ñ¼Å÷ìÌõ þýÀÁ¡õ ¸¡Ã¢¨¸§Â º£úãÄí 
¦¸¡ñ¼Å÷ìÌ ¿ýÁÕó¾¡í ÜÚ”. 
 
                    âÄ¡í ¸¢ÆíÌ 
Tamil name     : âÄ¡í ¸¢ÆíÌ    
Botanical name   : Curcuma zedoaria 
Family     : Zingiberaceae 
Parts used    : Tubers and leaves 
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Í¨Å     :  ¨¸ôÒ  
¾ý¨Á    : ¦ÅôÀõ 
À¢Ã¢×     : ¸¡÷ôÒ 
Chemical constituents   : Curcumin, Arabins, Albuminoids 
Therapeutics actions   : Stimulent, Carminative, Expectorant, Diuretic, 
      Alterative, Aromatic 
                      «Ãò¨¾ 
Tamil name     : «Ãò¨¾    
Botanical name   : Alpinia galanga 
Family     : Zingiberaceae 
Parts used    : Root 
Í¨Å     :  ¸¡÷ôÒ 
¾ý¨Á    : ¦ÅôÀõ 
À¢Ã¢×     : ¸¡÷ôÒ 
Chemical constituents   : Galangal, Galangin, Aromatic Oil 
Therapeutics actions   : Expectorent, Febrifuge, Stomachiac. 
¦À¡Ð Ì½õ: 
 
“¦¾¡ñ¨¼Â¢ü¸ð Îí¸Àò¨¾ò àÃò ÐÃò¾¢Å¢Îõ 
Àñ¨¼îº£ ¾ò¨¾ô ÀÈì¸ÊìÌõ ¦¸ñ¨¼Å¢Æ¢ 
Á¢ý§É ¸ÃôÀ¨É§Å È¡ìÌõ Àº¢¦¸¡ÎìÌõ 
¦º¡ý§½¡õ «Ãò¨¾î Í¸õ”. 
 
                    Å¡øÁ¢ÇÌ 
Tamil name     : Å¡øÁ¢ÇÌ    
Botanical name   : Piper cubeba  
Family     : Piperaceae 
Parts used    : Unripe fruit 
Í¨Å     :  ¸¡÷ôÒ 
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¾ý¨Á    : ¦ÅôÀõ 
À¢Ã¢×     : ¸¡÷ôÒ 
Chemical constituents   : Aromatic Oil, Olioresin, Cubebin, Arabic  
      Acid. 
Therapeutics actions   : Stimulant, Carminative, Diuretic, Expectorant. 
¦À¡Ð Ì½õ: 
 
“Å¡¾À¢ò¾ ³Âõ ÅÂ¢üÚ ÅÄ¢¾¡¨¸ï 
º£¾õ ÀÄ§¿¡ö º¢¨¾Ôí¸¡ñ §À¡¾ 
«¾£¾ ÀÉÁ¡õ «½í¸Ã§º ¿¡Ùó 
Ð¾¢Å¡ø Á¢Ç¸Õó¾î ¦º¡ø”. 
  
                       Å¡öÅ¢Çí¸õ 
Tamil name     : Å¡öÅ¢Çí¸õ    
Botanical name   : Embelia ribes 
Family     : Myrsinaceae 
Parts used    : Root bark 
Í¨Å     :  ¨¸ôÒ  
¾ý¨Á    : ¦ÅôÀõ 
À¢Ã¢×     : ¸¡÷ôÒ 
Chemical constituents   : Aromatic Oil, Fatty Oil, Embelic Acid,  
      Tannin, Christembine. 
Therapeutics actions   : Antihelmenthic, Carminative, Stomachic,  
      Stimulant. 
¦À¡Ð Ì½õ: 
 
“À¡ñÎÌð¼õ ÌýÁõ ÀÕóàÄ §¿¡öÅ¡¾ó 
¾£ñÎ ¾¢Ã¢Å¢¨¼ï º¢ÃóÐñ¼¡õ âñ¼ÁÊ 
§¿¡öÅ¢Çí¸ì ¸¡ð¼¡¾ Ññ¸¢ÕÁ¢ Â¡ºÉôÒý 
Å¡öÅ¢Çí¸í¸¡ð¼¡Å¢ÕÁ¡÷”. 
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                     ÀÈí¸¢ôÀð¨¼ 
Tamil name     : ÀÈí¸¢ôÀð¨¼    
Botanical name   : Smilax china 
Family     : Liciaceae 
Parts used    : Tuber 
Í¨Å     :  þÉ¢ôÒ 
¾ý¨Á    : ¾ðÀõ 
À¢Ã¢×     : þÉ¢ôÒ 
Chemical constituents   : Starch, Glucoside, Saponoin 
      Phytosterol 
Therapeutics actions   : Alterative, Anti Syphilitic,    
      Aphrodisiac, Depurative. 
¦À¡Ð Ì½õ: 
 
“¾¡¸õ ÀÄÅ¡¾ó ¾¡Ð¿ð¼õ ÒñÀ¢Ç¨Å 
§Á¸í ¸Ê¸¢Ãó¾¢ Å£úãÄó §¾¸Ó¼ý 
Ìð¨¼ À¸ó¾§Áü ¦¸¡ûÅÁÉõ §À¡õÀÈí¸¢ô 
Àð¨¼Â¢¨É ÔîºÃ¢ò¾¢ô À¡÷”. 
     
                     Ì§Ã¡º¡½¢ µÁõ 
 
Tamil name     : Ì§Ã¡º¡½¢ µÁõ   
Botanical name   : Hyoscyamus niger 
Family     : Solanaceae 
Parts used    : seeds 
Í¨Å     :  ¸¡÷ôÒ, º¢Ú¨¸ôÒ 
¾ý¨Á    : ¦ÅôÀõ 
À¢Ã¢×     : ¸¡÷ôÒ 
Chemical constituents   : Hyoscyamine, Scopolamine, Atropine,  
      Hyoscypikrin, Fatty Oil. 
Therapeutics actions   : Hypnotic, Sedative, Anodyne 
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¦À¡Ð Ì½õ: 
 
“¦ÅÌãò ¾¢ÃõÅ¡¾õ Å£Ã¢Â¿ð ¼õÒñ 
¯Ì§À¾¢ Ôð¸ÎôÀ¢ §É¡§¼ Á¢Ì¸ÃôÀ¡ý 
¾£Ã¡ì ¸ÀÁ¢¨Å§À¡õ ¦ºöÂÌ §Ã¡º¡É¢ÂýÈ¡ø 
Å¡Ã¡ ÁÂì¸ÓÚ Á¡ø”. 
 
                     ¸ÎÌ §Ã¡¸¢½¢ 
Tamil name     : ¸ÎÌ §Ã¡¸¢½¢    
Botanical name   : Picrorrhiza kurroa 
Family     : Scrophulariaceae 
Parts used    : Dried rhizomes 
Í¨Å     :  ¨¸ôÒ, ¸¡÷ôÒ 
¾ý¨Á    : ¦ÅôÀõ  
À¢Ã¢×     : ¸¡÷ôÒ 
Chemical constituents   : Picrorhizin, Kutkin, Kutkisterol 
Therapeutics actions   : Antiperiodic, Cathartic, Stomachiac 
¦À¡Ð Ì½õ: 
 
“Á¡ó¾ï ÍÃ¨ÁÂõ Å¡Ô¸Ãô À¡É¡¨Áï 
§º÷ó¾ÁÄì ¸ðÎ ¾¢Ã¢§¾¡¼õ §À¡ó¾¦À¡ðÎô 
ÒñÅÂ¢Ú §¿¡Â¢¨Å§À¡õ ¦À¡ü¦¸¡Ê¦Â §À¾¢Ôñ¼¡õ  
¾¢ñ¸ÎÌ §Ã¡¸½¢ìÌò §¾÷”. 
 
                     «ì¸Ã¸¡Ãõ 
Tamil name     : «ì¸Ã¸¡Ãõ     
Botanical name   : Anacyclus pyrethrum 
Family     : Asteraceae 
Parts used    : Root 
Í¨Å     : ¸¡÷ôÒ  
¾ý¨Á    : ¦ÅôÀõ 
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À¢Ã¢×     : ¸¡÷ôÒ 
Chemical constituents   : Pellitorin, Pyrethrin, Aromatic Oil 
Therapeutics actions   : Stimulant, Sialogogue 
¦À¡Ð Ì½õ: 
 
“«ì¸Ã¸¡Ãõ «¾ý§À÷ ¯¨Ãò¾ì¸¡ø 
¯ì¸¢Ãì¸¡ø «ò§¾¡¼õ µÎí¸¡ñ Óì¸¢ÂÁ¡öì 
¦¸¡ñ¼¡ø ºÄõ°Úõ ¦¸¡õÀ¨É¦Â ¾¡¸ÍÃõ 
¸ñ¼¡ø ÀÂó§¾¡Îí ¸¡ñ”. 
 
                 º¡¾¢ì¸¡ö 
Tamil name     : º¡¾¢ì¸¡ö    
Botanical name   : Myristica officinalis 
Family     : Myristicaceae 
Parts used    : Dried seed 
Í¨Å     :  ÐÅ÷ôÒ, ¸¡÷ôÒ 
¾ý¨Á    : ¦ÅôÀõ  
À¢Ã¢×     : ¸¡÷ôÒ 
Chemical constituents   : Volatile Oil, Fixed Oil, Fat, Starch, Mucilage 
Therapeutics actions   : Hypnotic, Sedative, Anodyne. 
¦À¡Ð Ì½õ: 
 
“¾¡Ð ¿ð¼õ §À¾¢ ºÕÅ¡º¢ Âïº¢Ã §¿¡ö 
µÐÍÅ¡ ºí¸¡ºõ ¯ð¸¢Ã½¢ §Å§¾¡ 
ÊÄì¸¡ö ÅÕõÀ¢½¢§À¡õ ²üÈÁÂø À¢ò¾í 
ÌÄì¸¡ ÂÕÅóÐÅ÷ìÌì ÜÚ”. 
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                   ¸Õïº£Ã¸õ 
Tamil name     : ¸Õïº£Ã¸õ     
Botanical name   : Nigella sativa 
Family     : Ranunculaceae 
Parts used    : Seeds and dried fruit 
Í¨Å     :  ¨¸ôÒ  
¾ý¨Á    : ¦ÅôÀõ  
À¢Ã¢×     : ¸¡÷ôÒ 
Chemical constituents   : Fatty Oil, Aromatic Oil, Melanthin, Metarbin 
Therapeutics actions   : Carminative, Diuretic, Emmenagogue,   
     Galactogogue, Anthelmintic, Staomachic.  
¦À¡Ð Ì½õ: 
 
“¸Õïº£ Ã¸ò¾¡ý ¸ÃôÀ¦É¡Î ÒñÏõ 
ÅÕïº¢Ã¡öô À£¿ºÓÁ¡üÚõ «Õó¾¢É¡ø 
¸¡öîºø ¾¨ÄÅÄ¢Ôí ¸ñÅÄ¢Ôõ §À¡ÓÄ¸¢ø 
Å¡öîº ÁÕó¦¾É§Å ¨Å”. 
 
                   þÄÅí¸ôÀð¨¼ 
Tamil name     : þÄÅí¸ôÀð¨¼    
Botanical name   : Cinnamomum zeylanicum 
Family     : Lauraceae 
Parts used    : Dried inner bark of the shoots from   
      truncated stalks and essential oil 
Í¨Å     :  ¸¡÷ôÒ, þÉ¢ôÒ    
¾ý¨Á    : ¾ðÀõ 
À¢Ã¢×     : þÉ¢ôÒ     
Chemical constituents   : Aromatic Oil, Cinnamic Acid, Tannin. 
Therapeutics actions   : Stimulant, Carminative, Aphrodisiac,  
      Antiseptic, Local Anaesthetic. 
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¦À¡Ð Ì½õ: 
 
“¾¡Ð ¿ð¼õ §À¾¢ ºÕÅÅ¢„õ ¬¸¢Â§¿¡ö 
â¾¸¢Ã ¸ïº¢Äó¾¢ô âîº¢Å¼ï º¡¾¢Å¢¼õ 
¬ðÎÁ¢¨Ãô §À¡ÊÕÁø ¬¸¢Â§¿¡öì Üð¼ÁÈ 
µðÎÁ¢Ä Åí¸ò ÐÃ¢”. 
 
                    º¡¾¢Àò¾¢Ã¢ 
Tamil name     : º¡¾¢Àò¾¢Ã¢ 
Botanical name   : Myrstica officinalis 
Family     : Myristicaceae 
Parts used     : Nutmegs 
Í¨Å     :  ¸¡÷ôÒ, ÐÅ÷ôÒ  
¾ý¨Á    : ¦ÅôÀõ  
À¢Ã¢×     : ¸¡÷ôÒ 
Chemical constituents   : Volatile Oil, Fined Oil, Fat, Starch, Mucilage 
Therapeutics actions   : Aphrodisiac 
¦À¡Ð Ì½õ: 
 
“º¡¾¢¾Õõ Àò¾¢Ã¢ìÌò ¾¡Àî ÍÃó¾½¢Ôõ 
µÐ¸¢ýÈ À¢ò¾õ ¯ÂÕí¸¡ñ ¾¡ÐÅ¢÷ò¾¢ 
Ôñ¼¡í ¸¢Ã¸½¢§Â¡ §¼¡¾ì ¸Æ¢îºÄÚõ 
Àñ¼¡í Ì¨È§Â À¸÷”. 
 
                    §¸¡‰¼õ 
Tamil name     : §¸¡‰¼õ    
Botanical name   : Costus speciosus 
Family     : Zingiberaceae 
Parts used    : Rhizomes 
Í¨Å     :  ¨¸ôÒ  
¾ý¨Á    : ¦ÅôÀõ  
À¢Ã¢×     : ¸¡÷ôÒ 
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Chemical constituents   : Rhizomes contains 2to 4% diosgenin,  
      corticosteroids, sex hormones, mucilage and 
      starch. 
Therapeutics actions   : Stomiachic, Expectorant, Stimulant,   
      Diaphoretic. 
¦À¡Ð Ì½õ: 
 
“¿¡ðÊÖÚ ¦Åð¨¼ ¿Îì¸õ ±Û§¿¡ö¸û 
§¸¡ð¼¦ÁÉî ¦º¡ýÉ¡ø Ì¨ÄÔí¸¡ñ ÜðÊü 
ÍÃ§¾¡¼ó ¦¾¡ñ¨¼§¿¡ö §¾¡Ä¡¾ À¢ò¾õ 
ÀÃ§¾ºõ §À¡§Á ÀÈóÐ”. 
                 º¢Ú§¾ìÌ 
Tamil name     : º¢Ú§¾ìÌ    
Botanical name   : Clerodendron serratum 
Family     : Verbenaceae 
Parts used    : Leaves, Root 
Í¨Å     :  ¨¸ôÒ,  
¾ý¨Á    : ¦ÅôÀõ  
À¢Ã¢×     : ¸¡÷ôÒ 
Chemical constituents   : Clerodin 
Therapeutics actions   : Stimulant, Sedative, Expectorant 
 
                        ¸¢Ã¡õÒ 
Tamil name     : ¸¢Ã¡õÒ     
Botanical name   : Eugenia caryophyllata  
Family     : Myttaceae 
Parts used    : Fruit,dried flower,buds and oil 
Í¨Å     :  ¨¸ôÒ  
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¾ý¨Á    : ¦ÅôÀõ  
À¢Ã¢×     : ¸¡÷ôÒ 
Chemical constituents   : Eugenol, Caryophyllene, Eugenin 
Therapeutics actions : Antispasmodiac, Carminative, Stomachic 
¦À¡Ð Ì½õ: 
 
“À¢ò¾ ÁÂì¸õ §À¾¢§Â¡Î Å¡ó¾¢Ôõ§À¡õ 
Íò¾Å¢Ãò ¾ì¸ÎôÒó §¾¡ñÚ§Á¡ ¦Áò¾ 
þÄÅí¸í ¦¸¡ñ¼ÅÕì §¸ü Í¸Á¡Ìõ 
ÁÄ¨Áí§¸ ¸ðÎ¦ÁÉ Å¡úòÐ”. 
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INGREDIENTS OF SIGAMANI CHOORANAM (INTERRNAL) AND 
ARKKASHERATHY THYLAM (EXTERNAL) 
 
Arugam ver (Cyonodon dactylon)   Veppam pattai (Azaridacta indica) 
     
   Narsangan ver pattai                       Chukku  
     (Azima tetracantha)         (Zingiber officinale) 
 
 
 
 
 
Omam (Carum copticum)  Narseeragam (Cuminumcyminum) 
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Thippili (Piper longum)                                   Milagu(Pipenigrum)  
  
 
 
 
 
 
 
Poolangkizhangu (Curcuma zeodora) Arathai (Alpinia galanga) 
  
 
Vaalmilagu (Piper cubeba)   Vaivilangam (Embelia ribes)  
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Parangisakkai (Smilax china)   Kurosaaniomam(Hyoscyamus niger) 
 
   
Kadukurogini (Veratri virdi)   Akkarakaram(Anacyclus pyrethrum) 
    
 
 
 
 
 
 
 
Siruthekku (Cleodendrum serratum)  Kirambu (Syzygiyum aromaticum) 
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Jaathikaai (Myristica fraganans)     Elam (Eletteria cardomum 
      
 
Karunjeeragam (Nigella sativa)   Lavangapattai (Cinnamomum verum) 
 
    
 
 
 
 
 
 
Jaathipathiri (Myristica fragnans)  Koshtam (Costus specious)                     
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Erukku (Calotropis gigantea)   Sathurakalli (Euphorbia antiqurom) 
   
 
Pirandai (Cissus quadrangularis) Parpadagam(Indoneesiella echioides) 
   
   Merugankizhangu                        Nallennai (Sesamum indicum)  
  (Dioscorea esculenta) 
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         Saerangkottai        Naervaalam (Croton tiglium) 
(Semicarous anacardium) 
 
   
 
 
 
 
 
 
 
 
TRAIL DRUG 
 
SIGAAMANI CHOORANAM   ARKKASHEERATHY THYLAM 
(INTERNAL)     (EXTERNAL) 
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TOXICITY STUDIES OF SIGAMANI CHOORANAM: 
The following in vivo toxicity studies were carried out on SIGAMANI 
CHOORANAM (SMC) by using Organization for Economic Co-operation and 
Development (OECD) guidelines. 
REPEATED DOSE 28 DAYS ORAL TOXICITY STUDY (OECD guidelines -407): 
 The toxicity study was carried out at National Institute of Siddha, Chennai -47. The 
study was done after getting permission from the Institutional Ethical Committee. (IAEC 
Approved No: NIS / IAEC-VI / 24042018 / 10.     
DESCRIBTION OF METHOD: 
SELECTION OF ANIMALS: 
 Animals were selected as per guidelines. The Wistar Albino Rats of weighting 150-
200 mg were obtained from authorized animal breeders of the animal laboratory in 
TANUVAS, Madhavaram, Chennai and stocked in the animal house at National Institute of 
Siddha, Chennai -47. Healthy adult animals of Wistar Albino Rats, both sex used in 
Repeated Dose-28 days oral toxicity study. The female animals used in nulliparous and non-
pregnant. 
 HOUSING AND FEEDING CONDITION : 
 The temperature in the experimental animal room- 22° C (±3°C) 
 Humidity :60 ±10% 
 Lightening: Artificial, the sequence being 12 hours light,12 hours dark. 
 The animals were housed in Polypropylene cage provided with bedding of 
husk. 
 The animals had free access to RO water. 
 For feeding, standard pellet diet.  
PREPARATION OF ANIMALS: 
 The animals were randomly selected to permit individual identification by cage 
number and individual marking on the fur of each animals with picric acid. The animals 
were kept in their cages for 7 days prior to dosing to allow for acclimatization to the 
laboratory conditions. The principles of laboratory animals care were followed. 
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TEST SUBSTANCES:  
           “ SIGAMANI CHOORANAM (SMC)” 
ROUTE OF ADMINISTRATION:  
 Oral route was selected because it is the normal route of clinical administration. 
 
 
 
 
 
 
 
 
 
 
 
 
REPEATED 28 DAYS ORAL TOXICITY STUDY: 
EXPERIMENTAL ANIMALS: 
GROUPING OF ANIMALS: 
Repeated dose 28 days oral toxicity study was carried out at different dose levels. 
The animals in both sexes were divided into four groups (Group I, II, III & IV). Each group 
consist of 10 animals (5 males and 5 females). 
Group I served as a control group and other three groups (I, II & III) were treated as 
test group. 
 
 
 
Species and strain  :          Wistar Albino Rats 
Sex                               :    Male and Female 
Age/Weight                  :   8-12 weeks,150-200 gm 
Test guidelines            :   OECD guidelines -407 
Groups /Treatment       :   Grouped by randomization  
Study duration             :    28 days 
Number of animals       :    3 Female+ Male / Group 
        40 animals 
Control group               :    Vehicle (Water) 
Route of administration :     Oral     
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The doses (low, mid and high) were fixed from the result of Acute toxicity study 
TABLE 1: GROUPING OF ANIMALS IN 28 DAYS ORAL TOXICITY STUDY: 
GROUPS NO. OFRATS 
Group I:  Control -   Vehicle (Water) 10(5M+ 5F) 
Group II: Test drug (SMC) - Low dose 450 mg/kg b. wt. 10(5M + 5F) 
Group III: Test drug (SMC) - Mid dose 900 mg/kg b. wt. 10(5M + 5F) 
Group IV: Test drug (SMC) - High dose 1800 mg/kg b. wt. 10(5M + 5F) 
Total   40 (20 Female + 20 Male) 
ADMINISTRATION OF DOSE: 
The animals were dosed with drug daily for a period of 28 days. The test drug 
administrated by oral gavage and this was done in a single dose to the animals, once in daily 
for 28 days. 
OBSERVATION: 
Animals were noted twice daily for morbidity and mortality during the experimental 
period. 
Body weight changes: 
 During the study period, body weight of all animals, food and water consumption 
per day were calculated weekly once. 
 Blood collection and laboratory investigations: 
 At the end of 28 days, blood samples were collected just prior to euthanasia in all 
overnight (12 hours) fasted rats from abdominal aorta using Sodium heparin containing 
vacutainer (200 IU/ml) for blood chemistry and Potassium EDTA containing vacutainer 
(1.5 mg/ml) for Hematology sample. Blood sample were processed by the following 
investigation. 
 Complete blood count 
 Renal function test 
 Liver function test 
 Lipid profile 
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NECROPSY: 
At the end of the 28 day, after blood collection, the animals were sacrificed by 
excessive anaesthesia. Animals were subjected to gross necropsy. Gross necropsy includes 
examination of the external surface of the body, all orifices, cranial, thoracic and abdominal 
cavities and their contents. Organs like brain, eye, thymus, lungs, heart, spleen, liver, 
kidneys, adrenals, testes, uterus were collected from all animals and preserved in 10% 
buffered neutral formation. 
HISTOPATHOLOGY: 
Control and highest dose groups animals will be initially subjected to 
histopathological investigation. If any abnormality found in the highest dose group then the 
low and mid dose group will also be examined. Various organs (brain, heart, lungs, liver, 
kidney, spleen, stomach, bone) will be collected from all the animals and preserved in 10% 
buffered neutral formalin, sliced, 5 or 6μm sections and will be stained with Haematoxylin 
and Eosin. Examined for histopathological changes. 
STASTICAL ANALYSIS: 
Finding such as clinical sign of intoxication, body weight changes, food 
consumption, Hematology and biochemical parameters were subjected to one-way ANOVA 
followed by Dunnet „t‟ test using computer software programed graph Pad Instat-3. 
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28 DAYS REPEATED ORAL TOXICITY STUDY: 
FOOD (G/DAY) INTAKE OF ALBINO RATS EXPOSED TO SIGAMANI 
CHOORANAM (SMC): 
 Food consumption of the animal‟s significant difference in Food intake the test 
group animals were observed when compared with control group during the study period 
but they are within physiological limit. 
TABLE 2: Food (g/day) intake of albino rats exposed to SMC: 
 
Dose  
(mg/kg/ 
day) 
 
1
st
 day 
 
7
th
 day 
 
14
th
 day 
 
21
st
 day 
 
28
th
 day 
Control 47.5 ± 3.53 54.5 ±5.80 63.42 ±6.5 71.3 ±3.5 75.7 ±3.76 
Low dose 51 ±1.41 54.1 ±2.36 63.21 ±2.39 70.6 ±2.30 77.25 ±2.1 
Mid dose 40.5 ±0.70 42.83 ±1.52 50 ±1.94 55.6 ±3.08 66.7 ±5.55 
High dose 49.5 ±13.4 53.1 ±9.52 59.8 ±9.8 68.16 ±9.62 76.6 ±8.27 
 
Values were expressed as mean± S.D. for N=10 rats in each group one-way ANOVA 
followed by Dunnett‟s test. Significant indicates that *P<0.05,**P<0.0 
 
Fig :1 
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WATER (ml/day) INTAKE OF WISTAR ALBINO RATS EXPOSED TO 
SIGAMANI CHOORANAM (SMC): 
 Water consumption the difference in Water intake of control and test group of 
animals observed during the study period. (Table 8), There was significant difference occurs 
in the group low and mid at 28 days compared with control group. 
 
Table 3: Water (ml/day) intake of albino rats exposed to SMC 
Dose 
(mg/kg/day) 
 
1
st
 day 
 
7
th
 day 
 
14
th
 day 
 
21
st
 day 
 
28
th
 day 
Control 52 ±7.07 59.42 ±5.9 68.9 ±8.66 79.71 ±6.87 89.7 ±6.42 
Low dose 54.5 ±6.36 5.5 ±5.90 73.14 ±7.9* 84.14 ±9.06** 95.14 ±10 
Mid dose 41 ±1.41 46 ±3.32 55.4 ±2.97** 65.71 ±2.81** 78.35 ±4.49 
High dose 47.5 ±3.53 50.64 ±5.1 64.2 ±4.49** 76.2 ±5.70 91.4 ±5.40 
  
 Values were expressed as mean± S.D. for N=10 rats in each group one-way 
ANOVA followed by Dunnett‟s test. Significant indicates that *P<0.05,**P<0.01. 
Fig :2 
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BODY WEIGHT (g) CHANGES OF ALBINO RATS (MALE) EXPOSED TO SMC: 
Table : 4 
Dose 
(mg/kg/day) 
 
1
st
 day 
 
7
th
 day 
 
14
th
 day 
 
21
st
 day 
 
28
th
 day 
Control 137 ± 7.48 142 ±7.47 153.2 ±7.19 153.2 ± 6.47 172.2 ±9.79 
Low dose 135 ±7.75 141.8 ± 9.57 153.6 ± 8.66 161.2 ±8.1** 169.8 ±11.2 
Mid dose 138.6 ± 5.2 151 ± 6.89** 162 ±8.78** 171.4 ±9.43** 179.4 ±9.97* 
High dose 157 ±6.78** 166.4 ±7.68** 175 ±7.89 ** 184.2 ±7.27** 189.6 ±6.08** 
 
Values were expressed as mean± S.D. for N=10 rats in each group one-way ANOVA 
followed by Dunnett‟s test. Significant indicates that *P<0.05,**P<0.01. 
 
Fig :3 
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BODY WEIGHT (g) CHANGES OF ALBINO RATS (FEMALE) EXPOSED TO 
SIGAMANI CHOORANAM (SMC): 
Table:5 
Dose 
(mg/kg/day) 
1
st
 day 7
th
 day 14
th
 day 21
st
 day 28
th
 day 
Control 151 ±6.63 159.8 ±4.62 167.2 ±3.72 177 ±5.62 185.6 ±7.55 
Low dose 156 ±13.5 166 ±14.31 174.8 ±13.8* 182.4 ±14.0 191.8 ±12.2 
Mid dose 147 ±7.48 161.6 ±5.4 170.2 ±5.91 180.4 ±4.49 188.8 ±3.81 
High dose 157 ±6.78 165 ±8.41 174.4 ±7.44* 183 ±8.36 191.8 ±7.33 
 
Values were expressed as mean± S.D. for N=10 rats in each group one-way ANOVA 
followed by Dunnett‟s test. Significant indicates that *P<0.05,**P<0.01. 
Fig :4 
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EFFECT OF SIGAMANI CHOORANAM (SMC) ON HEMATOLOGICAL 
PARAMETERS 
 The results of hematological investigations conducted at the end of the study, the 
group revealed slightly significant changes in levels of hematological parameters, when 
compared with control group and post retrieval group. The Hematological parameters are 
normal, when compared with control group.  
Table: 6 
Parameter Control LD MD HD 
RBC (x10
6
µl) 7.49 ± 0.164 7.44 ± 1.056 8.25 ± 0.2201 8.44 ± 1.401 
WBC(x10
3
µl) 9.21 ± 1.450 7.25 ± 2.433 7.69 ± 1.600 8.31 ± 0.891* 
Platelets (x10
3
µl) 619 ± 4.23 558.6 ± 90.16 650 .1 ± 33.93 580.9± 110.7 
HGB(g/dl) 9.87 ± 0.45 10.15 ± 0.639 11.7 ± 0.388** 11.9 ± 0.611* 
Neutrophil 
(10
3
mm
3
) 
4.33 ± 1.334 2.69 ± 1.002** 1.73 ± 0.3860** 2.48± 0.7130** 
Lymphocyte (%) 86.98 ± 4.04 80.58 ± 10.89 77.17 ± 4.608* 64.82± 12.03** 
Monocyte (%) 1.79 ± 0.633 2.81 ± 1.564 2.93 ± 1.223 2.18 ± 1.027 
Eosinophil (%) 1.79 ± 0.694 1.71 ± 0.662 1.32 ± 0.364 1.48 ± 0.666 
Basophil (%) 1.02 ± 0.4142 0.7 ± 0.483 0.85 ± 0.424 0.81 ± 0.671 
MCH (pg) 19.6 ± 2.881 17.89 ± 1.670 20.45 ± 2.747 18.28 ± 4.22 
MCV (fl) 63.89 ± 2.337 65.5 ± 2.646 57.2 ± 1.917** 63.58 ± 5.621 
 
Values were expressed as mean± S.D. for N=10 rats in each group one-way ANOVA 
followed by Dunnett‟s test. Significant indicates that *P<0.05,**P<0.01. 
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EFFECT OF SIGAMANI CHOORANAM (SMC) ON RBC, WBC & HGB 
Fig : 5 
             
 
EFFECT OF SIGAMANI CHOORANAM (SMC) ON NEUTROPHIL, 
LYMPHOCYTE, MONOCYTE, EOSINOPHIL AND BASOPHIL 
Fig :6 
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EFFECT OF SIGAMANI CHOORANAM (SMC) ON BIOCHEMICAL 
PARAMETERS 
 Biochemical investigations were conducted at the end of the study and the results 
were recorded. In test groups there was significant changes present in biochemical 
parameters, when compared with the control group. At the values were normal biological 
limits. 
Table: 7 
Dose (mg/kg) Control LD MD HD 
Total cholesterol 
(mg/dl) 
119.9 ± 4.66 145.4± 
18.759** 
150.5 ± 7.305** 139.8 ± 5.15** 
HDL (mg/dl) 51.5 ± 2.061 65.1± 15.772** 59.8 ± 5.959* 56.7 ± 2.830 
LDL (mg/dl) 49 ± 4 57.7 ± 9.043 68 ± 15.28** 60.14 ± 3.20* 
VLDL (mg/dl) 16.11 ± 0.767 20 ± 5.468 18.68 ± 7.085 22.53 ± 4.467* 
Triglycerides(mg/dl) 31.7 ± 3.316 26.3 ± 10.85 39.5 ± 3.628 38.3 ± 8.056* 
 
Values were expressed as mean± S.D. for N=10  rats in each group one-way ANOVA 
followed by Dunnett‟s test. Significant indicates that *P<0.05,**P<0.01. 
Fig : 7 
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EFFECT OF SIGAMANI CHOORANAM (SMC) ON RENAL PARAMETERS 
 The results of the renal functions test conducted at the end of study, test groups 
revealed significant changes in levels of renal parameters, when compared with control 
group, and post retrieval group Renal function parameters towards normal, when compared 
with control group. 
Table:8 
DOSE (mg/kg) control LD MD HD 
BUN (mg/dl) 15.9 ± 1.577 14.5 ± 1.354 15.1 ± 3.381 14.1 ± 1.449 
Creatinine(mg/dl) 0.54 ± 0.23 0.4 ± 0.249 0.43 ± 0.240 0.59 ± 0.196 
 
Values were expressed as mean± S.D. for N=10 rats in each group one-way ANOVA 
followed by Dunnett‟s test. Significant indicates that *P<0.05,**P<0.01. 
Fig : 8 
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EFFECT OF SIGAMANI CHOORANAM (SMC) ON LIVER PARAMETER 
 The results of the liver function test conducted at the end of the study, test groups 
revealed significant changes in levels of liver parameters, when compared with control 
group, and post retrieval group Liver function parameters towards normal, when compared 
with control group. 
Table: 9 
Dose (mg/kg) Control LD MD HD 
Total 
bilirubin(mg/dl) 
0.26 ± 0.066 0.15 ± 0.052 0.21 ± 0.099 0.2 ± 0.105* 
SGOT(U/L) 84.9 ± 3.207 71.7 ± 8.92 98.7 ± 29.859 81.5 ± 3.922 
SGPT(U/L) 18.9 ± 1.445 31.6 ± 13.09 37.5 ± 6.132** 28.9 ± 6.190** 
Values were expressed as mean± S.D. for N=10 rats in each group one-way ANOVA 
followed by Dunnett‟s test. Significant indicates that *P<0.05,**P<0.01. 
Fig : 9 
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Pathology Report 
Sample Id: CFH 
Brain The CA zones of brain are filles with densely packed Pyramidal cells  
 
Heart Showing the normal histological structure of myocardium 
 
Lung Pulmonary alveoli and blood lumen appears normal 
 
Stomach Gastric epithelium and mucosa appears normal 
 
Liver Hepatic cords appears normal with radiating morphology 
 
Kidney Showing normal, intact renal tubules as well as renal glomeruli 
Spleen Central arterioles radiating around the red pulp were observed 
 
Uterus Endometrial gland, epithelium and blood vessels appears normal 
 
Ovary Follicular cells, cytoplasm and nucleus appears normal 
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Sample Id: CMH 
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Histopathology of Lung  
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Histopathology of Liver  
 
Low Power Magnification 10X   High Power Magnification 40X 
   
 
Histopathology of Kidney 
 
Low Power Magnification 10X   High Power Magnification 40X 
    
 
95 
 
Histopathology of Spleen  
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Pathology Report 
Sample Id : CMH 
Brain Showed normal architecture in both cortex and medulla where three layers of 
cerebellar cortex 
Heart Normal histology of myocardial tissue with prominent inter fiber distance 
 
Lung Bronchial opening appears regular with no signs of infiltration 
 
Stomach Mucosal wall appears normal with regular arrangement of connective tissue 
Liver Normal hepatocytes with no signs of necrosis 
 
Kidney Appearance of proximal and distal convolutes tubules was normal with no 
evidence of atrophy 
 
Spleen Regular appearance of red pulp is composed of a three dimensional meshwork 
of splenic cords and venous sinuses were observed 
 
Testes Histocytology of testicular tissue shows well differentiated germ cells with 
respect of spermatogonia includes spermatid and sperm were observed 
 
 
 
 
 
 
 
 
97 
 
 
Sample ID: SMC- HM 
Histopathology of Brain  
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Histopathology of Liver  
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Pathology Report 
Sample ID: SMC- HM 
Brain Morphology of neurons in CA1, CA2 and CA3 zones are normal 
 
Heart Normal histology of myocardial fibres with no evident of necrotic fibres 
evident 
 
Lung Normal alveoli with equidistant arrangement and prominent histology 
 
Stomach Normal stomach cyto architecture with no signs of ulceration and 
infiltration 
 
Liver Hepatic cords appears normal with radiating morphology 
 
Spleen Morphology of capsule, nodes, red and white pulp appears normal 
 
Kidney Appearance of proximal and distal convolutes tubules was normal with no 
evidence of atrophy 
 
Testes Section of testis of showing normal interstitial connective tissue with 
ovoid or polygonal leydig cells and flat myoid cells 
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Sample ID: SMC- HF 
Histopathology of Brain  
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Histopathology of Lung  
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Histopathology of Liver  
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Histopathology of Spleen  
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Histopathology of Ovary  
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Pathology Report 
Sample ID: SMC- HF 
Brain Regular marginal alignment on the neurons with promising histology were 
observed 
 
Heart Myocardial fibres appears normal elongated and rod shaped 
 
Lung Perivascular region appears normal, Alveolar septa and wall appeared 
widen and normal 
 
Stomach Appearance of Sub-mucosa and gastric glands appear normal 
 
Liver Cytoplasm appears normal with widen portal tract 
 
Spleen Regular appearance of red pulp is composed of a three dimensional 
meshwork of splenic cords and venous sinuses were observed 
 
Kidney No evidence of interstitial inflammation and lymphocyte accumulation 
 
Uterus Normal cyto architecture of uterine layers and glands were observed 
 
Ovary Sequential arrangement of granulosa cells around oocyte was normal and 
regular 
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OBSERVATIONS AND RESULTS 
 
1). Age 
2).Gender 
3).Gunam 
4).Bodyconstitution 
5).Paruvakaalangal 
6).Thinai 
7). Socio economic status 
8).Diet 
9).Occupation 
10).Duration of illness 
11).Onset of illness 
12).Distribution of Vatham 
13).Distribution of Pitham 
14).Distribution of Kabham 
15).Neikkuri analysis 
16).Analysis of UdalThathukal 
17).Analysis of Kanmenthiriyam 
18). Analysis of Naadi 
19).Analysis of Envagaithervu 
20).Clinical features 
21).Outcome measures 
22).Result of treatment 
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1.DISTRIBUTION OF CASES BY AGE : 
 
Table.1 
              AGE      NO. OF CASES PERCENTAGE% 
20-30 1 2.5% 
31-40 8 20% 
41-50 20 50% 
51-60 11 27.5% 
TOTAL 40 100% 
 
 
 
      Fig :1 
 
Inference: 
 Among 40 cases, the disease was found to be higher in the age group of 41-50 
years, 20 cases (50%). 
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2.DISTRIBUTION OF CASES BY GENDER: 
 
Table :2 
 
S.NO GENDER NO. OF 
CASES 
PERCENTAGE% 
1. Male 15 37.5% 
2. Female 25 62.5% 
   
                           
      Fig.2 
 
Inference: 
Among 40 cases, 62.5% (25) females and 37.5% (15) males are affected. 
 
3.DISTRIBUTION OF CASES BY GUNAM: 
Table 3 : 
GUNAM NO.OFCASES PERCENTAGE% 
Sathuvagunam 0 0% 
Rasathagunam 40 100% 
Thamogunam 0 0% 
Total 40 100% 
Inference: 
Among 40 cases, all of them were comes under Rasatha gunam.  
Males Females 
1 2
37.50%
62.50%
GENDER
PERCENTAGE%        
111 
 
4.DISTRIBUTION OF CASES BY BODY CONSTITUTION: 
 
Table 4: 
BODY CONSTITUTION 
 
NO.OF CASES PERCENTAGE% 
Vaathapitha thegi 20 50% 
Piththavathathegi 15 37.5% 
Kabavathathegi 05 12.5% 
 Total 40 100% 
 
      Fig.3 
 
Inference: 
Among 40 cases,Vathapitha Thegi 20 (50%), Pithavatha Thegi 15 (37.5%), 
Kabavatha Thegi 05 (12.5%). 
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5.DISTRIBUTION OF CASES BY KAALANGAL: 
 
 
Table.5 
 
 
 
     Fig.4 
Inference: 
Among 40 cases, most of the cases 20 (50%) were recruited in Munpanikalam 18 
(45%) in Pinpanikalam,2 (5%) in Elavaenirkalam. 
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6.DISRTIBUTION OF CASES BY THINAI (LAND): 
 
Table :6 
S.NO THINAI (LAND) NO. OF 
CASES 
PERCENTAGE(%) 
1.  Kurinchi (Hill) 02 5% 
2.  Mullai (Forest) 0 0% 
3.  Marutham (Fertile) 02 5% 
4.  Neithal (Coastal) 36 90% 
5.  Paalai (Dessert) 0 0 % 
 Total  40 100% 
 
  
       Fig :5 
 
Inference : 
 Among 40 cases, 36 (90%) cases were from Neithal (Coastal), 2(5%) cases from 
kurinchi (Hill), 2 (5%) cases from Marutham (fertile) 
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7.DISRTIBUTION OF CASES BY SOCIO ECONOMIC STATUS: 
 
 Table.7 
 
 
    Fig:6 
Inference: 
 Among 40 cases 30 (75%) were belongs to low economic status, 10 (25%) were 
belongs to middle economic status. 
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SOCIO ECONOMIC 
STATUS 
NO.OF CASES PERCENTAGE% 
LowEconomicStatus 30 75% 
ModerateEconomicstatus 10 25% 
HighEconomicStatus 0 0% 
Total 40 100% 
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8.  DISTRIBUTION OF CASES BY DIETARY HABITS: 
 
Table :8 
DIET NO.OF CASES PERCENTAGE% 
Vegetarian 02 5% 
Non-vegetarian 38 95% 
Total 40 100% 
 
 
     Fig.7 
Inference: 
 Among 40 cases 2(5%) were vegetarian ,38 (95%) were non-vegetarian. 
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9.DISRTIBUTION OF CASES BY OCCUPATION: 
Table.9 
OCCUPATION NO.OF CASES PERCENTAGE% 
Agriculture 1 2.5% 
Home maker 14 35% 
I.T sector 5 12.5% 
Train driver 1 2.5% 
Welder 2 5% 
Machinery work 1 2.5% 
Tailor 8 20% 
Export company labor 2 5% 
Security 3 7.5% 
Supervisor 3 7.5% 
Total 40 100% 
 
  
     Fig.8 
Inference : 
 The majority of patients 14 (35%) in this study were home maker. 
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10. DISRTIBUTION OF CASES BY DURATION OF ILLNESS: 
Table. 10 
DURATION NO.OF CASES PERCENTAGE% 
Within a year 10 25% 
1-2Years 10 25% 
2-5Years 20 50% 
5-10years 0 0% 
Morethan10years 0 0% 
 
 
      Fig.9 
Inference: 
 Among 40 cases, the prevalence was more in 20 cases (50%) for  2-5 years, 10 
cases suffered for (25%) 1-2 years, 10 cases (25%) suffered within a year. 
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11.DISTRIBUTION OF CASES BY ONSET OF DISEASE: 
 
Table :11 
ONSET NO.OF CASES PERCENTAGE 
Sudden 0 0 
Gradual 40 100 
Total 40 100 
 
 
 
     Fig.10 
 
Inference : 
Among 40 cases, all the  cases belongs to gradual onset. 
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12.DISTRIBUTION OF CASES BY VATHAM: 
Table.12 
VATHAM NO.OF CASES PERCENTAGE 
Praanan 0 0% 
Abaanan 0 0% 
Viyaanan 40 100% 
Uthaanan 0 0% 
Samaanan 40 100% 
Nagan 0 0% 
Koorman 0 0% 
Kirukaran 0 0% 
Devadhathan 0 0% 
Dhananjayan - - 
 
Inference: 
Among the 40 cases, it is observed that all the 40 cases (100%) were affected by 
Viyanan and samanan. 
13. DISTRIBUTION OF CASES BY PITHAM: 
 
Table.13 
PITHAM NO.OF CASES PERCENTAGE 
Analagam 0 0% 
Ranjagam 0 0% 
Saathagam 40 100% 
Prasagam 0 0% 
Alosagam 0 0% 
Total 40 100% 
 
Inference: 
Among 40cases, Saathagam was affected in all the cases. 
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14. DISTRIBUTION OF CASES BY KABHAM: 
Table.14 
KABHAM NO.OF CASES PERCENTAGE% 
Avalambagam 0 0% 
Kilethagam 0 0% 
Pothagam 0 0% 
Tharpagam 0 0% 
Santhigam 40 100% 
 
Inference: 
Among 40 cases  Santhigam  was  affected 40 (100%) 
15.DISTRIBUTION OF CASES BY UDAL THATHUKAL: 
 
Table.15 
 
 
 
 
 
 
 
 
 
Inference: 
Among the 40 cases, Saaram 40 (100%), Senneer 40 (100%), Oon 40 (100%), 
Kozhuppu 23 (57.5%), Enbu 40 (100%). 
 
  UDALTHATHUKAL       NO OF PATIENTS       PERCENTAGE% 
Saaram 40 100% 
Senneer 0 0% 
Oon 40 100% 
Kozhuppu 23 57.5% 
Enbu 40 100% 
Moolai 0 0% 
Sukilam / Suronitham 0 0% 
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16.DISTRUBUTION OF CASES BY KANMAENTHIRIYAM: 
Table.16 
KANMAENTHIRIYAM NO OF PATIENTS PERCENTAGE% 
Kai 40 100% 
Kaal 0 0% 
Vaai 0 0% 
Karuvai 0 0% 
Eruvai 0 0% 
 
Inference: 
Among 40 cases, kai was affected in 40 cases (100%). 
 
17.ANALYSIS OF CASES BY NAADI: 
 
Table17: 
 
NAADI            BEFORE                 AFTER 
NO. OF 
CASES 
% NO. OF 
CASES 
% 
Vathapitham 20 50% 19 47.5% 
vathakabam - - 1 2.5% 
Pithavatham 19 47.5% 20 50% 
Pithakabam 1 2.5% 1 2.5% 
Kabavatham - - - - 
Kabapitham - - - - 
Total 40 100% 40 100% 
     
Inference: 
 Among 40 cases, Before treatment vathapitham naadi were found in 20 (50%) 
cases, pithavatha naadi were found in 19 (47.5%) cases, pithakaba naadi were found in 1 
(2.5%). After treatment vathapitha naadi were found in  19 (47.5%) cases, vathakaba naadi 
were found in 1(2.5%) case, pithavatha naadi were found in 20 (50%), pithakaba naadi 
were found in 1(2.5%) case. 
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18.ANALYSIS OF CASES BY ENVAGAITHERVUGAL: 
 
Table.18 
 
ENVAGAITHERVUGAL NO.OFCASES PERCENTAGE% 
Naa 10 25% 
Niram 0 0% 
Mozhi 0 0% 
Vizhi 0 0% 
Sparisam 0 0% 
Malam 0 0% 
Moothiram 0 0% 
 
Inference: 
 Among 40 cases, Naa 10 cases (25%) was affected. 
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19. ANALYSIS OF CASES BY NEIKURI: 
Table.19 
 
PATTERN 
BEFORE  AFTER 
NO. OF 
CASES 
% NO. OF 
CASES 
% 
Aravenaneendathu–
Vaathaneer 
11 27.5% 13 32.5% 
Aazhipolparaviyadhu–
Piththaneer 
17 42.5% 10 25% 
Muthothunindrathu–
Kabaneer 
12 30% 17 42.5% 
 
  
     Fig.11 
 
Inference: 
 Among 40 cases Vaatha Neer were found in 11 cases (21.5%), Piththa Neer were 
found in 17 cases (42.5%), Kabha Neer were found in 12 cases (30) 
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20.DISTRIBUTION  CASES BY CLINICAL FEATURES: 
Table.20 
SYMPTOMS      NO. OF CASES PERCENTAGE % 
BT AT BT AT 
Radiating pain to upper 
limb 
40 05 100% 12.5% 
Tenderness 27 05 67.5% 12.5% 
Stiffness of cervical 
spine 
40 04 100% 10% 
Numbness&paraesthesia 26 04 65% 10% 
 
 
     Fig.12 
 
Inference: 
 Among 40 cases, Before treatment radiating pain and stiffness were present 40 
(100%) cases, tenderness present in 27 cases (67.5%), Numbness and paresthesia 26(65%). 
After treatment 05 cases (12.5%) had radiating pain to upper limbs, 05 cases (12.5%) had 
tenderness in cervical region, 04 cases (10%) had stiffness of cervical spine, 04 cases (10%) 
had numbness & paraesthesia. 
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PAIN SCORE TRAIL DRUG (GROUP A) 
 
S.NO 
 
OP.NO 
 
NAME 
 
A/S 
PAIN RADIATI
NG PAIN 
ROM NUMBNE
SS 
BT AT BT AT BT AT BT AT 
1. I53772 Mr.S.Jayakumar 22/M 7 2 + _ G3 G1 - - 
2. I53772 Mrs.N.Dhanalakshmi 42/F 7 2 + - G3 G2 - - 
3. K63027 Mrs.B.Ashadevi 39/F 7 1 + - G3 G1 - - 
4. K81868 Mrs.S.Subbulakshmi 54/F 6 2 + - G3 G1 - - 
5. K97733 Mrs.M.Shawarbanu 46/F 8 1 + - G3 G1 + + 
6. K73022 Mrs.K.Sulochana 34/F 7 1 + - G3 G1 + - 
7. K81635 Mrs.R.Suganthi 54/F 7 2 + - G3 G1 + - 
8. J75907 Mrs.V.Rani 43/F 8 3 + + G2 G1 + + 
9. K96363 Mrs.R.Dhanalakshmi 42/F 7 2 + - G3 G1 + - 
10. L03490 Mrs.R.Kalavathy 50/F 8 4 + + G2 G1 + - 
11. K92700 Mrs.M.Madhuladevi 55/F 7 2 + - G2 G1 - - 
12. I30336 Mr.R.Jayashankar 42/M 6 2 + - G3 G1 - - 
13. L10556 Mrs.M..Banu 57/F 7 4 + - G3 G2 - - 
14. L03476 Mr.K.Mohanasundaram 49/M 8 2 + + G3 G1 + - 
15. J94001 Mrs.L.Judith 34/F 8 1 + + G3 G1 + - 
16. L03046 Mr.E.Ramesh 38/M 8 4 + + G3 G1 + - 
17. L30335 Mrs.G.Jayanthi 46/F 8 1 + - G3 G1 + - 
18. K75867 Mrs.U.Shakila 38/F 7 2 + - G2 G2 + - 
19. L11182 Mr.Egambaram 
Eswaran 
41/M 7 1 + - G3 G2 + - 
20 I38337 Mrs.S.Vanitha 34/F 8 2 + - G3 G2 - - 
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PAIN SCORE TRAIL DRUG WITH VARMAM (GROUP B) 
 
S.NO 
 
OP.NO 
 
NAME 
 
A/S 
 PAIN RADIATIN
G PAIN 
ROM NUMBNESS 
BT AT BT AT BT AT BT AT 
1. K02822 Mrs.R.Rajeshwari 50/F 8 0 + - G2 G1 - - 
2. K68058 Mrs.K.Sathya 41/F 9 5 + - G2 G1 + - 
3. K91986 Mrs.R.Malar 44/F 8 1 + - G2 G1 + - 
4. F30722 Mrs.R.Renuka 47/M 8 0 + - G3 G2 + - 
5. K77777 Mr.V.Umapathy 44/F 9 1 + - G3 G2 + + 
6. K91634 Mrs.P.Bhavani 49/F 7 0 + - G3 G1 + - 
7. I01928 Mr.G.Harihara 
Subramaniyam 
49/M 9 2 + - G2 G1 + - 
8. J61956 Ms.J.Sasikala 37/F 6 0 + - G3 G1 - - 
9. K77778 Mr.T.M.Kumar 58/M 8 0 + - G3 G2 + - 
10. K96012 Mr.N.Ravindar 43/M 8 1 + - G3 G1 + - 
11. K84007 Mr.C.Velmurugan 39/M 8 1 + - G3 G1 + - 
12. K74748 Mrs.S.Malarkodi 52/F 7 2 + - G2 G1 + - 
13. 1849-18 Mrs. V.Suganya 48/F 7 1 + - G3 G2 + - 
14. 1864-18 Mrs.K.Hemavathy 42/F 8 1 + - G2 G1 + - 
15. 1863-18 Mrs.S.Kumudha 60/F 8 1 + - G3 G2 + - 
16. J76413 Mr.B.V.Katheresan 42/M 9 2 + - G3 G1 + + 
17. L08360 Mr.D.Dilli 53/M 7 0 + - G3 G2 - - 
18. K68865 Mr.D.Design 49/M 7 0 + - G2 G1 - - 
19. L03496 Mr.G.Venkatesan 59/M 8 0 + - G3 G1 - - 
20 H25446 Mr.R.Ganasekaran 59/M 7 2 + - G3 G1 - - 
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21.OUTCOME MEASURES: 
RESTRICTED MOVEMENT ASSESMENT SCALE: 
Table.21 
 
GRADING 
BEFORE TREATMENT AFTER TREATMENT 
NO OF 
CASES 
% GRADING NO OF 
CASES 
% 
 
GRADE I 
 
0 
 
0% 
G3 -G1 19 47.5% 
G2 – G1 10 25% 
 
GRADE II 
 
11 
 
27.5% 
G3 -G2 10 25% 
G2 -G2 1 2.5% 
GRADE III 29 72.5%    
GRADE IV 0 0%    
TOTAL 40 100%  40 100% 
 
   
     Fig.13 
Inference: 
 Among 40 cases, movement restriction was reduced in 29 cases (72.5%) Grade1, 
Mild restriction was found in 11 cases (27.5%). 
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23.A.DISTRIBUTION OF CASES BY PAIN ASSSEMENT SCALE IN TRAIL 
DRUG SIGAMANI CHOORANAM (INTERNAL) WITH ARKASHEERATHY 
THYLAM (EXTERNAL). 
Table.23 (GROUP A) 
PAIN      
ASSESSMENT 
WITH TRAIL 
DRUG 
           BEFORE  AFTER 
NO. OFCASES  % NO. OF 
CASES 
% 
No pain 0 0% 0 0% 
Mild 0 0% 17 85% 
Moderate 2 10% 03 15% 
Severe 18 90% 0 0% 
Total 20 100% 20 100% 
 
 
     Fig.14 
Inference: 
 Among 20 cases, before treatment severe pain were present in 18 cases (90%), 
moderate pain present in 2 case (10%). After treatment mild pain present in 17 cases (85%), 
moderate pain present in 3 cases (15%). 
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23.B.DISTRIBUTION OF CASES BY PAIN ASSSEMENT SCALE IN (TRAIL 
DRUG WITH VARMAM): 
 Table.24 (GROUP-B) 
PAIN      
ASSESSMENT 
(TRAIL DRUG + 
VARMAM) 
BEFORE  AFTER 
NO. OFCASES   % NO. OF 
CASES 
 % 
No pain 0 0% 08 40% 
Mild 0 0% 11 55% 
Moderate 1 5% 1 5% 
Severe 19 95% 0 0% 
Total 20 100% 20 100% 
 
  
     Fig.15 
Inference: 
 Among 20 cases, before treatment severe pain present in 19 cases (95%), moderate 
pain present in 1 case (5%). After treatment pain nil in 8 cases (40%), mild pain present in 
11cases (55%), moderate pain present in 1 cases (5%). 
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24. QUETIONNAIRE OUTCOME WITH PAIN ASSESSEMENT OUTCOME: 
Table.25 
BOTH GROUP            BEFORE  AFTER 
NO. OFCASES  % NO. OF 
CASES 
 % 
No pain 0 0% 08 20% 
Mild 0 0% 28 70% 
Moderate 3 7.5% 4 10% 
Severe 37 92.5% 0 0% 
Total 40 100% 40 100% 
 
 
     fig:16 
Inference: 
 Among 40 cases, before treatment severe pain present in 37 cases (92.5%), 
moderate pain present in 3 case (7.5%). After treatment No pain in 08 cases (20%), mild 
pain present in 28 cases (70%), moderate pain present in 4 cases (10%). 
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25. RESULT: 
Table.26 
 
PAIN 
ASSESSMENT 
  TRAIL DRUG TRAIL DRUG +VARMAM 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
 NO.OF 
CASES 
% NO.OF 
CASES 
% NO.OF 
CASES 
% NO.OF 
CASES 
% 
No Pain 0 0% 0 0% 0 0% 08 40% 
Mild 0 0% 17 85% 0 0% 11 55% 
Moderate 2 10% 03 15% 1 5% 01 5% 
Severe 18 90% 0 0% 19 95% 0 0% 
Total 20 100% 20 100% 20 100% 20 100% 
 
 
 
 
 
 
 
 
 
 
 
132 
 
26.IMPROVEMENT OF CASES: 
Table.27 
 
PAIN ASSESSEMENT NO OF CASES PERCENTAGE % 
Sever – No pain 06 15% 
Severe – Mild pain 26 65% 
Severe – Moderate pain 04 10% 
Moderate – No pain 02 5% 
Moderate – Mild pain 02 5% 
Total 40 100% 
 
  
     fig:17 
Inference : 
Among 40 cases, severe – no pain in 06 cases( 15%), severe -mild pain in 27 cases 
(67.5%), severe – moderate pain in 03 cases (7.5%), Moderate- no pain in 02 cases (5%), 
moderate -mild pain in 02 cases (5%).  
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STASTICAL ANALYSIS: 
 All collected data were entered into MS Excel software using different columns as 
variables and rows as patients.SPSS software was used to perform statistical analysis. Basic 
descriptive statistics include frequency distributions and cross tabulations were 
performed.The quantity variables were expressed as Mean±Standard Deviation and 
qualitative data as percentage. A probability value of <0.05 was considered to indicate as 
statistical significance. Paired „t‟ test was performed for determining the significance 
between before and after treatment. 
PAIN ASSESSMENT SCALE BEFORE AND AFTER TREATMENT 
Painscale Samplesize Mean 
standard 
deviation 
95% 
confidence 
interval 
Significant 
Beforetreatment 40 7.55 0.78 7.31-7.39 
p<0.0001 Aftertreatment 
40 1.52 1.21 1.15-1.9 
 
PAINASSESSMENTATSTARTOFTREATMENTBETWEENTWOGROUPS: 
 Sample 
Size 
Mean Standard 
Deviation 
„t‟value „p‟value 
BT AT BT AT BT AT BT AT 
Without 
Varmam 
20 7.3 2.05 0.65 0.99 
 
2.121 
 
3.004 
 
0.2953 
 
0.3895 
With 
Varmam 
20 7.8 1.0 0.83 1.21 
There is mild significant difference between with and without varmam treatment. 
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LAB INVESTIGATIONS TRAIL DRUG ONLY (GROUP A) 
 
 
 
S. 
NO 
 
 
IP / OP.NO 
 
 
NAME 
 
AGE / 
SEX 
 
 
HB  (gm/dl) 
 
T.RBC (million 
Cells/cu.mm) 
 
 
ESR (mm/ 
Hours) 
 
T.WBC 
(cells/cu.mm) 
 
DIFFERANTIAL COUNT (%) 
         P           L 
    BT AT BT AT BT AT BT AT BT AT BT AT 
1 I53772 Mr.S.Jayakumar 22/M 15.2 15.1 5.7 10
6 5.6 106 08 08 6500 6400 63 62 34 34 
2 I53772 Mrs.N.Dhanalakshmi 42/F 12.6` 12.7 4.7 10
6 4.6 106 34 34 8800 8700 65 65 34 33 
3 K63027 Mrs.B.Ashadevi 39/F 12.7 12.8 4.4 10
6 4.1 106 10 11 9200 8000 57 55 38 36 
4 K81868 Mrs.S.Subbulakshmi 54/F 13.0 13.1 4.1 10
6 4.4 106 22 20 6100 6100 58 60 40 42 
5 K97733 Mrs.M.Shawarbanu 46/F 12.4 12.8 4.7 10
6 5.0 106 8 10 8600 7300 65 62 31 34 
6 K73022 Mrs.K.Sulochana 34/F 12.2 12.2 3.910
6 4.0 106 34 16 7600 7900 65 56 30 41 
7 K81635 Mrs.R.Suganthi 54/F 10.4 10.7 4.3 10
6 4.3 106 80 34 8000 7300 70 70 27 28 
8 J75907 Mrs.V.Rani 43/F 12.7 13.2 4.6 10
6 4.7 106 52 12 7500 7000 60 50 35 43 
9 K96363 Mrs.R.Dhanalakshmi 42/F 7.5 8.8 4.10 10
6 4.5106 46 46 8100 7900 82 75 17 15 
10 L03490 Mrs.R.Kalavathy 50/F 12 12 3.7 10
6 4.2 106 35 16 7600 7900 65 54 31 40 
11 K92700 Mrs.M.Madhuladevi 55/F 14.5 14.5 5.0 10
6 5.1 106 14 25 9900 8600 62 51 35 46 
12 I30336 Mr.R.Jayashankar 42/M 12.5 12.5 5.5 10
6 5.5 106 22 22 10200 10900 60 72 30 20 
13 L10556 Mrs.M..Banu 57/F 12.0 12.1 4.4 10
6 4.4 106 12 24 6700 6800 60 55 35 41 
14 L03476 Mr.K.Mohanasundaram 49/M 13.3 13.8 4.7 10
6 4.9 106 36 26 7000 6600 65 61 30 36 
15 J94001 Mrs.L.Judith 34/F 11.8 12.7 4.4 10
6 4.5 106 42 41 6800 6900 65 64 30 30 
16 L03046 Mr.E.Ramesh 38/M 14.1 13.5 5.9 10
6 5.3 106 16 12 5900 5100 60 57 33 38 
17 L30335 Mrs.G.Jayanthi 46/F 12.7 12.8 4.4 10
6 4.1 106 9 106 11 9200 8000 57 55 38 36 
18 K75867 Mrs.U.Shakila 38/F 14.7 14.7 5.1 10
6 5.2 106 16 26 9900 8600 62 50 36 45- 
19 L11182 Mr.EgambaramEswaran 41/M 16.3 15.8 5.7 10
6 5.5 106 10 22 7900 8400 65 63 30 30 
20 I38337 Mrs.S.Vanitha 34/F 12.9 12.9 5.1 10
6 5.0 106 34 34 9300 9200 60 61 37 38 
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S. 
NO 
 
 
IP / OP.NO 
 
 
NAME 
AGE / 
SEX 
 
BLOOD 
GLUCOSE 
(FASTING) 
BLOOD 
GLUCOSE 
(PP) 
SERUM 
CHOLESTROL 
 
LIPID 
PROFILE 
HDL 
LIPID 
PROFILE 
LDL 
 
LIPID 
PROFILE 
VLDL 
 
    BT AT BT AT BT AT BT AT BT AT BT AT 
1 I53772 Mr.S.Jayakumar 22/M 109 90 100 120 187 190 39 40 102 103 84 285 
2 I53772 Mrs.N.Dhanalakshmi 42/F 82 83 116 115 214 150 58 42 117 110 19 18 
3 K63027 Mrs.B.Ashadevi 39/F 87 88 132 120 195 160 68 40 100 98 16 15 
4 K81868 Mrs.S.Subbulakshmi 54/F 100 94 120 121 2`13 210 63 60 115 110 24 20 
5 K97733 Mrs.M.Shawarbanu 46/F 100 99 134 109 209 220 64 58 109 115 26 21 
6 K73022 Mrs.K.Sulochana 34/F 87 85 94 92 229 220 59 58 127 126 17 18 
7 K81635 Mrs.R.Suganthi 54/F 156 143 210 255 284 160 60 50 168 72 51 21 
8 J75907 Mrs.V.Rani 43/F 96 90 105 88 181 181 60 47 93 75 15 24 
9 K96363 Mrs.R.Dhanalakshmi 42/F 92 70 133 120 174 167 55 44 90 82 24 36 
10 L03490 Mrs.R.Kalavathy 50/F 94 89 162 120 237 211 55 53 124 114 19 22 
11 K92700 Mrs.M.Madhuladevi 55/F 87 90 100 114 189 172 37 60 93.5 91 15 22 
12 I30336 Mr.R.Jayashankar 42/M 99 98 131 137 201 231 57 66 106 116 19 27 
13 L10556 Mrs.M..Banu 57/F 98 97 130 110 210 184 55 55 105 94 29 21 
14 L03476 Mr.K.Mohanasundaram 49/M 96 90 105 88 181 181 60 47 93 75 15 24 
15 J94001 Mrs.L.Judith 34/F 93 90 110 111 270 210 73 72 134 130 74 70 
16 L03046 Mr.E.Ramesh 38/M 74 75 67 97 174 171 47 51 83 89 14 14 
17 L30335 Mrs.G.Jayanthi 46/F 87 88 132 120 195 160 68 40 100 98 16 15 
18 K75867 Mrs.U.Shakila 38/F 80 82 100 112 194 224 49 46 97 126 29 51 
19 L11182 Mr.Egambarameswaran 41/M 94 89 162 120 237 211 55 53 124 114 19 22 
20 I38337 Mrs.S.Vanitha 34/F 86 86 120 110 199 198 48 40 115 110 21 20 
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S. 
NO 
 
 
IP / OP.NO 
 
 
NAME 
AGE / 
SEX 
 
 
LIPID PROFILE 
(TGL) 
 
RFT mg/dl 
BLOOD UREA 
 
SERUM 
CREATININE 
 
TOTAL 
BILIRUBINE 
 
DIRECT 
BILIRUBINE 
 
INDIRECT 
BILIRUBINE 
 
    BT AT BT AT BT AT BT AT BT AT BT AT 
1 I53772 Mr.S.Jayakumar 22/M 420 150 16 15 1.0 1.1 0.5 0.2 0.2 0.1 0.3 0.2 
2 I53772 Mrs.N.Dhanalakshmi 42/F 96 90 17 15 0.9 0.8 0.6 0.5 0.1 0.1 0.5 0.5 
3 K63027 Mrs.B.Ashadevi 39/F 79 70 27 27 0.9 0.9 0.8 0.7 0.3 0.3 0.5 0.5 
4 K81868 Mrs.S.Subbulakshmi 54/F 119 110 15 14 0.8 0.7 0.3 0.4 0.1 0.1 0.3 0.2 
5 K97733 Mrs.M.Shawarbanu 46/F 130 107 17 17 0.9 0.9 0.3 0.3 0.1 0.1 0.2 0.2 
6 K73022 Mrs.K.Sulochana 34/F 85 90 18 20 0.9 0.8 0.6 0.4 0.2 0.2 0.4 0.2 
7 K81635 Mrs.R.Suganthi 54/F 256 104 19 19 0.8 0.9 0.7 0.2 0.2 0.1 0.5 0.1 
8 J75907 Mrs.V.Rani 43/F 76 120 15 14 0.8 0.8 0.5 0.4 0.2 0.2 0.3 0.2 
9 K96363 Mrs.R.Dhanalakshmi 42/F 121 180 18 11 0.8 0.8 0.7 04 0.2 0.2 0.5 0.2 
10 L03490 Mrs.R.Kalavathy 50/F 85 83 11 12 0.9 0.9 0.4 0.3 0.1 0.2 0.2 0.2 
11 K92700 Mrs.M.Madhuladevi 55/F 88 92 19 18 0.8 0.8 0.4 0.4 0.1 0.1 0.3 0.3 
12 I30336 Mr.R.Jayashankar 42/M 94 138 21 19 1.1 1.0 0.8 0.5 0.3 0.2 0.5 0.3 
13 L10556 Mrs.M..Banu 57/F 96 90 17 15 0.9 0.8 0.6 0.5 0.1 0.1 0.5 0.5 
14 L03476 Mr.K.Mohanasundaram 49/M 79 70 27 27 0.9 0.9 0.8 0.7 0.3 0.3 0.5 0.5 
15 J94001 Mrs.L.Judith 34/F 37 120 19 17 0.8 0.7 0.3 0.2 0.1 0.2 0.2 0.2 
16 L03046 Mr.E.Ramesh 38/M 72 68 14 13 1.0 0.9 0.8 1.2 0.3 0.5 0.5 0.7 
17 L30335 Mrs.G.Jayanthi 46/F 97 112 22 29 1.1 1.0 0.7 0.8 0.3 0.3 0.4 0.5 
18 K75867 Mrs.U.Shakila 38/F 146 254 10 17 0.9 0.8 0.7 0.5 0.2 0.2 0.5 0.3 
19 L11182 Mr.Egambarameswaran 41/M 97 112 22 29 1.1 1.0 0.7 0.8 0.3 0.3 0.4 0.5 
20 I38337 Mrs.S.Vanitha 34/F 109 110 11 12 0.7 0.6 0.5 0.4 0.2 0.1 0.4 0.3 
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S. 
NO 
 
 
IP / OP.NO 
 
 
NAME 
AGE / 
SEX 
 
 
LFT (mg/dl) 
TOTAL PROTEIN 
 
SERUM 
ALBUMIN 
 
SERUM 
GLOBULIN 
 
SGOT 
 
SGPT 
 
ALP 
 
    BT AT BT AT BT AT BT AT BT AT BT AT 
1 I53772 Mr.S.Jayakumar 22/M 7.2 7.1 4.2 4.1 3.0 3.1 22 21 95 89 9.7 9.8 
2 I53772 Mrs.N.Dhanalakshmi 42/F 6.8 6.7 3.7 3.6 3.1 3.0 17 17 14 14 82 81 
3 K63027 Mrs.B.Ashadevi 39/F 6.7 6.6 3.7 3.3 3.0 3.0 15 16 13 12 59 60 
4 K81868 Mrs.S.Subbulakshmi 54/F 6.9 7.0 4.0 4.1 2.9 2.9 23 24 23 23 68 69 
5 K97733 Mrs.M.Shawarbanu 46/F 7.3 7.3 3.9 3.8 3.4 3.5 24 28 26 33 103 106 
6 K73022 Mrs.K.Sulochana 34/F 6.7 6.8 3.7 3.8 3.0 3.0 15 17 07 16 89 91 
7 K81635 Mrs.R.Suganthi 54/F 6.7 6.8 3.9 3.8 2.9 2.9 18 16 13 14 105 88 
8 J75907 Mrs.V.Rani 43/F 7.4 7.4 3.9 3.8 3.5 3.7 13 16 14 17 120 125 
9 K96363 Mrs.R.Dhanalakshmi 42/F 7.4 7.3 3.9 3.8 3.5 3.5 09 20 12 22 69 70 
10 L03490 Mrs.R.Kalavathy 50/F 7.1 7.2 3.6 3.6 3.5 3.6 08 12 05 18 87 95 
11 K92700 Mrs.M.Madhuladevi 55/F 6.6 6.6 3.9 3.9 2.7 2.8 13 17 06 15 112 119 
12 I30336 Mr.R.Jayashankar 42/M 7.3 7.4 4.2 4.0 3.1 3.4 20 18 18 17 81 87 
13 L10556 Mrs.M..Banu 57/F 7.3 7.2 3.9 3.8 3.4 3.2 10.1 10.1 16 16 70 72 
14 L03476 Mr.K.Mohanasundaram 49/M 6.6 6.6 3.9 3.9 2.7 2.8 13 17 06 15 112 119 
15 J94001 Mrs.L.Judith 34/F 6.7 6.5 3.8 3.7 2.9 2.8 15 14 20 20 74 73 
16 L03046 Mr.E.Ramesh 38/M 7.3 7.2 4.0 3.9 3.3 3.3 17 17 18 14 74 64 
17 L30335 Mrs.G.Jayanthi 46/F 6.8 6.7 3.7 3.6 3.1 3.0 17 17 14 14 82 81 
18 K75867 Mrs.U.Shakila 38/F 7.6 7.8 4.2 4.0 3.4 3.8 20 15 21 61 61 66 
19 L11182 Mr.Egambarameswaran 41/M 7.1 7.3 4.0 4.0 3.1 3.3 22 19 27 23 97 93 
20 I38337 Mrs.S.Vanitha 34/F 7.3 7.2 3.9 3.8 3.4 3.2 10.1 10.1 16 16 70 72 
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S. 
NO 
 
 
IP / OP.NO 
 
 
NAME 
AGE / 
SEX 
 
 
SERUM  
CALCIUM 
 
SERUM 
PHOSPHORUS 
 
SERUM URIC 
ACID 
 
CRP 
 
ASO TITRE 
 
RA 
FACTOR 
 
    BT AT BT AT BT AT BT AT BT AT BT AT 
1 I53772 Mr.S.Jayakumar 22/M 9.7 9.8       -       - 7.3 7.1 Neg Neg Neg Neg Neg  Neg 
2 I53772 Mrs.N.Dhanalakshmi 42/F 9.9 9.8       -       - 3.6 3.5 Neg Neg POS Neg Neg Neg 
3 K63027 Mrs.B.Ashadevi 39/F 9.5 9.9       -       - 4.4 4.3 Neg Neg Neg Neg Neg  Neg 
4 K81868 Mrs.S.Subbulakshmi 54/F 9.1 9.0       -       - 4.3 4.4 Neg Neg Neg Neg Neg  Neg 
5 K97733 Mrs.M.Shawarbanu 46/F 9.9 9.7       -       - 3.4 3.7 Neg Neg Neg Neg Neg  Neg 
6 K73022 Mrs.K.Sulochana 34/F 8.7 8.6       -       - 4.5 4.7 Neg Neg Neg Neg Neg  Neg 
7 K81635 Mrs.R.Suganthi 54/F 9.5` 9.7       -       - 5.4 3.3 Neg Neg Neg Neg Neg  Neg 
8 J75907 Mrs.V.Rani 43/F 9.4 9.7       -       - 3.6 4.2 Neg Neg Neg Neg Neg  Neg 
9 K96363 Mrs.R.Dhanalakshmi 42/F 9.9 9.6       -       - 4.1 4.3 Neg Neg Neg Neg Neg  Neg 
10 L03490 Mrs.R.Kalavathy 50/F 9.5 9.5       -       - 3.6 4.2 Neg Neg Neg Neg Neg Neg 
11 K92700 Mrs.M.Madhuladevi 55/F 9.5 9.7       -       - 4.7 4.7 Neg Neg Neg Neg Neg Neg 
12 I30336 Mr.R.Jayashankar 42/M 9.3 8.4       -       - 5.3 4.3 Neg Neg Neg Neg Neg  Neg 
13 L10556 Mrs.M..Banu 57/F 8.7 8.6       -       - 4.5 4.7 Neg Neg Neg Neg Neg  Neg 
14 L03476 Mr.K.Mohanasundaram 49/M 9.5` 9.7       -       - 5.4 3.3 Neg Neg Neg Neg Neg  Neg 
15 J94001 Mrs.L.Judith 34/F 8.7 8.6       -       - 3.9 4.0 Neg Neg Neg Neg Neg Neg 
16 L03046 Mr.E.Ramesh 38/M 9.8 8.3       -       - 5.2 4.7 Neg Neg POS POS Neg Neg 
17 L30335 Mrs.G.Jayanthi 46/F 8.7 7.4       -       - 5.9 5.0 Neg Neg Neg Neg Neg  Neg 
18 K75867 Mrs.U.Shakila 38/F 9.9 8.3       -       - 3.5 3.6 Neg Neg Neg Neg Neg  Neg 
19 L11182 Mr.Egambarameswaran 41/M 8.7 7.4       -       - 5.9 5.0 Neg Neg Neg Neg Neg  Neg 
20 I38337 Mrs.S.Vanitha 34/F 9.2 9.1       -       - 2.4 2.4 Neg Neg Neg Neg Neg  Neg 
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S. 
NO 
 
 
IP / OP.NO 
 
 
NAME 
AGE / 
SEX 
 
 
URINE 
INVESTIGATION 
(ALBUMIN) 
 
SUGAR (F) 
 
SUGAR(PP) 
 
DEPOSITS 
 
BILE SALTS 
 
BILE 
PIGMENTS 
 
    BT AT BT AT BT AT BT AT BT AT BT AT 
1 I53772 Mr.S.Jayakumar 22/M Nil Nil Nil Nil Nil Nil 1-2epi 1-2 epi Nil Nil Nil  Nil 
2 I53772 Mrs.N.Dhanalakshmi 42/F Nil Nil Nil Nil Nil Nil 2-3epi 2-3 epi Nil Nil Nil  Nil 
3 K63027 Mrs.B.Ashadevi 39/F Nil Nil Nil Nil Nil Nil 2-3epi 1-2 epi Nil Nil Nil  Nil 
4 K81868 Mrs.S.Subbulakshmi 54/F Nil Nil Nil Nil Nil Nil 2-4epi 2-3 epi Nil Nil Nil  Nil 
5 K97733 Mrs.M.Shawarbanu 46/F Nil Nil Nil Nil Nil Nil 2-3epi 1-2 epi Nil Nil Nil  Nil 
6 K73022 Mrs.K.Sulochana 34/F Nil Nil Nil Nil Nil Nil 2-4epi 2-3 epi Nil Nil Nil  Nil 
7 K81635 Mrs.R.Suganthi 54/F Nil Nil Nil Nil Nil Nil 1-2epi 2-4 epi Nil Nil Nil Nil 
8 J75907 Mrs.V.Rani 43/F Nil Nil Nil Nil Nil Nil 1-2epi 2-4 epi Nil Nil Nil Nil 
9 K96363 Mrs.R.Dhanalakshmi 42/F Nil Nil Nil Nil Nil Nil 1-2epi 2-4 epi Nil Nil Nil Nil 
10 L03490 Mrs.R.Kalavathy 50/F Nil Nil Nil Nil Nil Nil 1-2epi 2-4 epi Nil Nil Nil Nil 
11 K92700 Mrs.M.Madhuladevi 55/F Nil Nil Nil Nil Nil Nil 2-4epi 2-5 epi Nil Nil Nil  Nil 
12 I30336 Mr.R.Jayashankar 42/M Nil Nil Nil Nil Nil Nil 1-2epi 2-4 epi Nil Nil Nil Nil 
13 L10556 Mrs.M..Banu 57/F Nil Nil Nil Nil Nil Nil 2-4epi 2-3 epi Nil Nil Nil  Nil 
14 L03476 Mr.K.Mohanasundaram 49/M Nil Nil Nil Nil Nil Nil 2-3epi 1-2 epi Nil Nil Nil  Nil 
15 J94001 Mrs.L.Judith 34/F Nil Nil Nil Nil Nil Nil 2-4epi 2-3 epi Nil Nil Nil  Nil 
16 L03046 Mr.E.Ramesh 38/M Nil Nil Nil Nil Nil Nil 2-4epi 2-5 epi Nil Nil Nil  Nil 
17 L30335 Mrs.G.Jayanthi 46/F Nil Nil Nil Nil Nil Nil 1-2epi 2-4 epi Nil Nil Nil Nil 
18 K75867 Mrs.U.Shakila 38/F Nil Nil Nil Nil Nil Nil 1-2epi 2-4 epi Nil Nil Nil Nil 
19 L11182 Mr.Egambarameswaran 41/M Nil Nil Nil Nil Nil Nil 1-2epi 2-4 epi Nil Nil Nil Nil 
20 I38337 Mrs.S.Vanitha 34/F Nil Nil Nil Nil Nil Nil 1-2epi 2-4 epi Nil Nil Nil Nil 
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LAB INVESTIGATIONS TRAIL DRUG WITH VARMAM (GROUP B) 
 
 
 
S. 
NO 
 
 
IP / OP.NO 
 
 
NAME 
 
AGE / 
SEX 
 
 
HB  (gm/dl) 
 
T.RBC (million 
Cells/cu.mm) 
 
 
ESR (mm/ 
Hours) 
 
T.WBC 
(cells/cu.mm) 
 
DIFFERANTIAL COUNT (%) 
         P           L 
    BT AT BT AT BT AT BT AT BT AT BT AT 
1 K02822 Mrs.R.Rajeshwari 50/F 13.2 14.18 4.4 10
6 4.7 106 22 22 6600 7300 69 72 30 24 
2 K68058 Mrs.K.Sathya 41/F 11.4 10.7 4.7 10
6 4.6 106 26 44 6300 6400 64 60 31 35 
3 K91986 Mrs.R.Malar 44/F 12.6 12.7 4.8 10
6 4.7 106 40 80 8300 8000 66 60 28 37 
4 F30722 Mrs.R.Renuka 47/M 12.6 13.8 4.1 10
6 4.4 106 42 70 9100 7400 63 60 34 35 
5 K77777 Mr.V.Umapathy 44/F 14.1 14.1 5.1 10
6 5.1 106 8 12 5800 6200 69 65 26 30 
6 K91634 Mrs.P.Bhavani 49/F 12.0 12.1 4.4 10
6 4.4 106 12 24 6700 6800 60 55 35 41 
7 I01928 Mr.G.Harihara Subramaniyam 49/M 14.6 14.2 5.0 10
6 4.8 106 50 20 6700 6100 60 63 35 33 
8 J61956 Ms.J.Sasikala 37/F 8.8 10.0 4.9 10
6 5.0 106 100 40 12,400 8600 65 64 30 33 
9 K77778 Mr.T.M.Kumar 58/M 14.6 15.1 5.0 10
6 5.2 106 10 20 5300 6000 65 70 30 25 
10 K96012 Mr.N.Ravindar 43/M 13.3 13.4 4.7 10
6 4.6 106 20 20 7500 7600 70 72 25 20 
11 K84007 Mr.C.Velmurugan 39/M 15.5 15.9 5.2 10
6 5.5 106 8 12 10200 11100 70 66 24 30 
12 K74748 Mrs.S.Malarkodi 52/F 11.6 11.5 5.1 10
6 5.1 106 16 16 8600 8700 52 50 45 42 
13 1849-18 Mrs. V.Suganya 48/F 12.6 12.0 4.2 10
6 4.0 106 60 44 7000 5400 76 75 22 22 
14 1864-18 Mrs.K.Hemavathy 42/F 15.2 14.3 5.1 10
6 4.7 106 08 10 9000 9600 60 62 35 37 
15 1863-18 Mrs.S.Kumudha 60/F 13.3 13.8 4.7 10
6 4.9 106 36 26 7000 6600 65 61 30 36 
16 J76413 Mr.B.V.Katheresan 42/M 14.3 14 4.8 10
6 4.6 106 22 44 7800 7900 55 56 43 44 
17 L08360 Mr.D.Dilli 53/M 15.2 14.3 5.1 10
6 4.7 106 08 10 9000 9600 60 62 35 37 
18 K68865 Mr.D.Design 49/M 15.4 15.4 5.5 10
6 5.5 106 22 22 10400 10400 69 68 27 26 
19 L03496 Mr.G.Venkatesan 59/M 16 15.5 5.6 10
6 5.5 106 08 08 6900 6000 65 67 33 27 
20 H25446 Mr.R.Ganasekaran 59/M 17.8 16.1 5.7 10
6 5.7 106 12 32 10100 8700 65 60 30 36 
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S. 
NO 
 
 
IP / OP.NO 
 
 
NAME 
AGE / 
SEX 
 
BLOOD 
GLUCOSE 
(FASTING) 
BLOOD 
GLUCOSE 
(PP) 
SERUM 
CHOLESTROL 
 
LIPID 
PROFILE 
HDL 
LIPID 
PROFILE 
LDL 
 
LIPID 
PROFILE 
VLDL 
 
    BT AT BT AT BT AT BT AT BT AT BT AT 
1 K02822 Mrs.R.Rajeshwari 50/F 101 82 100 126 273 260 73 74 152 156 31 21 
2 K68058 Mrs.K.Sathya 41/F 95 96 103 97 180 174 59 49 92 82 19 25 
3 K91986 Mrs.R.Malar 44/F 99 106 140 131 293 254 81 63 161 129 15 13 
4 F30722 Mrs.R.Renuka 47/M 96 97 100 149 239 236 66 54 128 119 25 20 
5 K77777 Mr.V.Umapathy 44/F 88 82 109 133 166 186 52 44 89 94 14 14 
6 K91634 Mrs.P.Bhavani 49/F 94 90 100 101 184 195 48 46 101 101 27 23 
7 I01928 Mr.G.Harihara Subramaniyam 49/M 96 93 93 70 205 207 57 47 110 100 24 17 
8 J61956 Ms.J.Sasikala 37/F 84 84 90 135 189 206 56 52 103 102 17 16 
9 K77778 Mr.T.M.Kumar 58/M 99 94 146 137 212 225 53 46 120 122 15 29 
10 K96012 Mr.N.Ravindar 43/M 120 110 160 150 150 152 37 36 83 82 22 20 
11 K84007 Mr.C.Velmurugan 39/M 96 98 130 128 196 202 45 35 110 100 31 34 
12 K74748 Mrs.S.Malarkodi 52/F 152 100 196 185 206 195 41 30 111 110 39 36 
13 1849-18 Mrs. V.Suganya 48/F 87 90 100 114 189 172 37 60 93.5 91 15 22 
14 1864-18 Mrs.K.Hemavathy 42/F 99 94 146 137 212 225 53 46 120 122 15 29 
15 1863-18 Mrs.S.Kumudha 60/F 101.3 93 93 126 206 185 50.5 50 107 89 17.8 18 
16 J76413 Mr.B.V.Katheresan 42/M 91 100 90 128 170 169 42 41 84 89 26 30 
17 L08360 Mr.D.Dilli 53/M 100 98 130 121 200 193 61 53 141 101 42 44 
18 K68865 Mr.D.Design 49/M 105 90 141 164 243 243 46 44 127 128 27 36 
19 L03496 Mr.G.Venkatesan 59/M 98 97 130 110 210 184 55 55 105 94 29 21 
20 H25446 Mr.R.Ganasekaran 59/M 140 139 220 210 259 236 45 40 144 130 42 31 
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S. 
NO 
 
 
IP / OP.NO 
 
 
NAME 
AGE / 
SEX 
 
 
LIPID PROFILE 
(TGL) 
 
RFT mg/dl 
BLOOD UREA 
 
SERUM 
CREATININE 
 
TOTAL 
BILIRUBINE 
 
DIRECT 
BILIRUBINE 
 
INDIRECT 
BILIRUBINE 
 
    BT AT BT AT BT AT BT AT BT AT BT AT 
1 K02822 Mrs.R.Rajeshwari 50/F 158 105 18 21 0.8 0.9 0.4 0.6 0.2 0.3 0.2 0.3 
2 K68058 Mrs.K.Sathya 41/F 93 123 19 20 1.0 1.0 0.3 0.3 0.1 0.1 0.2 0.2 
3 K91986 Mrs.R.Malar 44/F 73 65 20 22 0.8 0.8 0.6 0.5 0.2 0.2 0.4 0.3 
4 F30722 Mrs.R.Renuka 47/M 126 100 15 16 0.8 0.8 0.3 0.3 0.1 0.1 0.2 0.2 
5 K77777 Mr.V.Umapathy 44/F 69 73 13  18 0.9 0.9 0.9 0.7 0.4 0.3 0.5 0.4 
6 K91634 Mrs.P.Bhavani 49/F 134 116 13 20 0.8 0.8 0.5 0.5 0.2 0.2 0.3 0.3 
7 I01928 Mr.G.Harihara Subramaniyam 49/M 121 85 23 20 1.1 1.1 0.6 0.7 0.2 0.3 0.4 0.4 
8 J61956 Ms.J.Sasikala 37/F 85 83 11 12 0.9 0.9 0.4 0.3 0.1 0.2 0.2 0.2 
9 K77778 Mr.T.M.Kumar 58/M 78 143 12 14 1.0 0.9 0.9 0.8 0.3 0.3 0.6 0.5 
10 K96012 Mr.N.Ravindar 43/M 109 101 12 11 1.1 1.1 1.3 1.3 0.4 0.4 0.9 0.9 
11 K84007 Mr.C.Velmurugan 39/M 154 170 17 18 1.1 1.1 0.9 0.4 0.3 0.2 0.6 0.2 
12 K74748 Mrs.S.Malarkodi 52/F 160 141 22 21 1.1 1.0 0.7 0.7 0.2 0.1 0.5 0.2 
13 1849-18 Mrs. V.Suganya 48/F 75.2 112 16.6 19 0.9 0.9 0.5 0.5 0.24 0.2 0.3 0.3 
14 1864-18 Mrs.K.Hemavathy 42/F 85 83 11 12 0.9 0.9 0.4 0.3 0.1 0.2 0.2 0.2 
15 1863-18 Mrs.S.Kumudha 60/F 88 92 19 18 0.8 0.8 0.4 0.4 0.1 0.1 0.3 0.3 
16 J76413 Mr.B.V.Katheresan 42/M 128 141 18 22 1.2 1.0 0.9 0.6 0.3 0.2 0.6 0.4 
17 L08360 Mr.D.Dilli 53/M 161 170 16 17 1.0 1.0 0.9 0.9 0.3 0.3 0.6 0.6 
18 K68865 Mr.D.Design 49/M 134 179 23 31 1.0 0.9 0.5 0.5 0.2 0.2 0.3 0.3 
19 L03496 Mr.G.Venkatesan 59/M 143 105 14 17 1.2 1.0 0.5 0.6 0.2 0.3 0.3 0.3 
20 H25446 Mr.R.Ganasekaran 59/M 210 155 23 33 1.0 0.9 0.8 0.9 0.4 0.3 0.4 0.6 
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S. 
NO 
 
 
IP / OP.NO 
 
 
NAME 
AGE / 
SEX 
 
 
LFT (mg/dl) 
TOTAL PROTEIN 
 
SERUM 
ALBUMIN 
 
SERUM 
GLOBULIN 
 
SGOT 
 
SGPT 
 
ALP 
 
    BT AT BT AT BT AT BT AT BT AT BT AT 
1 K02822 Mrs.R.Rajeshwari 50/F 6.9 7.1 3.7 3.9 3.2 3.3 16 24 04 23 118 107 
2 K68058 Mrs.K.Sathya 41/F 7.2 7.2 3.8 3.4 3.6 3.8 17 16 12 03 63 67 
3 K91986 Mrs.R.Malar 44/F 7.6 7.3 4.0 3.9 3.6 3.4 40 22 96 27 90 91 
4 F30722 Mrs.R.Renuka 47/M 7.2 7.5 3.8 3.8 3.4 3.7 16 17 13 24 76 74 
5 K77777 Mr.V.Umapathy 44/F 7.0 6.9 4.0 3.0 3.0 3.0 19 19 19 24 79 84 
6 K91634 Mrs.P.Bhavani 49/F 6.7 6.8 3.9 3.8 2.8 3.0 18 15 17 17 69 70 
7 I01928 Mr.G.Harihara Subramaniyam 49/M 7.1 6.9 4.0 3.9 3.1` 3.0 14 18 15 23 52 55 
8 J61956 Ms.J.Sasikala 37/F 7.1 7.2 3.6 3.6 3.5 3.6 08 12 05 18 87 95 
9 K77778 Mr.T.M.Kumar 58/M 6.6 6.6 3.9 3.9 2.7 2.8 13 17 06 15 112 119 
10 K96012 Mr.N.Ravindar 43/M 6.6 6.7 4.0 4.1 2.6 2.5 16 15 15 14 63 64 
11 K84007 Mr.C.Velmurugan 39/M 7.4 7.4 4.0 3.8 3.4 3.6 19 28 37 40 139 146 
12 K74748 Mrs.S.Malarkodi 52/F 7.9 7.9 4.2 4.1 3.6 3.4 47 36 44 63 106 105 
13 1849-18 Mrs. V.Suganya 48/F 7.19 7.3 3.94 3.8 3.3 3.5 16 17 16.4 15 92 92 
14 1864-18 Mrs.K.Hemavathy 42/F 6.7 6.8 3.9 3.8 2.8 3.0 18 15 17 17 69 70 
15 1863-18 Mrs.S.Kumudha 60/F 7.5 7.2 3.9 3.8 3.7 3.4 23 26 20 25 108 108 
16 J76413 Mr.B.V.Katheresan 42/M 6.9 6.7 4.0 4.1 2.9 2.8 18 16 17 10 76 88 
17 L08360 Mr.D.Dilli 53/M 6.9 6.5 4.1 3.6 2.8 2.9 12 14 14 14 70 63 
18 K68865 Mr.D.Design 49/M 6.9 7.0 3.7 3.8 3.2 3.2 15 14 14 22 109 111 
19 L03496 Mr.G.Venkatesan 59/M 7.1 7.2 4.1 3.9 3.1 3.3 22 20 31 16 87 79 
20 H25446 Mr.R.Ganasekaran 59/M 7.2 6.4 4.4 3.9 2.8 3.2 24 15 37 23 113 100 
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S. 
NO 
 
 
IP / OP.NO 
 
 
NAME 
AGE / 
SEX 
 
 
SERUM  
CALCIUM 
 
SERUM 
PHOSPHORUS 
 
SERUM URIC 
ACID 
 
CRP 
 
ASO TITRE 
 
RA 
FACTOR 
 
    BT AT BT AT BT AT BT AT BT AT BT AT 
1 K02822 Mrs.R.Rajeshwari 50/F 8.7 10.1       -       - 4.9 4.8 Neg Neg Neg Neg Neg Neg 
2 K68058 Mrs.K.Sathya 41/F 8.5 8.9       -       - 4.2 4.1 Neg Neg Neg Neg Neg Neg 
3 K91986 Mrs.R.Malar 44/F 8.6 9.0       -       - 5.9 6.0 Neg Neg Neg Neg Neg Neg 
4 F30722 Mrs.R.Renuka 47/M 8.8 8.7       -       - 3.3 3.8 Neg Neg Neg Neg Neg Neg 
5 K77777 Mr.V.Umapathy 44/F 8.6 9.1       -       - 4.3 5.8 Neg Neg Neg Neg Neg Neg 
6 K91634 Mrs.P.Bhavani 49/F 9.7 8.7       -       - 4.2 4.1 Neg Neg Neg Neg Neg Neg 
7 I01928 Mr.G.Harihara Subramaniyam 49/M 9.7 8.9       -       - 6.1 6.2 Neg Neg Neg Neg Neg Neg 
8 J61956 Ms.J.Sasikala 37/F 9.5 9.5       -       - 3.6 4.2 Neg Neg Neg Neg Neg Neg 
9 K77778 Mr.T.M.Kumar 58/M 9.5 9.7       -       - 4.7 4.7 Neg Neg Neg Neg Neg Neg 
10 K96012 Mr.N.Ravindar 43/M 9.4 9.7       -       - 5.3 5.1 Pos Neg Neg Neg Neg Neg 
11 K84007 Mr.C.Velmurugan 39/M 9.5 9.4       -       - 4.1 3.9 Neg Neg Neg Neg Neg Neg 
12 K74748 Mrs.S.Malarkodi 52/F 9.8 9.7       -       - 4.4 4.2 Neg Neg pos Neg Neg Neg 
13 1849-18 Mrs. V.Suganya 48/F 8.6 9.1       -       - 4.7 4.1 Neg Neg Neg Neg Neg Neg 
14 1864-18 Mrs.K.Hemavathy 42/F 8.8 9.2       -       - 5.2 5.1 Neg Neg Neg Neg Neg Neg 
15 1863-18 Mrs.S.Kumudha 60/F 9.0 9.2       -       - 3.7 3.4 Neg Neg Neg Neg Neg Neg 
16 J76413 Mr.B.V.Katheresan 42/M 8.8 9.2       -       - 5.2 5.1 Neg Neg Neg Neg Neg Neg 
17 L08360 Mr.D.Dilli 53/M 11.1 11       -       - 3.5 2.9 Neg Neg Neg Neg Neg Neg 
18 K68865 Mr.D.Design 49/M 8.5 9.2       -       - 4.8 4.4 Neg Neg Neg Neg Neg Neg 
19 L03496 Mr.G.Venkatesan 59/M 9.5 9.7       -       - 6.7 7.0 Neg Neg Neg Neg Neg Neg 
20 H25446 Mr.R.Ganasekaran 59/M 9.8 8.2       -       - 5.3 5.8 Neg Neg Neg Neg Neg Neg 
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S. 
NO 
 
 
IP / OP.NO 
 
 
NAME 
AGE / 
SEX 
 
 
URINE 
INVESTIGATION 
(ALBUMIN) 
 
SUGAR (F) 
 
SUGAR(PP) 
 
DEPOSITS 
 
BILE SALTS 
 
BILE 
PIGMENTS 
 
    BT AT BT AT BT AT BT AT BT AT BT AT 
1 K02822 Mrs.R.Rajeshwari 50/F Nil Nil Nil Nil Nil Nil 1-2epi 1-2 epi Nil Nil Nil  Nil 
2 K68058 Mrs.K.Sathya 41/F Nil Nil Nil Nil Nil Nil 2-3epi 2-3 epi Nil Nil Nil  Nil 
3 K91986 Mrs.R.Malar 44/F Nil Nil Nil Nil Nil Nil 2-3epi 1-2 epi Nil Nil Nil  Nil 
4 F30722 Mrs.R.Renuka 47/M Nil Nil Nil Nil Nil Nil 2-4epi 2-3 epi Nil Nil Nil  Nil 
5 K77777 Mr.V.Umapathy 44/F Nil Nil Nil Nil Nil Nil 2-3epi 1-2 epi Nil Nil Nil  Nil 
6 K91634 Mrs.P.Bhavani 49/F Nil Nil Nil Nil Nil Nil 2-4epi 2-3 epi Nil Nil Nil  Nil 
7 I01928 Mr.G.Harihara Subramaniyam 49/M Nil Nil Nil Nil Nil Nil 1-2epi 2-4 epi Nil Nil Nil Nil 
8 J61956 Ms.J.Sasikala 37/F Nil Nil Nil Nil Nil Nil 1-2epi 2-4 epi Nil Nil Nil Nil 
9 K77778 Mr.T.M.Kumar 58/M Nil Nil Nil Nil Nil Nil 1-2epi 2-4 epi Nil Nil Nil Nil 
10 K96012 Mr.N.Ravindar 43/M Nil Nil Nil Nil Nil Nil 1-2epi 2-4 epi Nil Nil Nil Nil 
11 K84007 Mr.C.Velmurugan 39/M Nil Nil Nil Nil Nil Nil 2-4epi 2-5 epi Nil Nil Nil  Nil 
12 K74748 Mrs.S.Malarkodi 52/F Nil Nil Nil Nil Nil Nil 1-2epi 2-4 epi Nil Nil Nil Nil 
13 1849-18 Mrs. V.Suganya 48/F Nil Nil Nil Nil Nil Nil 2-4epi 2-3 epi Nil Nil Nil  Nil 
14 1864-18 Mrs.K.Hemavathy 42/F Nil Nil Nil Nil Nil Nil 2-3epi 1-2 epi Nil Nil Nil  Nil 
15 1863-18 Mrs.S.Kumudha 60/F Nil Nil Nil Nil Nil Nil 2-4epi 2-3 epi Nil Nil Nil  Nil 
16 J76413 Mr.B.V.Katheresan 42/M Nil Nil Nil Nil Nil Nil 2-4epi 2-5 epi Nil Nil Nil  Nil 
17 L08360 Mr.D.Dilli 53/M Nil Nil Nil Nil Nil Nil 1-2epi 2-4 epi Nil Nil Nil Nil 
18 K68865 Mr.D.Design 49/M Nil Nil Nil Nil Nil Nil 1-2epi 2-4 epi Nil Nil Nil Nil 
19 L03496 Mr.G.Venkatesan 59/M Nil Nil Nil Nil Nil Nil 1-2epi 2-4 epi Nil Nil Nil Nil 
20 H25446 Mr.R.Ganasekaran 59/M Nil Nil Nil Nil ++ ++ 1-2epi 2-4 epi Nil Nil Nil Nil 
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DISCUSSION 
The main aim of the treatment was to study the safety and therapeutic Efficacy of 
the drug Sigamani Chooranam to reduce pain, stiffness, restriction of movements and 
other clinical symptoms in the disease Cagana vaatham. 
The clinical features of Cagana vaatham can be correlated with Cervical 
Spondylosis in modern science. It is characterised by degeneration of the intervertebral 
disc and osteophyte formation. Such “wear and tear” is extremely common and 
radiological changes are frequently found in asymptomatic individuals over the age of 
50. Spondylosis may be associated with neurological dysfunction. In order of frequency, 
the C5/C6, C6/C7 & C4/C5 vertebra levels affect C6,C7 & C5 roots, respectively. 
The drugs which possess anti-Vaatha property as mentioned in Siddha literature 
were selected and the trial drugs were prepared by the Author in the Gunapadam 
practical laboratory of National Institute of Siddha, after getting proper authentication of 
raw drugs from the Medicinal botany department at NIS, Chennai 47, under the 
supervision of the members of the teaching faculty and guided by the Head of the 
Department of Sirappu Maruthuvam of the National Institute of Siddha, Chennai - 47. 
The trial drug was prepared by the standard operating procedure as mentioned in the 
protocol. 
The safety of the trial drug usage and standardization of the trial drug through 
biochemical analysis were also ensured during the study. 
The sub-acute toxicity studies for the above said trial drug was conducted at 
National Institute of Siddha after getting the proper acceptance and Permission from the 
Institutional Animal Ethical Committee. The trial drug was proved to be safe for human 
beings from the observations made from the study. 
The Biochemical qualitative and quantitative analysis were done at the Biochemistry 
lab of National Institiute of Siddha,Chennai. It revealed the presence of effective 
minerals and the existence of the drug molecules at micro level. 
The clinical study was conducted with a defined protocol and a proper proforma 
after the approval of the Institutional Ethical Committee. After screening patients 
reporting at the OPD of department of Sirappu Maruthuvam, 40 cases were selected for 
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induction to the trial. Before enrolment into the trial the informed consent was obtained 
from the patients.40 patients of both genders were recruited for this study. Among the 40 
patients 20 patients received medicine only and 20 patients received Varmam treatment 
along with the trial drugs.  
The treatment was aimed at normalizing the vitiated humours and providing relief 
from symptoms. By giving purgation we can normalize the vitiated Vaatham. 
 
Before treating with trail drug the patients were advised to take Agathiyar 
kuzhambu- 130 mg with hot water in early morning for purgation. The patient was 
advised to take rest without internal medicine. 
The patients were treated with trial drugs Sigamani Chooranam (internal) twice a 
day with Hot waterand Arkkasheerathy Thylam (external) for 48 days. Patients were 
instructed to take the medicines regularly advised to follow Pathiyam (avoid tamarind, 
tubers, etc) and advised to avoid cold exposure. Out-Patients were asked to visit the 
hospital once in 7 days. For Out- Patients the drugs were given for 48 days and the 
clinical assessment was done on 1
st
 day, 8
th
 day, 15
th
 day, 22
nd
 day, 29
th
 day, 36
th
 day, 
43
rd
 day and 49
th
 day. 
Among 40 patients, 20 patients the drugs were given for 48 days and the clinical 
assessment was done daily. 20 Patients were given Varmam treatment along with trial 
drugs. Varmam therapy is given for 3 alternative days in a week. 
After the treatment, the patients were advised to visit the Out-Patient ward of 
Department of Sirappu Maruthuvam for another 2 months for follow-up. The results 
observed during the study period were discussed by the author below.   
OBSERVATION: 
 Among 40 cases the disease was found to be higher in the age group of 41-50 
 years, 20 cases (50%). 
 The majority affected sex 63% (25) females and 37% (15) males are affected. 
 The common cause for this may bedepletion of calcium, nutritional deficiency 
 and increased house hold works. History taking reveals the above reasons for 
 female predominance. 
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 In this study, 36 (90%)cases were reported from Neithal land, 2 (5%) cases from 
 kurinchi(Hill), 2 (5%) cases from Marutham( fertile).In Siddha literatures, it was 
 mentioned that Neithal, which is responsible for Vaatha diseases. This study also 
 emphasized the same. 
 Among40 cases,all of them were belongs to 40(100%)Rasathagunam. 
 Among40 cases, Vathapitha thegi 20 (50%), Pithavatha thegi 15 (37.5%),
 Kabavatha thegi 05 (12.5%). 
 The incidence of cases 20 (50%) were recruited in Munpanikalam 18 (45%) in 
 Pinpanikalam, 2 (5%) in Elavaenirkalam. 
 Among 40 cases 30 (75%) were belongs to low economic status, 10 (25%) were 
 belongs to middle economic status. 
 Among 40 cases 2(5%) were belongs to vegetarian, 38 (95%) were belongs to 
 non-vegetarian. 
 Most of the cases shows 100% gradual onset of disease. 
 Viyanan, Samanan were affected in all 40 cases. 
 In all the cases the Sathaga pitham were affected. 
 Santhigam were affected in all the 40 cases. Santhiga kabam mainly lives in  
 joints and so it was affected in all the cases. 
 Among 40 cases, kai were affected in 40 cases 100%. 
 Pulse reading (Naadi) was observed in all patients. Among 40 cases, Before  
treatment vathapitham naadi were found in 20 (50%) cases, pithavatha naadi  
were found in 19 (47.5%) cases, pithakaba naadi were found in 1 (2.5%). After 
treatment vathapitha naadi were found in  19 (47.5%) cases, vathakaba naadi 
were found in 1(2.5%) case, pithavatha naadi were found in 20 (50%), pithakaba 
naadi were found in 1(2.5%) case. 
 In NeikuriVaatha Neer was found in 11 cases (21.5%), Piththa Neer was found 
 in 17 cases (42.5%), Kabha Neer was found in 12 cases (30%). 
OCCUPATIONAL REFERENCES: 
 Among 40 cases, 14 cases were homemaker (35%), and 8 cases were in (20%) 
tailoring occupation. Hence the study reveals that the disease is more prevelance in 
Homemaker may be due to  those who have lack of exercise.   
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CLINICAL MANIFESTATIONS: 
 Among 40 cases, Before treatment radiating pain and stiffness were present 40 
(100%) cases, tenderness present in 27 cases (67.5%), Numbness and paresthesia 
26(65%). After treatment 05 cases (12.5%) had radiating pain to upper limbs, 05 cases 
(12.5%) had tenderness in cervical region, 04 cases (10%) had stiffness of cervical spine, 
04 cases (10%) had numbness & paraesthesia. 
RESTRICTED MOVEMENT ASSESMENT SCALE: 
Among 40 cases, before treatment grade 2 present in 11 cases (27.5%), grade 3 
present in 29 case (72.5%). After treatment grade 1 in 29 cases (72.5%), grade 2 present 
in 11 cases (27.5%). 
QUETIONNAIRE OUTCOME WITH PAIN ASSESSEMENT OUTCOME: 
Among 40 cases, before treatment severe pain present in 37 cases (92.5%), 
moderate pain present in 3 case (7.5%). After treatment No pain in 08 cases (20%), mild 
pain present in 28 cases (70%), moderate pain present in 4 cases (10%). 
LABORATORY INVESTIGATIONS: 
 By laboratory investigation ESR was found raised in early stages but after 
 treatment it was found to be reduced. 
 At the same time Total WBC counts, T.RBC were increased in 5 patients. 
 Total cholesterol and LDL levels showed no changes in this study 
 Blood Urea and Serum Creatinine levels showed no changes in this study. 
 The radiographic studies showed narrowed joint space and presence of 
 Osteophytes. The trial drug showed improvement in prognosis of the disease 
 clinically rather than in radiographic changes. 
 
EFFECT OF TREATMENT: 
 Among 40 cases,20 patients are treated with medicines before treatment severe 
pain were present in 18 cases (90%), moderate pain present in 2 case (10%). After 
treatment mild pain present in 17 cases (85%), moderate pain present in 3 cases (15%). 
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The mean pain score before treatment patients who treated without Varmam was 
7.3+ 0.65 and after treatment it was reduced to 2.05+ 0.99 
EFFECT OF VARMAM WITH MEDICINE : 
 Among 40 cases,20 patients are treated with medicines along with Varmam before 
 treatment severe pain present in 19 cases (95%), moderate pain present in 1 case (5%). 
 After treatment pain nil in 8 cases (40%), mild pain present in 11cases (55%), moderate 
 pain  present in 1 cases (5%). In this clinical trial, patients who treated with Varmam 
 showed good result in the marked reduction of pain.  
The mean pain score before treatment was 7.8+ 0.83 and after treatment it 
was reduced to 1.0 + 1.21.  
EVALUATION OF MEDICINES: 
 The extract prepared from the given sample Sigamani Chooranam contains 
 Chloride, Tannic Acid, Unsaturated Compounds, Reducing Sugar and Amino 
 Acids. 
 Sub-Acute oral toxicity study conducted for 28 days and the drug did not exhibit 
 significant changes in blood counts. 
 All other observations were found to be normal before and after the study. In 
 Necropsy, the organs of the animal such as, Liver, Heart, Lungs, Pancreas, 
 Spleen, Stomach, Intestine, Kidney, Urinary bladder, Uterus all appeared normal. 
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SUMMARY 
The 40 cases of Cagana vaatham were diagnosed clinically and treated 
with the trial drugs in Department of Sirappu Maruthuvam in Ayothidoss 
Pandithar Hospital attached to National Institute of Siddha, Tambaraam 
Sanatoruim, Chennai-47. 
The study Protocol was approved by Institutional Ethics Committee(NIS). 
Before initiating the clinical trial, it was registered in Clinical Trials Registry of 
India and Ref. No Is: CTRI/2018/10/016011. 
Among 40 cases, 20 patients were treated with trail drug only and 40 patients 
were treated with trail drug along with varmam. 
The various Siddha methods of examination of the disease were carried out 
and the data were recorded in the prescribed Proforma for the 20 Cases. 
Initially in the  first Day of treatment Purgation was given by administering 
Agasthiyar kuzhambu-200mg with ginger juice in early morning with empty stomach 
to bring the thirithodam to equilibrium. 
From the second day onwards “Sigamani Chooranam” 1gm (twice a day) 
alomg with water was given internally and “Arkkasheerathy thylam” for external use 
were given to the patients. 
Laboratory Investigations were done for all the cases before and after 
treatment and radiological investigations were done for all the cases before 
treatment. 
 The observations made during the clinical study showed that internal drug 
and external drugs were effective in relieving pain in Cagana vaatham patients. During 
the study period, there was no adverse event reported. As per the Siddha Literature 
and recent research articles, the ingredients of the trial drugs was found to have 
Anti- inflammatory, analgesic properties owing to the disease manifestations. 
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The mean pain score before treatment is 7.55 after treatment it is reduced 
to1.52. Hence this study reveals that the patients treated with trial drugs and 
Varmam showed Good improvement when compared to those who are treated 
only with trial drugs. Statistical analysis showed significant reduction in the pain 
score. 
The outcome of the trial medicine was assessed by universal pain assessement 
scale and the results were as follows: 
The improvement of cases such as severe – no pain in 06 cases( 15%), severe -
mild pain in 27 cases (67.5%), severe – moderate pain in 03 cases (7.5%), Moderate- no 
pain in 02 cases (5%), moderate -mild pain in 02 cases (5%).  
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CONCLUSION 
 The dissertation is a comparative study on safety and efficacy of “Sigamani 
chooranam”and “Varmam”therapy in CaganaVaatham. 
 The study results showed that the improvement of cases such as severe – no pain 
in 06 cases( 15%), severe -mild pain in 27 cases (67.5%), severe – moderate pain in 03 
cases (7.5%), Moderate- no pain in 02 cases (5%), moderate -mild pain in 02 cases (5%).  
 Varmam treatment along with the trial drugs showed good improvement when 
comparedto patients treated only with trial drugs. 
 Repeated 28 days oral toxicity study in Wistar albino rats revealed that the drug 
was safe. Histo-pathological studies have shown that the drug has no toxic effects in the 
vital organs.  
 Clinically, no adverse effects were reported during the trial. The laboratory 
investigations shows ESR were found raised in early stages but after treatment it was 
found to be reduced, at the same time Total WBC counts, T.RBC were increased in 5 
patients & other laboratory investigations were also within normal limits. So, the drug is 
assumed to be safe for human beings. 
 Hence the study concludes that, the trial drugs were clinically effective in 
reduction ofpain, swelling, restriction of movements.  
 However further work with large number of patients should be carried out 
towards finding the ideal dose response. 
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BIOCHEMICAL ANALYSIS OF SIGAMANI CHOORANAM 
ANALYSED AT NATIONAL INSTITUTE OF SIDDHA 
 
S.No EXPERIMENT OBSERVATION INFERENCE 
1. Appearance of the sample Brown in color  
2. 
 
Solubility: 
a. A little (500mg) of the sample is 
shaken well with distilled water. 
b. A little (500mg) of the sample is 
shaken well with con. HCl/ Con. 
H2So4 
 
 
Sparingly soluble 
 
 
Presence of Silicate 
3. Action of Heat: 
A small amount (500mg) of the 
sample is taken in a dry test tube and 
heated gently at first and then strong. 
 
White fumes not 
evolved 
Absence of 
Carbonate 
4. Flame Test: 
A small amount (500mg) of the 
sample is made into a paste with con. 
HCl in a watch glass and introduced 
into non-luminous part of the Bunsen 
flame. 
 
 
No Bluish green 
flame appeared. 
 
 
Absence of Copper 
5. 
Ash Test: 
A filter paper is soaked into a mixture 
of sample and dil. cobalt nitrate 
solution and introduced into the 
Bunsen flame and ignited. 
 
No Yellow colored 
flame 
 
Absence of sodium 
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Preparation of Extract:  
5gm of “SIGAMANI CHOORANAM” was weighed accurately and placed in a 250ml 
clean beaker and added with 50ml of distilled water. Then it is boiled well for about 10 
minutes. Then it is cooled and filtered in a 100ml volumetric flask and made up to 100ml 
with distilled water. 
S..No Procedure Observation Inference 
1. Test for Calcium:  
2 ml of extract is taken in a clean test 
tube. To this add 2 ml of 4% ammonium 
oxide solution. 
 
white precipitate is 
formed 
 
Absence of calcium 
2. Test for Sulphate:  
2 ml of the extract is added to 5 % 
barium chloride solution. 
 
No white precipitate 
is formed 
 
Absence of 
Sulphate 
3. Test for Chloride:  
The extract is treated with Silver nitrate 
solution 
White precipitate is 
formed 
Presence of 
Chloride 
4. Test for carbonate:  
The substance is treated with Conc. HCl. 
No effervescence is 
formed 
Absence of 
carbonate 
5. Test for Starch:  
The extract is added with weak iodine 
solution 
 
No blue colour is 
formed 
 
Absence of starch 
6. Test for Iron (Ferric): The extract is 
treated with glacial acetic acid and 
potassium ferrocyanide 
 
No blue colour is 
formed 
 
Absence of Ferric 
iron 
7. Test for Iron (Ferrous): 
The extract is treated with Conc. HNO3 
and ammonium thiocyanate. 
 
Blood red colour is 
formed 
 
Presence of Ferrous 
iron. 
8. Test for phosphate: 
 The extract is treated with ammonium 
molybdate and conc. HNO3 
 
Yellow precipitate is 
formed. 
 
Absence of 
phosphate 
9. Test for Tannic acid: The extract is 
treated with Ferric chloride 
No Black precipitate 
is formed 
presence of Tannic 
acid 
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10. Test For Albumin: the extract is treated 
with Esbatch’s reagent. 
 
No yellow 
precipitate is formed 
Absence of 
Albumin 
10. Test for Unsaturation: 1ml of 
Potassium permanganate solution is 
added to the extract. 
It get decolourized. Presence of 
unsaturated 
compound 
11. Test for saponins: Dilute extract+ 1ml of 
distilled water shake well. 
No Froth formation Absence of 
saponins 
12. Test for sugars: 
Benedict method: 
 5ml of Benedict solution heated gently 
then add 8 drops of diluted extract then 
heated in a boiling water bath. 
Molisch test: 
 Dilute extract+2 drops of 
Molisch+3ml conc.H2SO4. 
colour change 
occurred. 
 
 
 
 
No Reddish violet 
zones appeared. 
 
Indicates the 
Absence of 
Sugar 
 
 
Absence of 
carbohydrate. 
 
13. Test for steroids: 
Liberman Burchard test 
Dilute extract +2 ml acetic anhydride+ 
conc.H2SO4  
 
No Formation of  
red colour 
 
Absence of steroids 
14. Test for amino acids: 
One or two drops of the extract is placed 
on a filter paper and dried well. After 
drying, 1% Nihydrin is sprayed over the 
same and dried well. 
Formation of violet 
colour 
Presence of amino 
acids 
15. Test for zinc: 
The extract is treated with potassium 
ferrocyanide 
 
No white precipitate 
is formed 
 
Absence of zinc 
 
INFERENCE: The extract prepared from the given sample “SIGAMANI 
CHOORANAM” contains Chloride, Tannic Acid, Unsaturated Compounds, Reducing 
Sugar and Amino Acids. 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
PRECLINICAL AND COMPARATIVE CLINICAL STUDY OF SIDDHA 
DRUG “SIGAMANI CHOORANAM ” (INTERNAL ) AND “ARKKASHEERATHY 
THYLAM” (EXTERNAL) IN THE TREATMENT OF “CAGANA VAATHAM” 
(CERVICAL SPONDYLOSIS) WITH AND WITHOUT VARMAM THERAPY. 
 
Principal Investigator: Dr.L.Nilopher                                                              
 
FORM I - SCREENING & SELECTION PROFORMA 
 
1. SERIAL NO:      2. OP /IP NO:                              
3. NAME:            4. AGE/GENDER:    
5. OCCUPATION:           6. INCOME:  
 
INCLUSION CRITERIA 
 Whether age is between 20-60                                  YES/ NO  
 Sex                            M /F/T 
 Pain in the neck radiating to the shoulder blades, top 
 of the shoulder, upper arm and back of the head   YES/NO    
 Numbness and paresthesia                                                     YES/NO  
 Willing to attend OPD or admission in IPD for the trial   YES/ NO 
 Willingness for consent       YES/ NO 
 Willing to give specimen of blood for the investigation     YES/ NO 
 Willing to undergo radiological investigation                            YES/ NO 
 
EXCLUSION CRITERIA  
       
 Spondylolisthesis                                                             YES/NO 
 Rheumatoid arthritis        YES/NO 
 Tuberculous arthritis        YES/NO 
 Cervical myelopathy        YES/NO 
 Cervical rib          YES/NO 
 Torticollis (wry neck)        YES/NO  
 Pyogenic bone infection        YES/NO 
 Compression fracture        YES/NO 
 Tumor in vertebral body        YES/NO 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
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 Osteochondritis         YES/NO 
 Metabolic bone disease        YES/NO 
 Ankylosing spondylitis        YES/NO 
 Spinal deformity         YES/NO 
 Sexually transmitted disease        YES/NO 
 
ADMITTED TO TRAIL 
YES  NO  
If Yes, OPD  IPD  
  Serial NO:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date:  
       
Station: 
 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                           Signature of the HOD   
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     NATIONAL INSTITUTE OF SIDDHA 
           AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
 PRECLINICAL AND COMPARATIVE CLINICAL STUDY OF SIDDHA DRUG 
“SIGAMANI CHOORANAM” (INTERNAL) AND “ARKKASHEERATHY 
THYLAM” (EXTERNAL) IN THE TREATMENT OF “CAGANA VAATHAM” 
(CERVICAL SPONDYLOSIS) WITH AND WITHOUT VARMAM THERAPY. 
 
Principal Investigator: Dr.L.Nilopher                                                              
 
STUDY  NO    :   OP / IP NO            : 
NAME             : AGE / GENDER   : 
ADDRESS       : CONTACT NO     : 
 RELIGION            :  H / C / M / O. 
 
 
OCCUPATION: 
INCOME               : 
 
MARITAL STATUS      :       1. Married      2. Unmarried 
 
DATE OF INTIAL ASSESSMENT:  
  
COMPLAINTS & DURATION:   
  
 
 
FORM II-A – HISTORY TAKING PROFORMA 
                                                                                                                                                                               
PERSONAL HISTORY: 
 
 
PERSONAL HABITS YES NO 
IF YES 
SPECIFY 
DURATION 
AMOUNT/Qty 
Smoking     
Tobacco Chewing     
Alcohol     
Narcotic Drug Addiction     
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HISTORY OF PREVIOUS ILLNESS AND TREATMENT TAKEN: 
FAMILY HISTORY:  
 
Whether this problem runs in family? 1. Yes            2. No    
If yes, mention the relationship of affected 
person(s) 
1._________________ 
 
2._________________ 
 
DIETARY STYLE: 1. Vegetarian    2. Non-vegetarian 
 
 
MENSTURAL AND OBSTETRIC HISTORY: 
 
                    
                                                                   
FORM –II B 
 
GENERAL EXAMINATION: 
 
1.Body weight [Kg]    :                      
2.Height [cms]                       :                        
3.Body Temperature [F]        :   
4.Blood Pressure (mm/Hg)  :      
5.Pulse Rate /min.        : 
6.Heart Rate / min.         : 
7.Respiratory Rate /min.  :  
  
                                                                                  Yes            No   
8.Pallor   :   
9.Jaundice   :   
10.Clubbing   : 
11.Cyanosis   : 
12.Pedal Oedema   : 
13.Lymphadenopathy            :                                        
14.Jugular venous pulsation   :   
 
SYSTEMIC EXAMINATION 
 
  Cardiovascular system  :  
  Respiratory system   :  
  Gastro-intestinal system  :  
  Central Nervous system  :  
  Urogenital system   :  
  Endocrine system              :  
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SIDDHA SYSTEM OF EXAMINATION 
1. THEGI (BODY CONSTITUTION): 
1. Vatha udal 
2. Pitha udal 
3. Kaba udal 
4. Thontha udal 
 
2. NILAM (LAND WHERE THE PATIENT LIVED MOST):  
1. Kurinji (Hilly terrain) 
2. Mullai (Forest range) 
3. Marutham (Plains) 
4. Neithal (Coastal belt) 
5. Paalai (Aridregion) 
 
3. KAALAM: 
1. Kaar kaalam    (Aavani-Purattasi) 
2. Koothir kaalam     (Ippasi-Kaarthigai) 
3. Munpani kaalam     (Maargazhi-Thai) 
4. Pinpani kaalam       (Maasi-Panguni) 
5. Ilavenil kaalam        (Chithirai-Vaigasi) 
6. Muthuvenil kaalam (Aani-Aadi) 
 
4. GUNAM: 
1. Sathuvam  
2. Rasatham 
3. Thamasam 
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5. PORIPULANGAL (SENSORY ORGANS):          
                  
  
6.KANMENDRIYAM (MOTOR ORGANS) : 
 Before treatment After treatment 
 
Mei (Skin) 
 
Normal  / Affected 
 
 
 
Normal  / Affected 
 
Vai 
(Tongue) 
 
Normal  / Affected 
 
 
 
Normal  / Affected 
 
Kann (Eye) 
 
Normal  / Affected 
 
 
 
Normal  / Affected 
 
Mooku 
(Nose) 
 
Normal  / Affected 
 
 
 
Normal  / Affected 
 
Sevi (Ear) 
 
Normal  / Affected 
 
 
 
Normal  / Affected 
 Before treatment After treatment 
 
Kai(Upper limb) 
 
Normal  /Affected 
 
 
 
Normal  /Affected 
 
Kaal (Lower limb) 
 
Normal  /Affected 
 
 
 
Normal  /Affected 
 
Vai (Oral cavity)   
 
Normal  /Affected 
 
 
 
Normal  /Affected 
 
Eruvai (Anal reg.) 
 
Normal  /Affected 
 
 
 
Normal  /Affected 
 
Karuvai(Uro-
genital  
region) 
 
Normal  /Affected 
 
 
 
Normal  /Affected 
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7.KOSANGAL (SHEATH):                
 
8. SEVEN UDAL THAATHUKKAL (SEVEN SOMATIC COMPONENTS) 
 
 Before treatment After treatment 
 
Saaram 
 
Normal  /Affected 
 
 
 
Normal  /Affected 
 
Senneer  
 
Normal  /Affected 
 
 
 
Normal  /Affected 
 
Oon 
 
Normal  /Affected 
 
 
 
Normal  /Affected 
 
Kozhuppu 
 
Normal  /Affected 
 
 
 
Normal  /Affected 
 
Enbu 
 
Normal  /Affected 
 
 
 
Normal  /Affected 
 Before treatment After treatment 
 
Annamaya kosam 
 
Normal  /Affected 
 
 
 
Normal  /Affected 
 
Pranamaya kosam  
 
 
 
Normal  /Affected 
 
Normal  /Affected 
 
Manomaya kosam  
 
 
 
Normal  /Affected 
 
Normal  /Affected 
 
Vignanamaya 
kosam 
 
  
 
Normal  /Affected 
 
Normal  /Affected 
 
Ananthamaya 
kosam 
 
 
 
Normal  /Affected 
 
Normal  /Affected 
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Moolai 
 
Normal  /Affected 
 
 
 
Normal  /Affected 
 
Sukkilam / 
Suronitham 
 
Normal  /Affected 
 
 
 
Normal  /Affected 
 
 
9. UYIR THAATHUKKAL: [THREE HUMORS] (VALI/ AZHAL/ IYYAM) 
 
A) VALI 
 
 
0
th
 
day 
8
th
 
day 
15
th 
 day 
22
nd
 
day 
29
th
 
day 
36
th
 
day 
43
rd
 
day 
49
th
 
day 
Praanan 
 
 
        
Abaanan 
 
 
        
Samaanan 
 
 
 
       
Udhaanan 
 
 
 
       
Viyaanan 
 
 
 
       
Naagan 
 
 
 
       
Koorman 
 
 
 
       
Kirukaran 
 
 
 
       
Devathathan 
 
 
 
       
Dhananjeyan 
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B) AZHAL 
 
 
0
th
 
day 
8
th
 
day 
15
th
 
day 
22
nd
 
day 
29
th
 
day 
36
th
 
day 
43
rd
 
day 
49
th
 
day 
Analakam 
 
 
 
       
Ranjakam  
 
 
       
Saathakam  
 
 
       
Prasakam          
Aalosakam         
 
 
 
 
C) IYYAM 
 
 
0
th
 
day 
8
th
 
day 
15
th
 
day 
22
nd
 
day 
29
th
 
day 
36
th
 
day 
43
rd
 
day 
49
th
 
day 
Avalambagam         
Kilethagam         
Pothagam         
Tharpagam         
Santhigam 
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10. ENVAGAI THERVU: [EIGHT TYPES OF EXAMINATION] 
 
I. NAADI: [PULSE PERCEPTION] 
 
NAADI 
0
th
 
day 
8
th 
day
 
15
th 
day 
22
nd
day 29
th
day 
36
th
 
day 
43
rd
day 49
th
day 
         
 
 
II. SPARISAM: [PALPATION] 
 
Day SPARISAM 
0
th
 day 
 
 
8
th 
day
  
 
15
th
 day 
 
 
22
nd
 day 
 
 
29
th
 day 
 
 
36
th
 day 
 
 
43
rd
 day 
 
 
49
th 
day  
 
 
 
 
III. NAA: [TONGUE] 
 
NAA 0
th
day 8
th
day
 
15
th
day 22
nd
day 29
th
day 36
th
day 43
rd
day 49
th
day 
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IV. NIRAM: [COMPLEXION]   
    1. Vadham         
     2. Pitham 
      3. Kabam  
 
 
V. MOZHI: [VOICE] 
      1. High Pitched 
      2. Low Pitched 
      3. Medium Pitched 
 
 
VI.VIZHI: [EYES] 
VIZHI 
0
th
 
day 
8
th 
day
 15
th
day 22
nd
day 29
th
day 
36
th
 
day 
43
rd
day 49
th
day 
         
 
 
VII. MALAM: [BOWEL HABITS / STOOLS] 
 Before treatment After treatment 
Niram  
 
 
Irugal 
 
 
 
Ilagal 
 
 
 
Others 
 
 
 
 
 
VIII. MOOTHIRAM [URINE EXAMINATION]  
NEERKKURI: 
Neerkkuri Before treatment After treatment 
Niram   
Manam   
Edai   
Nurai   
Enjal   
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NEIKKURI:  
 
Neikkuri Before treatment After treatment 
 Aravena neendathu/ 
Snake like pattern 
 
  
Azhipol paraviyathu 
Annular/Ringedpattern 
 
 
 
parav 
paraparavoiyadu 
  
Muththothu ninrathu  
Pearlbeadepattern 
 
 
Other patterns 
 
 
 
 
 
 
CLINICAL EXAMINATION:        
           
LOCOMOTOR SYSTEM: 
 CLINICAL SYMPTOMS: 
pain and stiffness  : 
(cervical region)         YES                                     NO 
 
Radiating pain        : Right arm   Left arm 
 
Numbness & paraesthesia  YES    NO 
 
Onset:                                Sudden                              Gradual 
 
 
 
 
 
 
 
 yes 
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CLINICAL EXAMINATION  
I.INSPECTION: 
 0
th
 day 
8
th
 
day 
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th
 
day 
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nd
day 
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th
 
day 
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th
 
day 
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rd
day 
49
th
 
day 
SWELLING         
STIFFNESS         
 
II.PALPATION: 
 
0
th
 
day 
8
th
 
day 
15
th
 
day 
22
th
 
day 
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th
 
day 
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th
 
day 
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rd
day 49
th
 day 
Tenderness         
Local heat         
 
III. MOVEMENTS 
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th
 
day 
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th
 
day 
22
nd
day 
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Flexion          
Extension          
Lateral 
flextion 
        
Rotation         
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IV. JOINT MESUREMENT: 
A. HEALTH ASSESSMENT QUESTIONNAIRE: 
 
 
 
 
 
 
 
 
 0
th
 day 
8
th
 
day 
15
th
 
day 
22
nd
day 
29
th
 
day 
36
th
 
day 
43
rd
day 
49
th
 
day 
PAIN 
A.Onset: 
Sudden/Gradual 
        
B. Early morning  
Stiffness 
(Present/absent) 
        
C. Nature of pain                                             
(Mild/ Moderate/ 
Severe) 
        
D. Aggravating   
factor- 
Movement  
(Yes/No) 
        
E. Relieving 
factor –Rest 
(Yes/No) 
        
G. Tenderness 
(Present/absent) 
        
RESTRICTION 
OF 
MOVEMENT  
(Fully/Partial/No) 
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CLINICAL TEST: 
PAIN ASSESMENT SCALE: 
1. UNIVERSAL PAIN ASSESMENT SCALE: 
 
 
 
 
 
   
 
 
            Grade 0 : No Pain 
Grade 1-3 : Mild pain 
   (nagging, annoying, interfering little with ADLs) 
Grade 4-6 : Moderate pain 
   (interfering significantly with ADLs) 
Grade 7-10 : Severe pain 
   (disabling, unable to perform ADLs) 
 0
th
 day 
8
th
 
day 
15
th
 
day 
22
nd
day 
29
th
 
day 
36
th
 
day 
43
rd
day 
49
th
 
day 
Spurling’s 
test 
        
Chin 
chest test 
        
Lateral 
flexion                                  
        
Shoulder 
abduction 
relief sign 
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SCALE 0
th
 day 8
th 
day
 
15
th
day 22
nd
day 29
th
day 36
th
 day 43
rd
day 49
th
day 
         
 
OUTCOME: 
0 - Good improvement 
1-3 - Moderate improvement 
4-6 - Mild improvement 
7-10 - No improvement 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date:          
 
Station: 
 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                           Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
 
PRECLINICAL AND COMPARATIVE CLINICAL TRAIL OF SIDDHA DRUGS 
“SIGAMANI CHOORANAM” (INTERNAL) AND “ARKKASHEERATHY THYLAM” 
(EXTERNAL) IN THE TREATMENT OF “CAGANA VAATHAM” (CERVICAL 
SPONDYLOSIS) WITH AND WITHOUT VARMAM THERAPY. 
 
Principal Investigator: Dr.L. Nilopher 
 
1. SERIAL NO  :      2. OP /IP NO         :                              
3. NAME            :           4. AGE/GENDER : 
 
 
 
 
FORM -III - LABORATORY INVESTIGATIONS 
 
 
BLOOD 
INVESTIGATIONS 
NORMAL 
VALUES 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
Hb( gm/dl) 
M:13-18 
W:11-16 
  
T.RBC(millions cells 
/Cu.mm) 
M:4.5-6.5 
W:3.5-5.5 
  
ESR (mm) 
½ hr. -   
1 hr. 
M:0-10 
W:0-20 
  
T.WBC (Cells /Cu.mm) 4000-11000   
Differential 
Count (%) 
Polymorphs 40-75   
Lymphocytes 20-35   
Monocytes 2-10   
Eosinophils 1-6   
Basophils 0-1   
 
 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
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BLOOD 
INVESTIGATIONS 
NORMAL 
VALUES 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
Blood 
glucose 
(mg/dl) 
Fasting 70-110   
PP 80-140   
Lipid 
profile 
(mg/dl) 
Serum cholesterol 150-200   
HDL 30-60   
LDL Up to 130   
VLDL 40   
TGL Up to 160   
RFT 
(mg/dl) 
Blood urea 16-50   
Serum creatinine 0.6-1.2   
LFT 
(mg/dl) 
Total bilirubin 0.2-1.2   
Direct bilirubin 0.1-0.2   
Indirect bilirubin 0.2-0.7   
Total protein 6-8   
Serum Albumin 3.5-5.5   
Serum globulin 2-3.5   
SGOT (IU/L) 0-40   
SGPT (IU/L) 0-35   
Alkaline 
phosphatase 
(IU/L) 
80-290   
 
Serum calcium 9-11   
Serum 
phosphorus 
2-5   
Serum Uric acid 
M:3-9 
W: 2.5-7.5 
  
 CRP   
 ASO titre   
 RA factor   
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B.URINE INVESTIGATIONS: 
URINE 
INVESTIGATIONS 
BEFORE TREATMENT 
AFTER 
TREATMENT 
Albumin   
Sugar (Fasting) 
        (PP) 
  
Deposits   
Bile salts   
Bile pigments   
 
C.RADIOLOGICAL EXAMINATIONS 
X- Ray: CERVICAL REGION 
1. Antero posterior  
2. Lateral view 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date: 
          
Station: 
 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                           Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
PRECLINICAL AND COMPARATIVE CLINICAL TRAIL OF SIDDHA DRUGS 
“SIGAMANI CHOORANAM” (INTERNAL) AND “ARKKASHEERATHY  THYLAM” 
(EXTERNAL) IN THE TREATMENT OF “CAGANA VAATHAM” (CERVICAL 
SPONDYLYOSIS) WITH AND WITHOUT VARMAM THERAPY. 
Name of Principal Investigator: Dr.L.Nilopher        
FORM –IV- DRUG COMPLIANCE FORM 
SERIAL NO: 
NAME:  
DRUG NAME:  
On 1
st    
 day-Date:  Drugs issued:  (Gms)   Drugs returned:    (Gms) 
On 8
th
   day-Date:   Drugs issued:  (Gms)    Drugs returned:    (Gms) 
On 15
th
 day-Date:              Drugs issued:  (Gms)  Drugs returned:    (Gms) 
On 22
th
 day-Date:           Drugs issued:  (Gms)  Drugs returned:    (Gms) 
On 29
th
 day-Date:             Drugs issued:  (Gms)  Drugs returned:    (Gms) 
On 36
th
 day-Date:              Drugs issued:  (Gms)  Drugs returned:    (Gms) 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                           Signature of the HOD 
 
   Day    Date          Morning   Evening   Day    Date    Morning   Evening 
Day 1    Day24    
Day2    Day25    
Day3    Day26    
Day4    Day27    
Day5    Day28    
Day6    Day29    
Day7    Day30    
Day8    Day31    
Day9    Day32    
Day10    Day33    
Day11    Day34    
Day12    Day35    
Day13    Day36    
Day14    Day37    
Day15    Day38    
Day16    Day39    
Day17    Day40    
Day18    Day41    
Day19    Day42    
Day20    Day43    
Day21    Day44    
Day22    Day45    
Day23    Day46    
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
PRECLINICAL AND COMPARATIVE CLINICAL TRAIL OF SIDDHA DRUGS 
“SIGAMANI CHOORANAM” (INTERNAL) AND “ARKKASHEERATHY THYYLAM” 
(EXTERNAL) IN THE TREATMENT OF “CAGANA VAATHAM” (CERVICAL 
SPONDYLOSIS) WITH AND WITHOUT VARMAM THERAPY. 
           
FORM-V– INFORMATION SHEET 
 
Name of Principal Investigator   :   Dr .L.Nilopher 
Name of the institute                    :   National Institute of Siddha, 
                                                                Tambaram Sanatorium, 
                                                                Chennai-47. 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN 
CLINICAL TRIAL: 
 
I, Dr.L.Nilopher Studying as M.D(Siddha) at National Institute of  Siddha, 
Tambaram Sanatorium is doing a trial on the study of CAGANA VAATHAM(cervical 
spondylosis).cervical spondylosis is a most common persistent joint disease, occurring 
throughout the world. In this regard, I am in a need to ask you few questions. I will 
maintain confidentiality of your comments and data obtained. There will be no risk of 
disclosing your identity and no physical, psychological or professional risk is involved 
by taking part in this study. Taking part in this study is voluntary. No compensation will 
be paid to you for taking part in this study. 
           You can choose not to take part. You can choose not to answer a specific 
question. There is no specific benefit for you if you take part in the study. However, 
taking part in the study may be of benefit to the community, as it may help us to 
understand the problem of defaulters and potential solutions. 
             If you agree to be a participant in this study, you will be included in the study 
primarily by signing the consent form and then you will be given the internal medicine 
“sigamani chooranam” (Internal medicine-, Twice a Day with water for 20 days) and 
“Arakkasheerathy thylam” (External medicine), if you wish to stay in the In patient 
ward “Varmam” Treatment will be provided to you assuring that you will not be 
definitely hurt in any course of treatment. 
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  The information I am collecting in this study will remain between you and the 
principal investigator (myself). If you wish to find out more about this study before 
taking part, you can ask me all the questions you want or contact Dr.L.Nilopher, PG 
Scholar, cum principal investigator of this study, attached to National Institute of 
Siddha, Chennai-47. You can also contact the Member-secretary of Ethics committee, 
National Institute Siddha, Chennai 600047, for rights and participation in the study. 
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FORM -V - ¾¸Åø ÀÊÅõ 
¬öÅ¡ÇÃ¡ø º¡ýÈÇ¢ì¸ôÀð¼Ð 
 
§¿¡öì¸¡É º¢ò¾ ÁÕóÐ¸Ç¢ý º¢¸¡Á½¢ ÝÃ½õ (¯û ÁÕóÐ) 
ÁüÚõ «÷ì¸„£Ã¡¾¢ ¨¾Äõ(¦ÅÇ¢ÁÕóÐ) ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ 
ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ. 
Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ¦ÀÂ÷  :  Ä¢.¿¢§Ä¡À÷  
¿¢ÚÅÉò¾¢ý ¦ÀÂ÷ : §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
   ¾¡õÀÃõ º¡É§¼¡Ã¢Âõ,¦ºý¨É-47. 
 §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉò¾¢ø Àð¼ §ÁüÀÊôÒ ÀÂ¢ýÚ ÅÕõ 
¿¡ý (ÁÕòÐÅ÷: Ä¢.¿¢§Ä¡À÷) º¸É Å¡¾õ ±ýÛõ §¿¡öì¸¡É ÁÕòÐÅ 
¬Ã¡öîº¢Â¢ø ®ÎÀðÎû§Çý. 
 þó¾ ¬Ã¡öîº¢ ºõÀó¾Á¡¸ º¢Ä §¸ûÅ¢¸¨Ç §¸ð¸×õ, §¾¨ÅÂ¡É 
¬öÅ¸ ÀÃ¢§º¡¾¨ÉìÌ ¾í¸¨Ç ¯ðÀÎò¾×õ ¯û§Çý. þó¾ 
¬Ã¡öîº¢ìÌ ¾¡í¸û Å¢ÕôÀò¾¢ý §ÀÃ¢ø ¯ðÀÎõ Àðºò¾¢ø ¯ûÁÕó¾¡¸ 
º¢¸¡Á½¢ ÝÃ½õ 1¸¢Ã¡õ 2 §Å¨Ç (¸¡¨Ä, Á¡¨Ä) ¯½×ìÌ À¢ý 20 
¿¡ð¸ÙìÌ ¯ð¦¸¡ûÇ §ÅñÎõ. ¦ÅÇ¢ÁÕó¾¡¸ «÷ì¸„£Ã¡¾¢ ¨¾Äõ 45 
¿¡ð¸ÙìÌ §¿¡ÔûÇ þ¼í¸Ç¢ø ¦ÅÇ¢§Â ¾¼Å§ÅñÎõ. ¦ÅÇ¢ 
§¿¡Â¡Ç÷ 7 ¿¡ð¸ÙìÌ ´Õ Ó¨È ÁÕòÐÅÁ¨ÉìÌ ÅÃ§ÅñÎõ. 
 þÐ ºõÀó¾Á¡É ¾í¸ÇÐ «¨ÉòÐ Å¢ÅÃí¸Ùõ Ã¸º¢ÂÁ¡¸ 
¨Åì¸ÀÎõ ±É ¯Ú¾¢«Ç¢ì¸¢§Èý. þ¾¢ø ÀÂ½ôÀÊÅõ Ó¾Ä¢Â ±ó¾ 
¯¾Å¢¦¾¡¨¸Ôõ ÅÆí¸À¼Á¡ð¼¡Ð. 
 þó¾ ¬Ã¡öîº¢Â¢ý §À¡Ð ¯¼ÖìÌ §ÅÚÀ¡¾¢ôÒ ²üÀÎõ Àðºò¾¢ø   
§¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø ¾ì¸ Á¡üÚ º¢¸¢î¨º «Ç¢ì¸ôÀÎõ.þó¾ 
¬Ã¡öîº¢Â¢ø ¾í¸¨Ç ¯ðÀÎò¾¢ÂÀ¢ÈÌ ¯í¸ÙìÌ Å¢ÕôÀÁ¢ø¨Ä¦ÂÉ¢ø 
±ô§À¡Ð §ÅñÎÁ¡½Öõ Å¢Ä¸¢ì ¦¸¡ûÇ ÓØ ¯Ã¢¨Á ¯ûÇÐ. 
 þó¾ ¬Ã¡öîº¢ ºõÀó¾Á¡¸ ÁüÈ Å¢ÀÃí¸ÙìÌõ §¿¡Â¢ý 
¾ý¨Á¨Â ÀüÈ¢Ôõ Ó¾ý¨Á ¬Ã¡öîº¢Â¡ÇÃ¡É Ä¢.¿¢§Ä¡À÷ (Àð¼ 
§ÁüÀÊôÀ¡Ç÷ ÁÕòÐÅ À¢Ã¢×) «Ï¸×õ. §ÁÖõ þó¾ ¬Ã¡öîº¢ìÌ IEC 
º¡ýÚ ¦ÀÈôÀðÎûÇÐ. 
 
§¾¾¢:                               ¨¸¦Â¡ôÀõ      : 
þ¼õ:                ¦ÀÂ÷       :         
                      º¡ðº¢ì¸¡Ã÷ ¨¸¦Â¡ôÀõ    : 
                                    ¦ÀÂ÷       :                         
           ¯È×Ó¨È      :  
Å¢Ã¢×¨ÃÂ¡Ç¡÷ ¨¸¦Â¡ôÀõ:           Ð¨Èò¾¨ÄÅ÷ ¨¸¦Â¡ôÀõ   : 
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NATIONAL INSTITUTE OF SIDDHA 
     AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
DDEPARTMENT OF SIRAPPU MARUTHUVAM 
  
PRECLINICAL AND COMPARATIVE CLINICAL STUDY OF SIDDHA DRUG 
“SIGAMANI CHOORNAM” (INTERNAL) AND “ARKKASHEERATHY THYLAM” 
(EXTERNAL) IN THE TREATMENT OF   “CAGANA VAATHAM” (CERVICAL 
SPONDYLOSIS) WITH AND WITHOUT VARMAM THERAPY. 
Name of Principal Investigator: Dr.L.Nilopher     
 
FORM-VI – CONSENT FORM 
 
“I have read the foregoing information, or it has been read to me. I have had the 
opportunity to ask questions about it and any questions I have asked have been answered 
to my satisfaction.  
            I consent voluntarily to participate as a participant in this study and understand 
that I have the right to withdraw from the study at any time without in any way it 
affecting my further medical care”. 
 
"I have received a copy of the information sheet/consent form". 
 
Date:  
Signature of the participant 
In case of illiterate participant 
 
        “I have witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm 
individual has given consent freely.”                                                   
 
Date: 
 
 
Signature of a witness  
(Selected by the participant bearing no connection with the survey team)   
       
          
            
 
 
   Left thumb Impression of the Participant  
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FORM –VI   ´ôÒ¾ø ÀÊÅõ 
¬öÅ¡ÇÃ¡ø º¡ýÈÇ¢ì¸ôÀð¼Ð 
¿¡ý º¸ÉÅ¡¾õ  ±ýÛõ §¿¡Â¢ý ¬ö¨Åì ÌÈ¢ò¾ «¨ÉòÐ 
Å¢ÀÃí¸¨ÇÔõ §¿¡Â¡Ç¢ìÌô ÒÃ¢Ôõ Å¨¸Â¢ø ±ÎòÐ¨Ãò§¾ý ±É 
¯Ú¾¢ÂÇ¢ì¸¢§Èý. 
 
§¾¾¢:                                        ¨¸¦Â¡ôÀõ: 
                     
þ¼õ:                         ¦ÀÂ÷:                                                
                                         
§¿¡Â¡Ç¢Â¢ý ´ôÒ¾ø 
±ýÉ¢¼õ  þó¾  ÁÕòÐÅ  ¬ö× ¸¡Ã½ò¨¾Ôõ,  ÁÕó¾¢ý ¾ý¨Á  
ÁüÚõ ÁÕòÐÅ  ÅÆ¢Ó¨È  ÀüÈ¢Ôõ  ¦¾¡¼÷óÐ  ±ÉÐ  ¯¼ø  
þÂì¸ò¨¾ì  ¸ñ¸¡½¢ì¸×õ, «¾¨Éô  À¡Ð¸¡ì¸×õ  ÀÂýÀÎõ  
ÁÕòÐÅ  ¬ö×ìÜ¼  ÀÃ¢§º¡¾¨É¸û  ÀüÈ¢  ¾¢Õô¾¢ «Ç¢ìÌõ  Å¨¸Â¢ø  
¬ö×  ÁÕòÐÅÃ¡ø  Å¢Çì¸¢ì  ÜÈôÀð¼Ð. 
¿¡ý þó¾ ÁÕòÐÅ ¬öÅ¢ý §À¡Ð, ±ô¦À¡ØÐ §ÅñÎÁ¡É¡Öõ  
þó¾  ¬öÅ¢Ä¢ÕóÐ   ±ý¨É Å¢ÎÅ¢òÐ  ¦¸¡ûÙõ  ¯Ã¢¨Á¨Âò 
¦¾Ã¢ó¾¢Õì¸¢ý§Èý. ¿¡ý ±ýÛ¨¼Â Í¾ó¾¢ÃÁ¡¸ò §¾÷× ¦ºöÔõ 
¯Ã¢¨Á¨Âì ¦¸¡ñÎ º¸ÉÅ¡¾õ §¿¡öì¸¡É º¢¸¡Á½¢î ÝÃ½õ (¯û 
ÁÕóÐ) ÁüÚõ «÷ì¸„£Ã¡¾¢ò ¨¾Äõ(¦ÅÇ¢ ÁÕóÐ) ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò  
¾¢È¨Éì  ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢üÌ ±ý¨É  ¯ðÀÎò¾ ´ôÒ¾ø 
«Ç¢ì¸¢§Èý. 
 
 
§¾¾¢:                               ¨¸¦Â¡ôÀõ      : 
þ¼õ:                ¦ÀÂ÷       :         
                      º¡ðº¢ì¸¡Ã÷ ¨¸¦Â¡ôÀõ    : 
                                    ¦ÀÂ÷       :                         
           ¯È×Ó¨È      :  
 
 
Å¢Ã¢×¨ÃÂ¡Ç¡÷ ¨¸¦Â¡ôÀõ:            
Ð¨Èò¾¨ÄÅ÷ ¨¸¦Â¡ôÀõ   : 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS  PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
 DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
 PRECLINICAL AND COMPARATIVE CLINICAL TRIAL OF SIDDHA DRUG  
SIGAMANI CHOORANAM (INTERNAL) AND “ARKKASHEERATHY THYLAM” 
(EXTERNAL) IN THE TREATMENT OF “CAGANA VAATHAM”(CERVICAL 
SPONDYLOSIS) WITH AND WITHOUT VARMAM THERAPY. 
Name of Principal Investigator: Dr.L.Nilopher      
 
FORM VII - WITHDRAWAL FORM 
 
1. SERIAL NO OF THE CASE:    
2. OP / IP NO:     
3. NAME:      
4. AGE:         
5. GENDER:                          
6. DATE OF TRIAL COMMENCEMENT:  
7. DATE OF WITHDRAWAL FROM TRIAL:  
8. REASONS FOR WITHDRAWAL: 
Long absence at reporting:               Yes/ No 
Irregular treatment:                           Yes/ No 
Shift of locality:                                     Yes/No 
Increase in severity of symptoms:     Yes/No 
Development of severe adverse drug reactions:   Yes/No 
Development of adverse event:                                              Yes/No 
(If YES, give the details of adverse reaction in Form VII -B – Adverse      Reaction Form 
/ Pharmaco Vigilance Form) 
 
 
 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                          Signature of the HOD 
 
191 
 
NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
PRECLINICAL AND COMPARATIVE CLINICAL STUDY OF SIDDHA DRUG 
“SIGAMANI CHOORANAM” (INTERNAL) AND “ARKKASHEERATHY THYLAM” 
(EXTERNAL) IN THE TREATMENT OF  “CAGANA VAATHAM”(CERVICAL 
SPONDYLOSIS) WITH AND WITHOUT VARMAM. 
Name of Principal Investigator: Dr.L.Nilopher     
 
FORM VII - A – ADVERSE REACTION FORM / PHARMACO VIGILANCE 
FORM 
 
SERIAL NO:                                                                                                           
OP/IP NO: 
NAME:                                                             AGE:                     GENDER: 
DATE OF TRIAL COMMENCEMENT: 
DATE OF THE ADVERSE REACTION OCCUR: 
DESCRIPTION OF ADVERSE REACTION: 
 
 
 
 
 
 
 
 
 
 
Date:                                                                              
Station:  
Signature of the Investigator: 
Signature of the Lecturer:                                                            Signature of the HOD 
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FORM VII- PHARMACOVIGILANCE/WITHDRAWAL FORM 
1. Patient / consumer identification (please complete or tick boxes below as 
appropriate) 
NATIONAL PHARMACOVIGILANCE PROGRAMME FOR  SIDDHA DRUGS 
 
 
Please note:  i.All consumers / patients and reporters information will remain 
confidential. 
         ii. It is requested to report all suspected reactions to the concerned, 
even if it does not have complete data, as soon as possible. 
Peripheral Center code:     State: 
Name  Father name Patient / Record 
No. Ethnicity  Occupation 
Address  
Village / Town 
Post / Via 
District / State   
Date of Birth / 
Age: 
Sex:     M / F 
Weight : 
Degam: 
 
2. Description of the suspected Adverse Reactions (please complete boxes below) 
Date and time  of 
initial observation 
 Season: 
Description of 
reaction   
 Geographical area: 
 
3. List of all medicines / Formulations including drugs of other systems used by the 
patient during the reporting period: 
Medicine Daily 
dose 
Route of 
administration 
& Vehicle - 
Adjuvant 
Date  Diagnosis for 
which medicine 
taken  
Starting Stopped 
Siddha      
Any other 
system of 
medicines 
     
 
Reporting Form for Suspected Adverse Reactions to Siddha 
Drugs 
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4. Brief details of the Siddha Medicine which seems to be toxic : 
Details Drug – 1 Drug – 2 Drug – 3 
a) Name of the medicine    
b) Manufacturing unit 
and batch No. and date 
   
c) Expiry date    
d) Purchased and 
obtained from 
   
e) Composition of the 
formulation / Part of the 
drug used 
   
 
b) Dietary Restrictions if any 
c) Whether the drug is consumed under Institutionally qualified medical supervision or 
used as self medication.  
d) Any other relevant information. 
5. Treatment provided for adverse reaction: 
6. The result  of the adverse reaction / side effect / untoward effects (please complete 
the boxes below) 
Recovered:           Not 
recovered: 
 Unknown: Fatal: If Fatal 
Date of death: 
Severe:   Yes   /   
No. 
Reaction abated after drug stopped or dose reduced: 
Reaction reappeared after re introduction: 
 
 
Was the patient admitted to hospital? 
If yes, give name and address of 
hospital 
 
 
7. Any laboratory investigations done to evaluate other possibilities?  If Yes specify:  
8. Whether the patient is suffering with any chronic disorders? 
Hepatic    Renal    Cardiac    Diabetes    Malnutrition  
Any Others  
9. H/O previous allergies / Drug reactions:  
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10. Other illness (please describe): 
11. Identification of the reporter: 
 
Type (please tick):  Nurse / Doctor / Pharmacist / Health worker / Patient / 
Attendant / Manufacturer / Distributor / Supplier / Any others (please specify) 
Name: 
Address: 
Telephone / E – mail if any : 
 
Signature of the reporter:     Date: 
Please send the completed form to:  
    The Director 
    National Institute of Siddha, 
(Pharmacovigilance Regional Centre For Siddha 
Medicine), 
    Tambaram Sanatorium, Chennai-600 047. 
 (O) 044-22381314 Fax : 044 – 22381314 
Website : www.nischennai.org 
Email: nischennaisiddha@yahoo.co.in 
 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  
This filled-in ADR report may be sent within one month of observation /occurrence 
of ADR   
 
 
 
 
 
 
Date:                                                                              
Station:  
Signature of the Investigator: 
Signature of the Lecturer:                                                  Signature of the HOD 
 
  
Who Can Report? 
 Any Health care professionals like Siddha Doctors /  
Nurses / Siddha Pharmacists / Patients etc.  
What to Report?  
 All reactions,  Drug interactions,  
Confidentiality  
 The patient’s identity will be held in strict confidence 
and protected to the fullest extent.  
 Submission of report will be taken up for remedial 
measures only not for legal claim  
Name & address of 
theRRC-ASU/ PPC-ASU 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
PRECLINICAL AND COMPARATIVE CLINICAL TRAIL OF SIDDHA 
DRUG “SIGAMANI CHOORANAM”  (INTERNAL) AND “ARKKASHEERATHY 
THYLAM” (EXTERNAL) IN THE TREATMENT OF CEGANA VAATHAM  
(CERVICAL SPONDYLOSIS) WITH AND WITHOUT VARMAM THERAPY. 
Principal Investigator: Dr.L.Nilopher 
FORM - VIII  DIETARY ADVICE FORM 
 
§º÷ì¸ ÜÊÂ ¯½×¸û ¾Å¢÷ì¸ §ÅñÊÂ¨Å¸û 
¸¡ö¸û (Vegetables): 
¸ò¾Ã¢ôÀ¢ïÍ (Unripe brinjal) 
ÓÕí¨¸ôÀ¢ïÍ (Unripe drumstick) 
«Å¨ÃôÀ¢ïÍ (Unripe Dolichos bean) 
¸£¨Ã¸û(Greens): 
¦À¡ýÉ¡í¸ñ½¢ (Sessile plant 
[Alternanthera sessilis] ) 
ãì¸¢Ãð¨¼ (Hog weed [Boerhaavia diffusa] ) 
àÐ§Å¨Ç (Climbing brinjal [Solanum 
trilobatum] ) 
ÓÕí¨¸ì¸£¨Ã (Leaves of Drumstick 
[Moringa oleifera] ) 
¸È¢§ÅôÀ¢¨Ä (Curry leaf [Murraya koenigii] ) 
Ó¼ì¸Úò¾¡ý (Winter cherry [Cardiospermum 
halicacabum] ) 
«Ú¸£¨Ã (Amaranthus tristis) 
¸Ã¢º¡¨Ä (trailing eclipta [Eclipta prostrate] ) 
ÀÆí¸û(Fruits): 
Á¡Ð¨Ç (Pomegranate) 
¬ôÀ¢û (Apple) 
ÀôÀ¡Ç¢ (Papaya) 
¬ÃïÍ (Orange) 
§ÀÃ£î¨º (Dates) 
«ò¾¢ (Fig) 
¿¡Åø (Jambul [Syzygium cumini] ) «¨ºÅõ 
(Non-vegetarian diet): 
¦ÅûÇ¡ðÎì¸È¢ (Meat)  
¸¡¨¼ (Quail) , º¢Ú þÈ¡øÁ£ý (Prawn) 
 
Í¨Ã (Bottle gourd) 
âº½¢ (Pumpkin) 
¦ÅûÇÃ¢ì¸¡ö (Cucumber) 
Ò¼¨Ä (Snake gourd) 
À£÷ìÌ (Ridged gourd) 
¯ÙóÐ (Black gram) 
¦Á¡î¨º (Indian butter Bean) 
¸¡Ã¡Á½¢ (Cow gram) 
¦¸¡ûÙ (Horse gram) 
¸ÎÌ (Mustard) 
±ñ¦½ö (Gingelly oil) 
ÒÇ¢ôÒ (Sour) 
¯ôÒ (Salt) 
Å¡Ôô ¦À¡Õð¸û (Vatha diet) 
¯Õ¨Çì ¸¢ÆíÌ (Potato) 
Å¡¨Æì ¸¡ö (Plantain) 
Ò¨¸Â¢¨Ä (Tobacco) 
ÁÐ «ÕóÐ¾ø (Alcohol) 
¦Àñ§À¡¸õ (þîº¡ Àò¾¢Âõ) [Sexual 
intercourse] 
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